

**CURRICULUM VITAE
DR. SCOTT B. PATTEN**

I: BIOGRAPHICAL DATA

Department of Community Health Sciences
University of Calgary
3280 Hospital Drive N.W.
Calgary, Alberta, Canada
T2N 4Z6

Department of Psychiatry
Consultation-Liaison Psychiatry
Peter Lougheed Hospital
3500 - 26th Ave. N.E.
Calgary, Alberta. T1Y 6J4

II: ACADEMIC RECORD

Doctor of Philosophy (Epidemiology), Department of Community Health Sciences, Faculty of Medicine, University of Calgary, June 1994.

Fellow, Royal College of Physicians and Surgeons of Canada, since July 1991

Registered with the Alberta College of Physicians and Surgeons,
July 1991 to present

Licensure of the Medical Council of Canada (LMCC),
July 1991

Completed Residency in Psychiatry, Department of Psychiatry,
The University of Calgary, Calgary, Alberta, June 1991

Medical Doctorate with Distinction and First Class Standing,
The University of Alberta, Edmonton, Alberta, June, 1986

Bachelor of Medical Science with Distinction and First Class Standing,
The University of Alberta, Edmonton, Alberta, June 1984

III. AWARDS AND DISTINCTIONS

Peak Scholar (University of Calgary – Research on the epidemiology of mood disorders in Canada) 2017

10,000 Citation Award (Recipient of the International Achievement Award, University of Calgary) 2017

Robert M. Herndon Award (International Journal of MS Care for Outstanding Article) 2016

O'Brien Institute Research Excellence Award (June 2016)

GREAT Supervisor Award (Faculty of Graduate Studies, My Supervisor Skills) Sept 2015

R.O Jones Best Paper Award (3rd place), 2015. Canadian Psychiatric Association Annual Conference, October 1-3 2015. (Lauria-Horner & **Scott Patten**. Skill-Based Approaches, Effective in Reducing Stigma in Health Professionals. Canadian Psychiatric Association Annual Conference, Vancouver, October 1-3, 2015).

Graduate Students Association Award for Supervisory Excellence, 2014.

Alex Leighton Joint CPA-CAPE Award in Psychiatric Epidemiology, 2009

Alberta Heritage Foundation for Medical Research, Senior Health Scholar, 2009 - 2016.

Medical Sciences Graduate Students' Association. Golden Apple Award. Golden Apples are awarded to faculty members who demonstrate an "outstanding interest and participation in education and student issues" Year of award, 2006.

CPA-COPCE Award for Most Outstanding Continuing Education Activity in Psychiatry in Canada (Academic Setting). Co-recipients: Dr. Steve Simpson, Dr. Jordan Cohen. Psychiatry On-line Journal Club, Awarded November 2006.

Watanabe Distinguished Achievement Award for Overall Excellence, Faculty of Medicine, 2005/2006.

Cochrane Distinguished Achievement Award for Research, Faculty of Medicine, 2004/2005.

Alberta Heritage Foundation for Medical Research, Health Scholar, 2004-2009.

Medical Sciences Graduate Students' Association. Golden Apple Award. Golden Apples are awarded to faculty members who demonstrate an "outstanding interest and participation in education and student issues" Year of award, 2001.

(Inaugural) Supervisory and Teaching Excellence Award. Selected by the Graduate Students in the Department of Community Health Sciences, 2001.

Petro-Canada Young Innovator Award in Community Health, 2000.

United Nations Development Project (UNDP) Award to visit Public Health College, Harbin Medical University. Lecture Series: Advanced Lectures in Epidemiology. March 19 - April 8, 1999.

World Psychiatric Association Fellowship, 1996 (Awarded to a limited number of applicants holding a full-time faculty appointment for less than two years: based on academic achievement).

Alberta Heritage Foundation for Medical Research Population Health Investigator, 1996 - 2002.

Alberta Heritage Foundation for Medical Research Clinical Fellowship, 1991 - 1994.

1990 Laughlin Fellowship - The American College of Psychiatrists (awarded to fifteen psychiatry residents in American and Canadian training programs on the basis of departmental nominations).

Dr. S. S. Spaner Prize in Psychiatry (University of Alberta), 1986 (awarded to a fourth year medical student for outstanding performance in the field of Psychiatry).

Louise McKinney Post-Secondary Scholarship, 1985.

Lange Publications Award in Medicine, 1984.

The Nat Christie Foundation Scholarship, 1984.

The Board of Governors Prize in Medicine, 1984 (awarded to the student with the highest academic average at the end of each of the first and second years in the faculty).

Louise McKinney Post-Secondary Scholarship, 1984 (awarded on the basis of outstanding academic achievement).

Fisons Corporation Ltd. Bursary in Immunology, 1983.

IV. ACADEMIC APPOINTMENTS

Cuthbertson and Fischer Chair in Pediatric Mental Health, Cumming School of Medicine, University of Calgary (2017 – Present)

Professor, Departments of Community Health Sciences and Psychiatry, Faculty of Medicine, University of Calgary (2006 to Present).

Associate Professor, Departments of Community Health Sciences and Psychiatry, Faculty of Medicine, University of Calgary (2000 to 2006).

Research Fellow. Institute of Health Economics, June 2000 to 2006.

Assistant Professor, Departments of Community Health Sciences and Psychiatry, Faculty of Medicine, University of Calgary (1994 to 2000).

V. EDUCATIONAL ACTIVITIES

Course Chair: MDCH 640 Fundamentals of Epidemiology: Fall Term, 2011 - Present.

Course Co-chair: MDCH 740: Advanced Epidemiology: Winter Term, 2018 - Present

Course Chair: MDCH 642: Psychiatric Epidemiology: Fall Term 2017

Course Chair: MDCH 700-03: Community Health Directed Study (Psychiatric Epidemiology). Spring Term 2014

Course Chair: MDSC 648: Psychiatric Epidemiology, Spring Term, 2007.

Course Chair, MDSC 647.01 (Fundamentals of Epidemiology). Fall Term, 2005-2010.

Co-Instructor, MDSC 709 (Advanced Epidemiology), Winter Term, 2004

Instructor, MDSC 647.08 (Psychiatric Epidemiology and Critical Appraisal in Psychiatry), 2001-2004.

Course Co-chair, MDSC 647.01 (Fundamentals of Epidemiology), Fall Term, 1995 - 1999.

Co-Instructor, MDSC 709 (Advanced Epidemiology), Fall Term, 1994.

Co-Instructor, MDSC 709 (Advanced Epidemiology), Fall Term, 1993.

VI. ADMINISTRATIVE RESPONSIBILITIES

Research Director, Department of Psychiatry. University of Calgary. October 1, 2002 – Present.

Interim Acting Head (Academic), Department of Psychiatry, University of Calgary, July 1 – August 31, 2008.

Director, Psychiatric Emergency Services, Department of Psychiatry, Calgary General Hospital. 1994 – 1996.

Chief Resident, Psychiatry, July 1, 1990 - December 31, 1990.

VII. PROFESSIONAL ACTIVITIES

Editorial

Editor-in-Chief, Canadian Journal of Psychiatry, October 2014 – present.

Editorial Board, Chronic Diseases in Canada, June 2009 – present.

Editorial Board, Clinical Practice and Epidemiology in Mental Health, July 2010 – present.

Senior Associate Editor, Epidemiology and Psychiatric Sciences, 2014 - present

Associate Editor, Canadian Journal of Psychiatry, April 1, 2009 – September 2014.

Member:

Member, Canadian Medical Association.

Member, Alberta Medical Association.

Member, Canadian Psychiatric Association.

Committee:

Advisor to the Editor-in-Chief, Australian & New Zealand Journal of Psychiatry. 2016-Present

Co-Chair (with Dr. Garth Bray), Synthesis Panel. National Population Study on Neurological Conditions (2013-present)

Chair, Scientific Advisory Committee: Toward Optimized Practice (TOP), Clinical Practice Guideline (CPG), Identification and Management of Depression in Multiple Sclerosis (MS). <http://www.topalbertadoctors.org/cpgs/> 2016 – 2017.

Chair, Grant Review Committee, Wellness Research Grant Initiative MS Society of Canada. 2016

Member, Scientific Advisory Committee. Consensus Development Conference on Improving Mental Health Transitions. Held November 4-6, Edmonton, Alberta.

Member, Graduate Education Committee. Department of Community Health Sciences. 2001 – 2005, 2009 – 2013

Member, Depression Clinical Network Steering Committee. Alberta Health Services. 2010 - 2012.

Member, Expert Scientific Group. Ontario Burden of Mental Health Study, 2011-2012. Final report: Ratnasingham S, Cairney J, Rehm J, Manson H, Kurdyak PA. *Opening Eyes, Opening Minds: The Ontario Burden of Mental Illness and Addictions Report*. An ICES/PHO Report. Toronto: Institute for Clinical Evaluative Sciences and Public Health Ontario; 2012.

Member, Scientific Advisory Committee. National Population Study on Neurological Conditions (2010-2013).

Expert Advisory Committee. Canadian Community Health Survey, Mental Health and Wellbeing (to be conducted in 2012). 2009-2013.

Scientist member: Research Ethics Review Committee. College of Physicians and Surgeons of Alberta/Alberta Innovates, Health Solutions. January 2010-2013.

Member, Neurological Disease Surveillance Advisory/Steering Committee, Public Health Agency of Canada, 2009-2014.

Invited participant: The Brain, Mental Health and Addiction: From Synapse to Society. The 2nd “Inukshuk Conference” Banff, November 11-14th, 2007.

Conference Co-Chair (with Dr. Christine Friedenreich, Alberta Cancer Board), Canadian Society for Epidemiology and Biostatistics Biennial Meeting: Held in Calgary, May 28-31st, 2007.

Member, National MS Society (USA) Task Force on Epidemiology. Chair: Dr. N. LaRocca. 2006-2008.

Invited Member. CIHR Workshop to Develop a Research Agenda on Mental Health in the Workplace. Toronto, April 28 and 29, 2004.

Member, Canadian Advisory Committee. IXth International Congress of the International Federation of Psychiatric Epidemiology. May 12 - 15, 2002

Member, Local Arrangements Committee. Canadian Association for Population Therapeutics Annual Meeting. Banff, Alberta. April 1-3, 2001.

Member of the Board. Canadian Academy of Psychiatric Epidemiologists. October 2000 to present (Appointed Treasurer, 2004 - present).

Member of the Board. Canadian Association for Population Therapeutics. Member at Large, April 2000-2002. President Elect, 2003. President, 2004, Past President, 2005.

Member, Expert Advisory Council. Canadian Community Health Survey, C.C.H.S. 1.2 - Mental Health Content (Statistics Canada).

Member, Health Trainee Advisory, Alberta Heritage Foundation for Medical Research, 1998 -

1999.

Member, Local Arrangements Committee. Canadian Psychiatric Association Annual Meeting, September 16 - 19, 1997, Calgary, Alberta.

Member, Studentship Advisory Committee, Alberta Heritage Foundation for Medical Research, 1996 to 1998.

Reviewer - Journals:

Addiction

American Journal of Cardiovascular Drugs

American Journal of Clinical Dermatology.

American Journal of Epidemiology

American Journal of Psychiatry

American Heart Journal

Annals of General Psychiatry

Annals of Medicine

Applied Bioinformatics

Archives of General Psychiatry

Australian and New Zealand Journal of Psychiatry

Biological Psychiatry

Bipolar Disorders

BMC Family Practice

BMC Health Services Research

BMC Medical Informatics and Decision Making

BMC Musculoskeletal Disorders

BMC Psychiatry

BMC Research Notes

Canadian Journal of Community Mental Health

Canadian Medical Association Journal

Canadian Geriatrics Journal

Canadian Journal of Psychiatry

Chronic Diseases in Canada

Clinical Journal of Sport Medicine

Clinical Practice and Epidemiology in Mental Health

Clinical Psychology Reviews

Comprehensive Psychiatry

Cost Effectiveness and Resource Allocation
Current Psychiatry
Depression & Anxiety
Depression: Mind & Body
Disease Primers
Drugs and Aging Journal
Epidemiologic Perspectives & Innovations
Epidemiology and Psychiatric Sciences
European Journal of Clinical Pharmacology
European Journal of General Medicine
European Journal of Neurology
European Psychiatry
Expert Review of Neurotherapeutics
Expert Review of Pharmacoeconomics and Outcomes Research
Functional Neurology
General Hospital Psychiatry
Geriatrics & Aging
Haematologia
Healthcare Policies
Health Reports
International Clinical Psychopharmacology
International Journal of Geriatric Psychiatry
International Journal of Mental Health Systems
Internet Journal of Mental Health
International Journal of MS Care
International Journal of Neuropsychopharmacology
International Journal of Neuroscience
International Journal of Psychiatry in Medicine
International Journal of Psychology
International Journal for Obesity
International Multiple Sclerosis Journal
J Neuropsychiatry and Clinical Neurosciences
Journal of Affective Disorders
Journal of Applied Economics and Health Policy

Journal of Clinical Epidemiology
Journal of Clinical Psychiatry
Journal of General Internal Medicine
Journal of Internet Medical Research
Journal of Neurology, Neurosurgery and Psychiatry
Journal of Personality Disorders
Journal of Pharmacoepidemiology and Drug Safety
Journal of Population Therapeutics and Clinical Pharmacology
Journal of Psychiatric Research
Journal of Psychosomatic Research
Journal of the Neurological Sciences
Lancet Psychiatry
Multiple Sclerosis Journal
Nature Reviews
Neuroscience & Biobehavioral Reviews
Pain
Patient Preference and Adherence
Pharmacology Research
PLoS ONE
Progress in Neuro-Psychopharmacology & Biological Psychiatry
Psychiatric Services
Psychosomatics
Psychotherapy and Psychosomatics
Quality of Life Research
Research on Aging
Social Psychiatry and Psychiatric Epidemiology
Social Science in Medicine.
The Canadian Journal of Cardiology.
The Canadian Medical Association Journal.
The Lancet
Turkish Journal of Rheumatology
World Journal of Psychiatry

Reviewer - Technical Reports:

CTFPHC (Canadian Task Force on the Preventive Health Care) Recommendation statement on screening for depression – external reviewer.

CCHOTA, Emerging Technology Bulletin Review. Sativex for the Management of Symptoms of Multiple Sclerosis, 2005.

CCHOTA, Canadian Emerging Technology Assessment Program (CETAP). Vagus Nerve Stimulation for Treatment Resistant Depression, 2002.

Reviewer - Canadian Grants:

University of Ottawa Medical Research Fund (UMRF) Grants/Awards Competition (1 review)

ICSS-CISS Regional Data Centre Data Access Application Review Committee (multiple reviews)

Health Sciences Centre Foundation, Winnipeg, Manitoba (three reviews)

Health Services Utilization and Research Commission, Saskatchewan (one review).

Canadian Institutes for Health Research (multiple reviews as external reviewer, peer review committee membership 2010 – 2015)

Social Sciences and Humanities Research Council (three reviews).

University of Manitoba Ethics Review Board (one review).

The Ontario Mental Health Foundation (three reviews)

Physician Services Incorporated Fund (PSI): Ontario. (1 review).

Reviewer - International Grants

Health and Health Services Research Fund, Hong Kong (3 reviews)

Council for Medical and Health Research. Netherlands Organization for Scientific Research (NWO) (two reviews).

The Wellcome Trust (U.K.) Fellowships (one review).

National MS Society (USA) (one review)

Netherlands Organization for Health Research and Development (ZonMw) (5 reviews)

The Raine Foundation. Government of Western Australia (1 review)

Multiple Sclerosis Society (UK) (1 review)

External Reviewer –Faculty Promotions

University of Toronto (n=2)

University of Manitoba (n=3)

Western University (n=1)

Dalhousie University (n=1)

University of British Columbia (n=1)

VIII. RESEARCH SUPPORT

2018-2020: Benedetti A, Thombs BD (PI's), Wilchesky M, Boruff J, Chertkow H, Cuijpers P, Gilbody S, Ismail Z, Levis B, McMillan D, Mitchell N, Monette DJ, **Patten SB**, Shrier I, Steele R, Tonelli M, Ziegelstein. Improving depression screening in geriatric patients by reducing bias and generating individualized accuracy estimates: An individual patient data meta-analysis of the Geriatric Depression Scale (GDS). CIHR. \$120,000.

2018-2022: Tremlett H (PI), Evans CD, Fisk JD, Marrie RA, **Patten SB**, Kingwell E, Svenson L, Zhao Y. Prescription drug safety and effectiveness in Multiple Sclerosis (DRUMS): a population-based, multi-province platform for comprehensive pharmacovigilance. CIHR. \$1,220,175.

2018-2020: Benedetti A, Thombs BD (PI's), Boruff J, Cuijpers P, Gilbody S, Levis B, McMillan D, **Patten S**, Shrier I, Steele R, Ziegelstein R. Using Individual Patient Data Meta-Analyses to Develop Individual Prediction Models for Depression Screening. CIHR Catalyst Grant: Personalized Health. \$200,000

2017-2018: Guichon J, **Patten SB**. The relationship between choir singing and mental health of parents of chronically ill or disabled children. URGC – Seed Grant. \$15,000.

2017-2019: Sajobi T S, **Patten SB**, Amoozegar F, Jette N. A longitudinal study of determinants of severity and burden of disease in persons with migraine. Alberta Health Services and the University of Calgary. \$32,000.

2016-2019: Wang JL, **Patten SB**, Macqueen G, Manel D, Schmitz N, Lashewicz B. The impact of disclosing personalized depression risk information on high risk individuals' outcomes. (CIHR): \$611,600

2015 – 2017: **Patten SB**. The Alberta Depression Research Hub (UofA Sub contract). Canadian Depression Research Innovation Network (CDRIN). \$82,000.

2015 - 2016: Thombs BD, Cuijpers P, Benedetti A, Loiselle C, Cuijpers P, Gilbody S, Henry M, Ismail Z, Kloda L, McMillan D, Mitchell N, **Patten SB**, Shrier I, Steele R, Tonelli M, Ziegelstein R. Improving depression screening in medically ill patients by reducing bias and including individual patient characteristics in accuracy estimates: An independent patient data meta-analysis of the Hospital Anxiety and Depression Scale (HADS). Canadian Institutes of Health Research (CIHR): \$100,000.

2015 – 2016: Jette N, Bulloch A, Holroyd-Leduc J, **Patten SB**, Wiebe S. (Co-PI's). Building a Foundation for a Depression eHub for Neurological Patients. Hotchkiss Brain Institute/Pfizer Research Competition \$50,000

2015 – 2022 Sareen J, Afifi TO, Alessi-Severini S, Asmundson GJG, Bernstein CN, Blouw M, Bolton JM, Boyle MH, Chateau D, Enns MW, Fikretoglu D, Gibbons R, Graff L, Jetly R, Katz LY, Leong C, Leslie WD, Lix LM, Logsetty S, Mackenzie C, Marrie RA, Olafson K, **Patten SB**, Pedlar D, Pietrzak RH, Richardson D, Schellenberg F, Snider C, Stein MB, Van Til L, Walker JR, Wang JL, Zamorski MA. Collaborators - Bolton SL, El-Gabalawy R, Henriksen CA, Klassen K, Mota N, Spiwak R, Whitney D, Wong JY. Defining the Longitudinal Course, Outcomes, and Treatment Needs of Vulnerable Canadians with Posttraumatic Stress Disorder. Canadian Institutes of Health Research Foundation Scheme. \$1,886,073. My Role: Project Expert, this is a CIHR Foundation Grant awarded to J. Sareen.

2015: Patten SB, Greenshaw A, Sajobi T. New statistical approaches to inter- and intra-provincial comparisons of regional and temporal trends in major depression prevalence and its treatment. Addiction and Mental Health Strategic Clinical Network: \$15,000

2014-2018. Wang JL. Co-investigators: Aiken A, Attridge M, Bulloch, A Gundu S, Hanrahan M, Ho K, Hodgins D, Lam R, Lashewicz, B, Legge A, Manuel D Z, Marchand A, Merali Z, Meurs J, Michalak E, Patten SB, Schmitz N. Early identification and prevention of major depression in male workers. Movember Foundation: Canadian Mental Health Initiative: \$2,135,281. (Nov 2014 – Oct 2018)

2014 - 2019. Defining the burden and managing the effects of psychiatric comorbidity in chronic immunoinflammatory disease. CIHR Team Grant, P.I. = Dr. Ruth Ann Marrie, University of Manitoba (\$2,443,500).

2014 – 2016: Moll S, et al. (incl. **Patten SB**). Beyond silence: Comparing the impact of contact-based education with mental health literacy training on early intervention for healthcare workers with mental health issues. Type A Grant. Ontario Mental Health Foundation. \$150,000 (\$75,000 per year over two years).

2014 – 2015: Thombs BD, Joffres MR, Benedetti A, Kloda L., **Patten SB**, Shrier I., Steele R. Improving depression screening by reducing bias in accuracy estimates: An independent patients data meta-analysis of the PHQ-9. CIHR, \$100,000 over one year.

2014-2017. Khenti AA, Corrigan P, Agic B, Bobbili S, Hamilton H, Mann R, **Patten SB**, J. Sapag Muñoz De La Peña J. Exploring Stigma, Discrimination and Recovery-Based Perspectives toward Mental Illness and Substance Use Problems among Primary Health Care Providers across Ontario. CIHR \$575,115 (3 years).

2013 – 2019: Patten SB. Depression in the Community. Hotchkiss Brain Institute. \$220,000 (3 years – Sept 2013- Aug 2016)

2013-2015: Patten SB, Wang JL, Bulloch AGM. Is mental health changing over time? Canadian Institutes of Health Research. \$114,704.00 (2 years).

2013-2014: Patten SB. Health outcomes in adolescents and young adults in relation to childhood exposures and experiences. Investigator-Driven Small Grant from The Alberta Centre for Child, Family and Community Research. \$40,000 (2 years).

2012-2013: Thombs BD, Ickkowitz A, Baltzer F, Katz L, **Patten S**, Rousseau C, Roy D.

Depression screening and mental health outcomes in children and adolescents: A systematic review. Canadian Institutes of Health Research. \$99,977 (1 year).

2012-2015: Wang JL, Schmitz N, Currie SR, **Patten SB**. A population-based longitudinal study on work and health. The Canadian Institutes of Health Research. Operating grant: \$469,856. (3 years – March 1, 2012 – Feb 28 2015)

2012-2013: Pringsheim TM, Davis MA, Ageranioti Belanger, **Patten S**, Petermann L. Knowledge translation and dissemination of an antipsychotic safety monitoring guideline for children. Canadian Institutes of Health Research. \$75,227 (1 year).

2011-2012: Thurston WE, Roy A, **Patten S**, Tough S, Crowshoe L, Beran T. Understanding depression among pregnant Aboriginal women: a constructivist grounded theory study in the city of Calgary. Investigator-Driven Small Grant from The Alberta Centre for Child, Family and Community Research. \$40,000 (2 years).

2011-2013: Korngut L, Jetté N, Pringsheim T. et al. (inc. **Patten SB**). Neurological registry best practice guidelines and implementation toolkit. National Population Health Study of Neurological Conditions & Public Health Agency of Canada. \$209,496. (2 yrs)

2011-2014: Jetté N, **Patten SB**, Bulloch A, Coutts S, Dobson K, Korngut L, Macrodimitris S, MacQueen G, Pringsheim T, Sherman E, Yeung M, Wang JL. The Neurological Disease and Depression Study (NEEDS) – Understanding the burden, course and impact of depressive disorders in neurological conditions. Alberta Health Services/Faculty of Medicine Team Grant Competition (with \$150,000 contribution from HBI), \$300,000. Total funding \$450,000. (3 yrs)

2011-2013: McIntyre L, **Patten SB**. Long-term mental health outcomes of childhood hunger. Canadian Institutes of Health Research. Operating Grant: Secondary Analysis of Databases (\$96,182). (3 years)

2011-2014: Meadows GN, **Patten SB**, Kamruzzaman J, Karmakar G, Inder BA, Gordon-Brown L, Albrecht SL, Gibbs P, McDermott DM. Improving management decisions in mental health care through applications of advanced simulation modelling. Australian Research Council (\$184,000 AUD) (3 yrs)

2011-2013: Wang JL, Manuel D, **Patten S**, Schmitz N. Development and validation of risk algorithms for major depression in the general population. Canadian Institutes of Health Research (\$200,260). (2 yrs)

2011-2012: Meadows G, Gordon-Brown L, **Patten SB**. Monash University Strategic Grants Initiative (Melbourne, Australia). Modelling mental health care services: Providing evidence to support management decision-making regarding service configuration. (\$48,000 AUD).

2010-2012: **Patten SB**. Institute of Health Economics. Depression and comorbid pain conditions: Patterns of influence on HUI ratings & health outcomes. (\$123,960)

2010-2013: Jetté N, Pringsheim T, et al. (incl. **Scott B. Patten**). Public Health Agency of Canada. Understanding the epidemiology of neurological conditions and building the methodological foundation for surveillance. (\$402,000) (3 yrs)

2010-2013: **Patten SB (PI)**, Metz LM, Rodgers J, Bulloch AGW, Fredrek C, Edmond C, Trew

M. Alberta Mental Health Research Partnership Program – Collaborative Research Grant Initiative: Mental Wellness in Seniors and Persons with Disabilities. Mental Health and Disability in People with MS (\$210,000) (3 yrs)

2009-2010: Tamara Pringsheim & **Scott Patten**. Post Market Drug Safety and Effectiveness of Atypical Antipsychotics in Children With Disruptive Behaviour Disorders, Mood Disorders and Developmental Disorders. C.I.H.R. - Catalyst Grant. (\$66,626).

2009-2012: Maxwell CJ (PI), Strain LA, Hogan DB, **Patten SB**, Hagen B, Sales AE, Gruneir A. Alberta Mental Health Research Partnership Program – Collaborative Research Grant Initiative: Mental Wellness in Seniors and Persons with Disabilities. Enhancing system capacity to improve the quality and continuity of mental health care for seniors in assisted living and long-term care. (\$210,000). (3 yrs)

2009-2010: Pedlar D (PI), Fikretoglu D, Loiser P, **Patten S**, Savoie S, Van Til L, Wang J, Zamborski M. C.I.H.R. Workplace Reintegration of Veterans with Mental Disorders. \$80,000 (1 year – starting in July 2009)

2009-2010: Colman I (PI), **Patten S**, Senthilselvan A. C.I.H.R. Long-term outcome of antidepressant treatment in a general population sample. \$96,315 (total for 2 years).

2008-2011: **Patten S** (PI), Eliasziw M, Marra C. C.I.H.R. Major Depression and Health Status Changes. \$70,00 per year (\$210,000 – Total for 3 yrs.).

2008-2011: Wang JL (PI), Currie S, **Patten SB**, Sareen J, Schmitz N. C.I.H.R. Perceived needs and utilization of workplace mental health accommodations among workers with depressive and anxiety disorders. \$63,345 per year (\$190,035 Total for 3 years).

2007-2011: Co-Investigator with Wang JL (PI). C.I.H.R. A community-based longitudinal study of work and mental health. \$143,113 per year.

2007-2008: Frosk P (PI-medical student), Kheraj N, **Patten SB**, Cohen J. Calgary Health Region. Health Issues of Sexual Minorities in Medical Curricula. \$5,000.

2007-2008: **Patten SB** (PI). C.I.H.R. Health-Related Transitions in Major Depression. \$85,819.

2007-2008: Madan S(PI), **Patten SB**, Kivakumar C. Calgary Health Region – Mental Health Research Funding competition. Validity of Nursing Delirium Assessment in Comparison to Physician Gold Standard Assessment. \$19,954.

2007-2008: Wang JL (PI), **Patten SB**, Tiwari SK. C.I.H.R. Strengthening Psychiatric Epidemiology and Primary Mental Health Care in Nepal. \$25,000.

2006-2009: Maxwell C (PI), Eliasziw M, Hepple R, Hogan D, Parboosingh J, **Patten S**, Schmaltz H, Strain Voon Yong S. C.I.H.R. Frailty, inflammatory mechanisms and adverse health outcomes among vulnerable seniors. \$177,042.

2006: **Patten SB (supervisor)** International Resident Fellowship. Dr. Eleanora Esposito, University of Verona. \$6,000

2005-2006: Weibe S, Quan H, **Patten P (Co-investigator)**. The Comorbidity of Epilepsy: A multiple Data Source Analysis. M.S.I. Foundation (University of Alberta). \$150,000.

2005 – 2006: **Patten SB**. Medical-Psychiatric Comorbidity in the Canadian Population. Institute of Health Economics. \$50,314

2005 – 2007: **Patten SB**, Metz L, Mitton C, Newman S. Institute of Health Economics. Alberta Depression Initiative. Disease management for depression in MS. \$157,584.

2005 - 2007: **Patten S**, Wang JL, Adair C, Beck C, Sevcik M, Schopflocher D, Dobson K, Mitton C, Barbui C, Newman S. Institute of Health Economics. Alberta Depression Initiative. Frequency and adequacy of depression treatment in Alberta. \$185,530

2004 – 2006: Dr. Cynthia Beck (PhD student under my supervision), Fellowship Award, Canadian Institutes of Health Research.

2004 – 2006: PI: Maxwell C. Co-investigators: Anderson T, Parboosingh J, Hogan DB, Ghali W, Faris P, Galbraith D, Knudtson M, **Patten SB**, Shewchuk L. Homocysteine, Folic Acid and Vascular Outcomes among Elderly Cardiac Patients: Exploring Relevant Gene-Environment Interactions. : M.S.I. Foundation \$49,280.

2003: **Patten SB**. Preventive Health Care Among Canadian Adults with Major Mental Illness. Calgary Health Region \$4,993

2003-2006: **Patten SB** (Co-Investigator), Maxwell CJ (Principal Investigator). The Prevalence and Pharmacological Management of Pain in Older Persons Across Clinical Settings. Institute of Health Economics \$115,000

2003-2004: **Patten SB**, Wang JL, Currie SR, Maxwell CJ, El-Guebaly N. Descriptive epidemiology of major depression in the Canadian population. Canadian Institutes of Health Research \$39,299

2003-2007: Maxwell CJ (PI), Hogan DB, Ghali W, Faris P, Galbraith D, Knudtson ML, **Patten S**, Maitland A, Demchuk A, Parboosingh J, Jelinski S. The Impact of Neurocognitive and Psychological Factors on Quality of Life and Functional Recovery among Older Patients Undergoing Coronary Revascularization Procedures”. CIHR-Institute of Aging \$204,819.

2003-2004: **Patten SB**. Canadian Institutes for Health Research. A Descriptive Markov Model for Major Depression in the General Population. \$52,051

2003-2004: **Patten SB**, (Co-Principal Investigator :C. Adair, R. Brant, A. Casebeer). Mental Health Surveillance in Alberta. Alberta Mental Health Board \$250,000

2003-2004: **Patten SB**. Adult Research Committee, Calgary Health Region. Isotretinoin Use for Acne: Can Battling Blemishes Lead to Depression?. Principal Investigator/Student Project: Dr. Jordan Cohen. \$7,500.

2002-2003: **Patten SB**. Mental Health of the Calgary Population. Centre for Advancement of Health/Calgary Health Region 1st Annual Mental Health Funding Competition. \$25,000, supplemented by \$10,000 from the Regional Department of Psychiatry Research Overhead Fund.

2002 - 2003: Patten SB. Major Depression and MS in the Canadian Community Health Survey. Centre for Advancement of Health. \$4105.

2002-2004: Patten SB. Coronary Revascularization and Neurocognitive Outcomes among Older Patients with Ischemic Heart Disease: A Pilot Study. MSI Foundation - \$70,000 (2 years). Maxwell CJ (PI).

2002-2003: Patten SB. Carlos Ogilvie Fund. Cardiac Risk Factors among Persons with Schizophrenia (for support of research by graduate student Cynthia Beck). \$7500

2002-2003: Patten SB. Institute of Health Economics. Antidepressant Utilization in Canada. \$22,000

2002-2003: Patten SB. CRHA Perinatal Research Funding Competition. Current Practice and Knowledge on Postpartum Depression: Alberta Physicians' Survey. P.I. Dr. C.E. Adair. \$13,417.88

2001: Patten SB. Institute of Health Economics. Research and Development Grant: Markov Models of Major Depression. \$3400.

2001-2003: Patten SB. A.H.F.M.R. Health Research Fund. Outcome in Early Psychosis. A Five Year Follow-up. P.I. Dr. Jean Addington. \$67,000.

2001-2003: Patten SB. A.H.F.M.R. Clinical Fellowship Support for Masters Student: Dr. Cynthia Beck.

2001-2002: Patten SB. A.H.F.M.R. Health Research Fund. Development of a Population-based Surveillance Program for Mental Health in Alberta. \$45,000 per annum for one year (matched by an equal amount from the Provincial Mental Health Board).

2001-2003: Patten SB. A.H.F.M.R. Health Research Fund. Selecting and Testing Quality Indicators for Evaluating Early Psychosis Treatment and Prevention Programs. P.I. Dr. Donald Addington. \$45,000 per annum for two years.

2001-2002: Patten SB. Studentship Support for Masters Student: Dr. Cynthia Beck - The Novartis Studentship Award. \$15,000.

2001-2005: Patten SB. Canadian Institutes for Health Research. Member, Interdisciplinary Health Research Team. Co-Principal Investigator on 2 of 8 Component Projects: Matrix metalloproteinases (MMPs) in Multiple Sclerosis (MS): Environmental influence, biology, pathology and therapeutic strategies. \$989,650 per year for 5 years.

2001: Patten SB. Institute of Health Economics. Sampling procedures for Population-based Studies of Irritable Bowel Syndrome. \$33,753

2000-2001: Patten SB. Petro-Canada Young Innovator Award in Community Health. \$25,000.00

2000 - 2001: Patten SB. Ares Serono. Depression and Interferon Beta-1a in Secondary

Progressive Multiple Sclerosis. Co-investigator with Dr. L. Metz. \$21,600.

2000 - 2001: Patten SB. Institute of Health Economics. Evaluation of the Alberta Multiple Sclerosis Drug Program: Patterns of Drug Use, Review of Patient Support, and Program Costs Over the First 24 Months. Principal Investigator: L. Metz . Co-investigator with G. Currie, C. Harris, J. Rogers, M.L. Myles. \$78,500

2000 - 2001: Patten SB. National Health Research and Development Program (NHRDP). An Epidemiological Model of Incidence-Prevalence Relationships for Major Depression in Canada: A Tool for Public Health Policy Development. \$25,500

2000: Patten SB. Provincial Mental Health Board (Alberta). Addington D, Addington J, Donaldson C, Gordon A, Patten S, Purdon S. Project Development Grant: Randomized Controlled Cost Effectiveness Study of Early Onset Psychosis Treatment. \$9,024

2000-2002: Patten SB. Calgary Regional Health Authority Special Competition. Patten SB. Randomized Controlled Clinical Trial of an HTML-based Preventive Intervention for Depressive Symptoms. \$20,000.

2000-2001: Patten SB. Drug Compliance and Health Outcomes in the Community-Dwelling Elderly: A Comparison of Urban and Rural Home Care Clients. Institute of Health Economics (Merck Company Foundation Program on Pharmaceutical Policy Issues), \$96,030. PI=Maxwell CJ. Co-investigators: Vik SA, Hogan DB, **Patten SB**, Johnson JA, Romonko-Slack L.

2000: Patten SB. Serono Pharmaceuticals. Research Contract Depression as a possible adverse effect of interferon- α 1 in the PRISMS Clinical Trial. \$5,600. (Co-investigator, Dr. Luanne Metz).

2000-2002: Patten SB. Alberta Heritage Foundation for Medical Research. Mental Health Studentship: Ms. Jeanne Williams \$19,500 per annum (24 months, renewable).

1999: Patten SB. University of Calgary Faculty of Medicine Endowment Award: Biological Correlates of Major Depression in the Calgary Community. \$3,539.

1999: Patten SB. University of Calgary Research Grants Committee. Short-term Project Operating Grant. Post-natal Depression in a Community Agency in Calgary. \$5,540.

1999 - 2002: Patten SB. A.H.F.M.R. Senior Investigator Research Allowance. Population Health Investigator Renewal. \$10,000.

1999-2000: Patten SB. A.H.F.M.R. Health Research Fund. Prevention of Depression. \$67,270. (Principal Investigator).

1999: Patten SB. Headwaters Health Authority. Health Behaviours/Client Satisfaction/Service Use Survey: \$36,000. (Co-principal Investigator). Jan-May.

1998-1999: Patten SB. Calgary Regional Health Authority. Internal Research and Development Grant: \$10,000. A Comparison of Two RDD Strategies for Community Surveys in Calgary, Alberta.

1998 - 2002: Patten SB. Eli Lilly Canada. Zyprexa Research Fund. Evaluation of Effectiveness of an Early Onset Psychosis Clinic. \$349,670. (Principal Investigator = Dr. D. Addington)

1998: Patten SB. AHFMR Travel Grant. For Travel to the American Psychiatric Association Meeting, Toronto, Ontario.

1998: Patten SB. Government of Alberta Summer Temporary Employment (STEP) Program position for Robin Oldfield, May - August.

1998: Patten SB. Calgary Regional Health Authority Annual Research Funding Competition. \$15,500. Major Depression as a Cost Determinant in Multiple Sclerosis.

1998-1999: Patten SB. Calgary Regional Health Authority. Internal R & D Grant: \$5000. A Community Study of the Determinants of Major Depression.

1997-1998: Patten SB Calgary Regional Health Authority. Internal R & D Grant: \$5000. The Predictive Value of Dysgraphia and Constructional Apraxia for Delirium in Psychiatric Inpatients. This was a medical student research project, where I was the supervisor.

1997: Patten SB. Lam Foundation Endowment. \$2,000. (Pilot Study for) A Case-control Study of the Determinants of Delirium in a Psychiatric Inpatient Population: Pilot Study.

1997-1999: Patten SB. Alberta Heritage Foundation for Medical Research. Mental Health Studentship: Ms. Dina Busch \$15,500 per annum (24 months, renewable).

1997-1998: Patten SB. N.H.R.D.P. \$31,080 (with co-investigators: J Arboleda-Florez and H. Holley). The epidemiology of major depression among Canadians.

1996-1999: Patten SB. Alberta Heritage Foundation for Medical Research Establishment Grant: \$50,000 per annum.

1996-1997: Patten SB. The University of Calgary Degenerative Diseases Endowment: \$2,900. An evaluation of the impact of selection bias on a prospective cohort study of the incidence of delirium in psychiatric inpatients.

1996: Patten SB. Travel Grant: \$1,320. University of Calgary Research Grants Committee: for travel to World Psychiatric Association Meeting, August 22-28, Madrid, Spain. 1996.

1995-1997: Patten SB. The University of Calgary Research Grants Committee, Starter Grant: \$7,825. Associations Between Depressive Disorders and Non-Psychiatric Diagnoses: A Pilot Study Using Hospital Case-Summary Data.

1995: Patten SB. Ruth Rannie Memorial Endowment Fund: \$5000. An Instrument to Diagnose Organic Depressive Disorders, A Pilot Study.

1995-1997: Patten SB. MRC/PMAC: \$115,008 (MRC Contribution), \$460,032 (Industry Contribution). Double-blind, placebo controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. Addington D (Principal Investigator), Patten S

1995-1996: Patten SB. Alberta Mental Health Research Fund: \$32,618. The Incidence of

Delirium in Acute Care Psychiatric Units. (Principal Investigator in a Study Co-Authored by J. McCrudden and J. Arboleda-Florez)

1993-1994: Patten SB. Calgary General Hospital Research and Development Committee Research Grant: \$4,986. Prescription drugs as risk factors for depression: A series of case-control investigations. (With Dr. E.J. Love)

1992-1993: Patten SB. Calgary General Hospital Research and Development Committee Research Grant: \$15,000. Drugs and Depression: A Prospective Cohort Study of Medical Inpatients. (With Dr. E.J. Love)

1992-1993: Patten SB. Canadian Psychiatric Research Foundation Research Grant: \$21,500 (Royal Bank Award). Drug and Depression: A Prospective Cohort Study of Medical Inpatients. (With Dr. E.J. Love)

1991-1994: Patten SB. Alberta Heritage Foundation for Medical Research Allowance, \$3,000 per annum.

1988-1989: Patten SB. MSI Foundation, Research Grant. Clinical Evaluation of the Modified Mini-Mental State Examination: \$9,000. (With Dr. C.J. Lamarre)

IX. INVITED PRESENTATIONS

- 1.
2. The Epidemiology of Mood Disorders, an International Perspective. 6th Qatar International Mental Health Conference. Nov 30th – Dec 2nd 2017. Doha, Qatar.
3. Medical-Psychiatric Comorbidity. 6th Qatar International Mental Health Conference. Nov 30th – Dec 2nd 2017. Doha, Qatar.
4. Light, Exercise and Yoga: Evidence Based Treatments for Depression. Prevention and Longevity Conference – University of Calgary, January 27, 2017.
5. Seasonal Affective Disorder. Lunch and Learn. University of Calgary, January 18, 2017.
6. Depression in MS. 2016 endMS Conference. Toronto, Ontario. December 8, 2016 (Invited Keynote Presentation)
7. Knowledge Synthesis of National Survey Data Sets. Co-presented with Ruth Diaz. Alberta Health Services ARES Team. Southport, Alberta Health Services. November 25, 2016.
8. Fighting Stigma in Health Professionals. Campus Alberta 2016 Symposium. Neuroscience Innovation for Improving Brain Health. October 20-21, Edmonton.
9. Major Depression Epidemiology in Canada. University of British Columbia Research Rounds. Vancouver, May 11, 2016.

10. DSM-5 – The good, the bad and the ugly. Keynote presentation. Atlantic Psychiatric Conference. Charlottetown, PEI. May 26-27th 2016
11. Depression in MS. Multiple Sclerosis and Neuroinflammation update for family physicians. May 7th and 8th, 2016. Jasper, Alberta, Canada.
12. Major Depression – Epidemiology in Canada (Keynote Speaker). 2015 CRDCN National Conference. Research and Public Policy: Health, Economic and Social Perspectives. Toronto, Ontario. November 5 – 6, 2015.
13. Data Synthesis Strategies for Major Depression Epidemiology. “Big Data” Symposium. Campus Alberta Neuroscience Symposium 2015. Calgary. October 28-30, 2015.
14. Academic Publishing. Canadian Psychiatric Association, Junior Investigator Research Colloquium 2015. Vancouver, October 2, 2015.
15. (Keynote co-presented with Dr. Rivian Weinerman). Mental Health Commission of Canada: Stigma and Research, How the Truth Shall Set us Free. Keynote presentation. Alberta Psychiatric Association Annual Meeting March 20-22, 2015. Banff.
16. Presenter. What is the magnitude of the problem? IHE Consensus Development Conference on Improving Mental Health Transitions. November 4, 2014. Edmonton, Alberta.
17. Parkinson Alberta Education Event. Mental Health in Parkinson’s Disease. October 18th, 2014. Red Deer, Alberta.
18. Invited Panelist: The Nature of Risk – What Happens If We Get it Wrong (What Keeps Me Up at Night). My presentation: Plague and Pestilence. Calculating Risk and Its Influence on Public Policy. The Institute of Public Policy. University of Calgary Downtown Campus. June 23, 2014.
19. Invited Lecture: Simulation as a Strategy for Understanding Major Depression Epidemiology University of Groningen, Department of Psychiatry. Groningen NL. March 24, 2014.
20. Closing Theme Presentation. Do psychotropic medications improve mental health in the population? And, why is such a simple question so hard to answer? Tenth International Conference of the European Network For Mental Health Service Evaluation (ENMESH). Verona, Italy. October 3rd-5th, 2013.
21. Invited Lecture. CPA Lunch and Learn: Delving into DSM-5: A First Look. Symposium Presenters Darrel A. Regier, Joel Paris and **Scott Patten**. Canadian Psychiatric Association’s 63rd Annual Conference. Ottawa. September 27th, 2013.
22. Depression and Anxiety in MS. EndMS Program, Alberta (Teleconferenced to University of Alberta and Lethbridge). July 23, 2013.
23. Fireside Chat: Major Depression Epidemiology, Implications for Health Policy. CHNET-WORKS. A project of the Population Health Improvement Research Network, University of Ottawa. This was a national on-line seminar, January 22, 2013.

24. Mental Health in MS. Drumheller Health Centre MS Support Group. Drumheller AB, November 27, 2012.
25. Simulation as a Strategy for Linking Epidemiologic Data to Health Policy Decisions. Symposium at the Canadian Academy of Psychiatric Epidemiology, Montreal, QC. September 27, 2012.
26. Major Depression Epidemiology in Canada. Clinical Rounds. Alberta Hospital Edmonton. April 27, 2012.
27. Major Depression Epidemiology: Trying to See the Mountain Through the Fog. Psychosocial Axis Seminar Series. McGill University/Jewish General Hospital. Montreal, QC. March 14th, 2012.
28. Depression and Anxiety in MS. Knowledge and Nurturing for MS Nurses. Feb 3rd – Feb 5th 2012. Vancouver B.C.
29. Depression and Work Impairment. Occupational Health Physicians of Edmonton 3rd Wednesday Club. University of Alberta, Faculty Club. December 21, 2011.
30. Affective Disorders in MS. Invited presentation as part of a Symposium: Affective and Cognitive Disorders in MS. Consortium of MS Clinics Annual Meeting. San Antonio TX, June 1-5th, 2010.
31. Mental Health Issues in MS: A population Health Perspective. EndMS Summer School. May 17-27th, 2010. Halifax, Nova Scotia.
32. Surveillance Methods for Epidemiological Data to Monitor Mental Health in Alberta. Invitational Symposium: "Using Data to Predict the Future." Banff Centre March 29th & 30th, 2010. Banff, Alberta.
33. A Heartfelt sadness. What is the connection between depression and heart disease? CIHR Café Scientifique presentation. March 6, 2010. Windsor, Ontario, Canada.
34. Major depression in the workplace and in the population. The presentation was made at the "Rogers Mental Health Summit", December 9, 2009. Vancouver, BC.
35. The threshold problem. Evidence-based Perspectives on Detection and Clinical Care of Depression: Critique and Conversation. October 22, 2009. Montréal, Quebec, Canada.
36. More care or more consistent care? Evidence from simulation models. Evidence-based Perspectives on Detection and Clinical Care of Depression: Critique and Conversation. October 23, 2009. Montréal, Quebec, Canada.
37. Mood Disturbance in MS. Why, prevalence, presentations, assessment, treatment. Alberta MS Project Mental Health Meeting. Canmore, Alberta. June 20, 2009.
38. What is depression and how common is it? A Consensus Development Conference on Depression in Adults: How to Improve Prevention, Diagnosis and Treatment. Calgary, Alberta. October 15-17th, 2008.

39. What further research is needed in the field? A Consensus Development Conference on Depression in Adults: How to Improve Prevention, Diagnosis and Treatment. Calgary, Alberta. October 15-17th, 2008.
40. Major Depression and the Workplace: Implications of Epidemiologic Research for Disability and Dysfunction. Economics of Depression in the 21st Century. 6th Annual Edmonton Mood and Anxiety Day. September 26, 2008.
41. History and Methods of Psychiatric Epidemiology. Strengthening Psychiatric Epidemiology and Primary Mental Health Care in Nepal. April 15-16th, 2008. Kathmandu, Nepal.
42. Primary Mental Health Care in Canada. Strengthening Psychiatric Epidemiology and Primary Mental Health Care in Nepal. April 15-16th, 2008. Kathmandu, Nepal.
43. Depression & Anxiety in Multiple Sclerosis. Neuroprotection in MS. Knowledge and Nurturing for MS Nurses. Jan 24 - 26, 2007. Victoria, BC.
44. Depression in MS. MS Society of Canada, Calgary Chapter, Speaker Series. Calgary, October 3, 2007.
45. Psychiatric Epidemiology of MS. National MS Society Task Force on Epidemiology. New York City, September 10th and 11th, 2007.
46. Epidemiology of Depression in MS. Component of a symposium entitled: Affective Disorders in MS. Consortium of MS Centers/ACTRIMS Annual Meeting. Washington DC. May 31st, 2007.
47. Workshop: From the Population to the Patient. Can Epidemiological Data Help to Guide Clinical Care? Mood Day: Mood Disorders Throughout the Lifespan. Calgary, Alberta, February 9, 2007.
48. The Impact of Comorbidity on Psychiatric Epidemiology. CAPE 2006 Annual Scientific Symposium. November 9, 2006. Toronto.
49. Depression in MS. Multiple Sclerosis Society of Canada, Calgary Chapter. Speaker Series. Calgary, Alberta, October 4, 2006.
50. Treatment of Somatic Symptoms in Fibromyalgia. First Italian Congress of Federdolore. Cascina Terme (Pisa), June 16-18, 2006.
51. Mood Disorders in Alberta, Canadian Mental Health Association (Pincher Creek). Pincher Creek, Alberta. April 7, 2006
52. CANMAT Mood and Anxiety Forum. Workshop: Tips and Tricks in data presentation. Calgary, Alberta. November 19th, 2005
53. CCHS 1.2. What have we learned and where do we go from here. Thematic symposium presentation. Canadian Academy of Psychiatric Epidemiology. Vancouver, BC. November 3, 2005.
54. Major Depression Epidemiology in Canada. Alberta Psychiatric Association Annual Meeting, Banff, April 2, 2005.

55. Plenary Lecture. Epidemiological Modeling and Major Depression Pharmacoepidemiology. International Federation of Psychiatric Epidemiology, 10th International Congress. Bristol. September 12, 2004.
56. Neurobehavioral Disorders in MS, and their Treatment. European Federation of Neurological Societies. Paris. September 4, 2004
57. Career Panel and Discussion. Heritage Your Researcher Summer Program (sponsored by AHFMR). Presented in Calgary, Alberta on July 28, 2004
58. Bernoulli's Lens. Keynote Address. Spring Research Day. Department of Psychiatry. Queens University, Kingston, Ontario. June 14, 2004.
59. Population Mental Health Survey. Alberta Health & Wellness (Hot Topics). Presented in Edmonton, Alberta on June 11, 2004.
60. Epidemiological Incidence-Prevalence Models for Major Depression. Institute of Health Economics. Presented in Edmonton, Alberta, on June 11, 2004.
61. Clinical Management of Depression. 39th Annual Meeting of the Canadian Congress of Neurological Sciences. Presented in Calgary, Alberta on June 8, 2004.
62. Major depression epidemiology in multiple sclerosis. Consortium of Multiple Sclerosis Centers. The Art and Science of Multiple Sclerosis. Toronto, June 2-6, 2004.
63. Depression in MS. 5th Annual Western Canada MS Nurses Update. Vancouver, BC. April 30 to May 2, 2004.
64. Mental Illness in the Alberta Population. Calgary Health Region – Calgary Health Research Day. Presented in Calgary, Alberta on April 24, 2004
65. Approach to Patients with Somatoform Disorders. Neuroscience Grand Rounds, University of Calgary. Presented in Calgary, Alberta, on February 27, 2004
66. Somatization Disorder & Hypochondriasis. Presented at the Shared Mental Health Conference, University of Calgary, Faculty of Medicine, Calgary, Alberta, January 30, 2004.
67. Emotions in MS. Multiple Sclerosis Society, Wellness Seminar Series. CNIB February 10, 2003.
68. Depression in Medical Illness. Solutions to Family Practice Challenges. Waterton Park, Alberta. June 7th – 9th, 2002.
69. Pathophysiology and Treatment. Cognitive and Psychiatric Disorders in Multiple Sclerosis. Sero Symposia, International. Taormina, Italy, June 1-3rd, 2002.
70. Etiological Impact of Treatment. Cognitive and Psychiatric Disorders in Multiple Sclerosis. Sero Symposia, International. Taormina, Italy, June 1-3rd, 2002.
71. Treatment of Mood Disorders in Multiple Sclerosis: Pharmacotherapy. Conference on Identification and Treatment of Mood Disorders in MS. New York City, January 17th-18th, 2002.

72. Nature of Mood Disorders in Multiple Sclerosis. Lillian Goldman Consensus Conference on Identification and Treatment of Mood Disorders in MS. New York City, January 17th-18th, 2002.
73. Management of Mood and Affect. Cognitive Function and Quality of Life in Multiple Sclerosis. Research Advances and Future Perspectives. Banff, January 11-12, 2002.
74. Depression. Living Well with Multiple Sclerosis. MS Society of Saskatchewan Family Meeting. Regina October 27, 2001.
75. Depression. Mental Health Awareness Week Public Lecture. Sponsored by the Alberta Mental Health Board. October 10, 2001.
76. Depression in Lupus. The Alberta Lupus Society Symposium. Calgary, April 21, 2001.
77. Depression. Multiple Sclerosis Preceptorship Symposium. Canadian Consortium of Multiple Sclerosis Clinics. University of Calgary, March 2-5, 2001.
78. The Clinical Epidemiology of Delirium in Psychiatric Inpatients. Special Grand Rounds. Department of Psychiatry, Queen's University. Kingston, Ontario. August 18, 2000.
79. Delirium in Psychiatric Inpatients. Special Grand Rounds. Department of Psychiatry, Queen's University. Kingston, Ontario. July 21, 1999.
80. Plenary Lecture: Bias in Psychiatric Epidemiology. Canadian Society for Epidemiology and Biostatistics 1998 Student Meeting. Department of Community Health Sciences, University of Calgary, November 1998.
81. Can Drugs Cause Depression? A Review of the Evidence. Mood Disorder Association of Alberta Workshop. Medicine Hat College, September 1998.
82. Drug-induced Depression. Alberta Psychiatric Association Annual Meeting. Banff, March 1996.

X. GRADUATE STUDENT SUPERVISION AND EXAMINATION

i) Post-Doctoral Students

Supervision

Sloka, J. Scott. Smoking and the Natural History of Multiple Sclerosis. AHFMR Clinical Fellowship 2008 – 2010. (*co-supervisor* with Drs. Wee young & Luanne Metz).

Kassam, Aliya. Evaluation of the Mental Health Commission of Canada's "Opening Minds" Anti-stigma Initiative. 2009 – 2011. Dr. Kassam is now a full-time faculty member at the University of Calgary.

ii) Ph.D. Students

Supervision and Co-Supervision

Kamala Adhikari Dahal (Co-Supervisor with Dr. Amy Metcalfe). Examining Neighbourhood Socioeconomic Status, Anxiety and Depression during Pregnancy and Preterm Birth. Recipient of a Vanier Scholarship and AIHS graduate scholarship.. July 2017 -

Michael Sanderson. Began program in 2015. Prediction of Suicide.

Vallerand, Isabelle (Co-supervision with Dr. Andrew Bulloch). Began program in 2013. Mental Disorders in the THIN Database: Age of Onset and Mortality. Successful defense April 1, 2016. Subsequently admitted into the MD program, U of C, Leaders in Medicine Program.

Freiheit, Elizabeth (Co-Supervisor: Dr. Colleen Maxwell), assumed this role late in Elizabeth's program (January 2015): Frailty, Cognition, and Depression in Older Subjects with Coronary Artery Disease. Successful defense September 15, 2015. Currently Managing director, with SABER (Statistical analysis in Biomedical and Educational Research), housed within the Biostatistics Department at the School of Public Health, University of Michigan.

Fiest KM (Co-supervisor with Dr. Nathalie Jetté). 2011-2014. Depression in Epilepsy. (Ms. Fiest is supported by an AIHS Studentship Award). Successful completion of candidacy examination on March 27th, 2013 & Successful dissertation defense on April 2nd, 2014. Now full time faculty (Assistant Professor) with Critical Care Medicine at U of C.

Cepoiu-Martin, Monica (Co-Supervisor with Dr. Colleen Maxwell) 2010 – 2016. Transitions of Seniors with Dementia in the Continuing Care System. (Ms. Cepoiu-Martin is supported by an AXA Doctoral Award). Successful dissertation defense on August 31, 2016.

Berzins, Sandy (Co-Supervised with Dr. Andrew Bulloch). Determinants of Depression in Multiple Sclerosis. 2008 – 2014. (Ms. Berzins was supported by an EndMS Studentship. Successful Defense July 14th, 2014. Appointed Director, Research & Outcomes at Calgary Counselling Centre, December 2014.

Khaled, Salma. The Association between Cigarette Smoking and Major Depression in the Canadian Population: a Longitudinal Investigation of Competing Non-causal and Causal Models. 2006 – 2011 (Ms. Khaled supported by an AHFMR Studentship). Successful defence, December 5, 2011. Now, full time faculty (Assistant Professor) at the University of Qatar.

Specogna, Adrian (Co-Supervisor, with Dr. Michael Hill), Community Health Science, Evidence for the Appropriate Testing and Implementation of New Therapies for Intracerebral Hemorrhage in Canada. Started program September 2006, Successful Defence of dissertation April 23, 2012. Now an Assistant Professor at the University of Central Florida.

Vik, Shelly (Co-Supervisor with Dr. David Hanley). Alternative Medicine Use in Persons with Osteoporosis and Osteopenia. Current Student (supported by CIHR Studentship) – started program, January 2003. Successful dissertation defence: September 2007. Now a senior analyst with Alberta Health Services.

Wang Jian Li (Co-Supervisor with Dr. Reg Sauve). Doctorate Program. Alcohol as a Risk Factor for Major Depression in the Canadian Population. Successful dissertation defence: July 31, 2000. Now a Full Professor at the University of Ottawa.

Member of Supervisory Committee

Hetherington, Erin. (Co-Supervisors: Suzanne Tough, Sheila McDonald). Maternal Mental Health and Social Support. Dec 2015 – present. Successfully completed her Candidacy exam on May 20, 2016.

Ejaredar, Maede (Supervisor Deborah Dewey). Neuropsychological Outcomes of Prenatal Exposure to Bisphenol A and Phthalates in Young Children: The Modifying Role of Maternal Psychological Distress. Sept. 2012 – Present. *Candidacy exam passed successfully on May 13, 2015.*

Roy, Amrita. Supervisor, Dr. Billie Thurston. Understanding depression among pregnant aboriginal women. 2009 – 2016. Successful defense February 12, 2016.

Brown, Lauren. University of Alberta. Supervisor, Dr. Jeff Johnson, Public Health Sciences. 2006 – 2010 (successful defence June 1, 2010). Cardiovascular disease and cardiovascular risk factors in people with Schizophrenia.

Davison, Karen. Co-Supervisors, Dr. Marja Verhoef & Dr. Bonnie Kaplan: The Determinants of Food Choice in Individuals with Mood Disorders – Started September 2002 – 2009 (Successful completion November 30, 2009)

Alison Supina. Supervisor, Dr. Colleen Maxwell. The Risk of Death, Hospitalization and Institutionalization with Concurrent Use of Cholinesterase Inhibitors and Contraindicated Medications in Alzheimer's Disease: 2005 – 2008.

Crisanti, Annette. A Descriptive Longitudinal Cohort Study of Involuntary Psychiatric Inpatients. Successful Defense, January 1998. Supervisor, Dr. E.J. Love.

Member of Examining Committee

Anna Ymkje. Assessment of Dissertation for Magna Cum Laude Designation. University of Groningen. February 21, 2018.

Leanne Quigley (Clinical Psychology). PhD Thesis: An examination of executive control biases and rumination in currently, remitted and never depressed individuals. University of Calgary, February 3, 2016. External Examiner.

Zaheed Damani. A comprehensive case study of an orthopedic surgery central intake service in the Winnipeg Regional Health Authority: A single-entry model to manage waiting times for total joint replacement surgery of the hip and knee. University of Calgary. Neutral Chair. June 21, 2016.

External reader for *Cum Laude* designation: “Data-driven subtypes of major depressive disorder.” PhD Thesis. Hanna Maria van Loo. Promotors RA Schoevers & Peter de Jonge. University of Groningen. May 22, 2015.

Boffa, Jody. PhD Candidacy. Department of Community Health Sciences, University of Calgary, July 4th 2013. Examination Committee Member.

Epp, Amanda (Clinical Psychology). Cognitive vulnerability to depression: Investigating the role

of culture. Internal/External Examiner. June 25th, 2013.

Martin, Rachel (Clinical Psychology). Reducing stigma against depression: Evaluation of a metacognitive intervention targeting processes of stigmatization. Internal/External Examiner, PhD Dissertation Defense, June 18, 2012.

Anhold, Michelle (Medical Science Graduate Program, Veterinary Medicine, University of Calgary). External Examiner, PhD Candidacy. November 4, 2010.

Lemstra, Mark (University of Saskatchewan). External Examiner, PhD Defence, August 13, 2008.

Baroud, Radwan (Community Health Sciences). Neutral Chair, PhD Dissertation Examination, February 26, 2007.

Haubert, Lauren (PhD Program, Clinical Psychology). Candidacy Examination. June 5th, 2006.

Dean, Stafford (Community Health Sciences). Neutral Chair. Repeat Candidacy Examination, September 28, 2004.

Woolcott, Christy (Community Health Sciences). Examiner, Doctoral Candidacy Examination. February 13, 2002.

Backs-Dermott, Barbara. PhD (Clinical Psychology, University of Calgary). Internal External Examiner, Doctoral Thesis Defense. December 19, 2001.

Norris, Colleen. PhD (Public Health Sciences, University of Alberta). External Examiner, PhD Defense, December 12, 2001.

Mitton, Craig. PhD (Community Health Sciences). Chair, Doctoral Thesis Defence. September 5th, 2001.

Carruthers, Patricia. PhD (Medical Science). Chair, Doctoral Thesis Defence. December 11, 2000.

Mitton, Craig. PhD Candidacy Examination (Community Health Sciences): June 18th, 1999.

iii) Masters Students

Supervision

Diaz, Ruth. The healthy immigrant effect for major depression in Canada. 2014 – 2017. Successful defense March 29th, 2017.

Hirsch, Lauren (co-supervised with Dr. Tamara Pringsheim). Trends in second-generation antipsychotics, and associated adverse effects in the Canadian Health Measures Survey. 2014 – 2016. Successful defense June 3rd, 2016. Now in Leaders in Medicine (MD) program.

Doktorchik ,Chelsea (co-supervised with Shaharise Premji - Nursing). Temporal Changes of Biological and Psychosocial Responses to Stress in Women Who Delivered Preterm Infants. 2014- 2017. Successful thesis defense January 12, 2017.

Omid Javizian (co-supervised with Marcus Koch). Smoking and MS progression. 2014-present.

Wiens, Kathryn. Temporal trends in youth mental health in Canada. 2014-2016. Successful defense on June 22, 2016. Now a PhD student, University of Toronto.

McDonald, Keltie. Epidemiological assessment of bipolar disorders in Canada. 2013-2015. Successful defense on April 29th, 2015. Now a PhD student, Department of Psychiatry, Oxford University, UK.

Roberts, Jodie (Co-supervisor with Dr. Nathalie Jetté). Physical activity, smoking, and other health-related behaviors in Canadians with epilepsy: are trends changing over time? 2012-2014. Successful defense May 30th, 2014. Now in the MD/Leaders in Medicine program at the University of Calgary.

Amoozegar, F (Co-supervisor with Dr. Nathalie Jetté). Current Student (Co-supervised with Dr. Nathalie Jetté). 2011 – 2014. Depression in Migraine. Successful defense April 16, 2014. Now Clinical Faculty at U of C.

Beck, Cynthia. Preventive Health Care Among Canadian Adults with Schizophrenia and Related Disorders. Successful defense on December 18, 2013. Subsequently, Assistant Professor at U of C (Psychiatry, now retired).

Reyes, Ryan. The Impact of Residual Symptoms on the Recurrence of Depression: A Population-based Study, 2011 – 2013. Successful defense on September 11, 2013. Now working as an analyst at the Alberta Health Quality Council.

Modgill, Geeta, Master's Degree Program. Investigating the Association between Migraine and Major Depression. A Retrospective Cohort Study. 2006 – Successful defence Dec. 14th, 2010. Now a research assistant with Alberta Health Services.

Yelland, Jennifer, Master's Degree Program. Descriptive Epidemiology of Schizophrenia in Canada. 2007 – Successful thesis defence August 14th, 2010. Employed with Alberta Health Services.

Kassam, Aliya. Master's Degree Program. Pharmacoepidemiology of Benzodiazepine use in Canada. Successful dissertation defence: January 24, 2005. Subsequently a PhD student under the supervision of Dr. Graham Thornicroft at the Institute of Psychiatry, Kings College, London, UK, Post-doctoral student at U of C (funded by the Mental Health Commission of Canada) and Assistant Professor, University of Calgary as of April 1, 2010. Now full-time faculty member at U of C.

Williams, Jeanne. Master's Degree Program. An epidemiological study of the impact of a population based early psychosis program in Calgary. Supported by an AHFMR Studentship. Successful thesis defence, July 2001. Now, research assistant at U of C.

Lavorato, Dina. Master's Degree Program. Drugs and Depression in the 1994 Canadian National Population Health Survey. Supported by an AHFMR Studentship. Successful Thesis Defence, June 11, 1999. Now, research assistant at U of C.

Member of Supervisory Committees

Heisler, Courtney (Community Health, Dalhousie University). Mood and anxiety symptoms: Potential risk indicators for major mood disorders among offspring of bipolar parents. Supervisors: Dr. Adrian Levy and Dr. Anne Duffy. Successful defense August 18, 2017.

Jasau Carranza, Yamile (Medical Sciences). Effects of rTMS and Possible Predictors of Response in Youth with Treatment Resistant Depression. Supervisor, Dr. Frank MacMaster. Successful defence October 14, 2016.

Bolo, Carmelle Angelie (Community Health Sciences). Workplace factors and the transition to major depression in a representative sample of Alberta employees. Supervisor: Dr. Jian Li Wang. Successful defense December 2, 2014.

Nash, Tina. (Community Health Sciences). Life in the shadows. Supervisor: Dr. Wilfreda Thurston. Successful Defense October 17th, 2016.

Goodarzi, Zahra (Community Health Sciences). Understanding the barriers to guideline use for depression & anxiety in patients with Parkinson's disease and dementia. Supervisor: Dr. Jayna Holroyd-Leduc. Successful defense June 23, 2016.

Prentice, Jennifer Lynn (Clinical Psychology). Conceptualizing stigma: the development and preliminary validation of a cross-cultural scale to measure stigma related to depression. Supervisor: Keith Dobson. Successful defense August 27, 2014.

Courtright, Allegra (Medical Sciences). Effect of Aerobic Exercise on Hippocampal Volume in Depressed Adolescents. Supervisor: Frank McMaster. Successful defense June 13th, 2014.

Mahnke, Devin. (Medical Sciences). Cerebellar Vermis Volume in Bipolar Disorder. Supervisor: Frank McMaster. Successful defense on April 14th, 2014.

Marriott, Brian (Community Health Sciences). Assured Income for the Severely Handicapped (AISH): The Impact of Raising Employment Income Exemption Limits on Employment Rates – A Focus on Recipients with Schizophrenia. Supervisor: Dr. Herb Emery. Successful defense on August 26th, 2013.

Cook, Trevor (Community Health Sciences). Employment changes and depression among the elderly in Canada. Entry into program: September 2009. Successful defense on February 26, 2012.

Gabriel, Adel (Medical Education Graduate Program). The Development and Psychometric Assessment of Instruments to Measure Depression Knowledge and Attitudes Toward its Treatments in Patients Suffering from Non-Psychotic Depression. Supervisor, Dr. Violato. Successful defence of thesis on June 4, 2008.

Tamburrini, Ame-Lia (Community Health Sciences). The Relation between dietary and serum cholesterol and mammographic density as a risk factor for breast cancer. Supervisor, Dr. Christine Friedenreich. Successful defence of thesis on June 16, 2008

Wasil, Bushra. Physician knowledge and attitudes towards post-partum depression. M.Sc.

Program in Community Health Sciences. Supervisor, Dr. Carol Adair. Successful defence of thesis on September 16, 2004

Brandon-Christie, Jennifer. Measurement in Surveillance of Post-operative Infections. Supervisor, Dr. E. Henderson. Successful thesis defence, April 3, 2003.

Vik, Shelly. Medication Compliance Among Elderly Home Care Clients. M.Sc. Program in Community Health Sciences. Supervisor, Dr. Colleen Maxwell. Successful thesis defence on September 11, 2001.

Gasbarre, Lisa. Neuropsychological Functioning in Schizophrenics Compared with that of Other Mentally Ill Subjects. Behavioural Science Graduate Program, successfully completed: 1998. Supervisor, Dr. J. Addington.

Ilkew, Mary. Attitudes About Insomnia and Insomnia Among Older Adults. Successful defence of thesis: April 17th, 2000. Supervisor: Dr. David Hogan.

Member of Examination Committees

Bras, Ana Luisa Lopes. Internal-External Examiner. Master's Veterinary Medical Sciences Program, Epidemiology of Mycoplasma bovis in fanned bison in Western Canada. (Supervisor: Dr. M.K. Claire Windeyer). Successful Defence: September 11, 2013.

Ferri, Mauricio. Evidence-based design in an intensive care unit: End-user perceptions. Master's in Community Health Sciences, Health Services Stream. (Supervisor, Dr. Tom Stelfox). Successful defence June 1, 2015. I was the Neutral Chair.

Collins, Ramona. Internal-External Examiner. Master of Nursing. University of Calgary (Supervisor, Dr. Karen Benzies). Successful Defence October 29th, 2014.

Stowkowy, Jacque. Medical Sciences Master's Program (Supervisor, Dr. Jean Addington). Successful Defence September 12, 2012.

Puchala, Chassidy (University of Saskatchewan). External Examiner, MSc Defence, August 18, 2010. (<http://library2.usask.ca/theses/available/etd-09012010-123917/>)

Sanyal, Chiranjeev (Dalhousie University). External Assessor. August 5, 2009.

Potestio, Melissa (Community Health Sciences). June 20, 2005.

Hyman, Melissa (Community Health Sciences). Neutral Chair. Master's Thesis Oral Examination, May 16, 2005.

Murphy, Brendan (Community Health Sciences). Neutral Chair. Master's Thesis Defense. March 24, 2004.

Duregon, Kelly (Community Health Sciences). Neutral Chair. Neutral Chair. Master's Thesis Defence. September 23, 2003.

Raj, Sakina (Community Health Sciences). Neutral Chair, Master's Thesis Defence, December 18, 2002.

Stoian, Cristina (Community Health Sciences). Neutral Chair, Master's Thesis Defence. March 21, 2002.

XI. PUBLICATIONS/PRESENTATIONS

i) Non Peer Reviewed Publications

1. **Patten SB.** Age of onset of mental disorders. (Editorial). The Canadian Journal of Psychiatry 2017; 62(4):235-236.
2. **Patten SB.** Updated CANMAT Guidelines for Treatment of Major Depressive Disorder (Editorial). The Canadian Journal of Psychiatry 2016; 61(9):504-505.
3. **Patten SB.** Suicide (Editorial). The Canadian Journal of Psychiatry 2016; 61(7):380-381.
4. **Patten SB.** Mental Health in the Canadian Armed Forces: New Data, New Answers and New Questions". The Canadian Journal of Psychiatry 2016; 61: 1Suppl. 4S-6S. (April)
5. Barbui C, Gureje O, Puschner B, **Patten S**, Thornicroft G. Implementing a data sharing culture. Epidemiology and Psychiatric Sciences 2016;
http://journals.cambridge.org/download.php?file=%2F1746_BF321D845188FA9CEBBC32E877F8C586_journals_EPS_S2045796016000330a.pdf&cover=Y&code=18bd3c8c05598a703592b187924f0996
6. **Patten SB.** Bupropion confirmed not to cause weight gain in a real-world clinical population. (Commentary) Evidence-Based Mental Health 2015; 18(2): 57; **E-Pub** doi:10.1136/eb-2014-101978. <http://ebmh.bmj.com/content/18/2/57.full.pdf+html>
7. **Patten SB.** The Canadian Journal of Psychiatry in 2014 and Beyond. The Canadian Journal of Psychiatry 2015; 60(1):1-3.
8. **Patten SB.** Problems from the Past and Prevention for the Future. The Canadian Journal of Psychiatry 2015; 60(1):4-5.
9. Barbui C, **Patten SB.** Antidepressant dose and the risk of deliberate self-harm. Epidemiology and Psychiatric Sciences 2014;23(4):329-331.
10. **Patten SB.** Delicate considerations and blunt instruments. Can J Psychiatry. 2014;59(3):117
11. **Patten SB.** Important Messages for Clinical Care and Health Policy on Suicide (Editorial). The Canadian Journal of Psychiatry 2014; 59(10):509-510.
12. **Patten SB.** Support, patience, and expectancy: therapeutic options alongside intensified treatments for depression? Canadian journal of psychiatry. 2014; 59(7): 347-8.
13. **Patten SB.** The Global Burden of Disease 2010 update: keeping mental health in the spotlight. Epidemiology and psychiatric sciences 2014; 23 (3): 255-257.
14. Kassam A. and **Patten S.** Quantitative Analysis of the 'Mental Illness and Addictions: Understanding the Impact of Stigma' Program. Calgary: Mental Health Commission of Canada,

2011. Located at <http://www.mentalhealthcommission.ca/English/initiatives-and-projects/opening-minds?terminal=39>
15. Modgill G. and **Patten S**. British Columbia's Interior Health Authority's Usage of the Ontario Central LHIN Anti-stigma Training Program Evaluation Report. Mental Health Commission of Canada, 2011. located at <http://www.mentalhealthcommission.ca/English/node/5180?terminal=39>).
 16. GBD 2001 Country Collaboration (including **Patten SB**¹). GBD 2010 country results: a global public good. *Lancet* 2013; Volume 381, Issue 9871, Pages 965-970
 17. Hogan DB, Warner J, **Patten S**, Godlovitch G, Mehina E, Dagenais L, Fiebelkorn G, deRobles P, MacKean G, Casselman L, Jette N, Pringsheim T, Korngut L, Johnston M. Ethical and Legal Considerations for Canadian Registries. *Canadian Journal of Neurological Sciences* 2013; 40 (Suppl.2): S5-S23.
 18. Korngut, L. et al. (**Scott Patten**, as acknowledged contributor). Canadian Neurological Registry Best Practice Guidelines and Toolkit. <http://canadianregistrynetwork.org>. Posted online Feb, 2013.
 19. **Patten SB**. Prevalence inflation. *Canadian Journal of Psychiatry* 2012;57(11):649-50.
 20. Pringsheim T, Doja A, Belanger S, **Patten S**, groupe des lignes directrices de la Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA). Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l'utilisation d'antipsychotiques de deuxième génération chez les enfants et les adolescents. *Paediatr Child Health* 2012; Suppl. B: 22B-30B.
 21. Fiest KM, **Patten SB**. The multiple sclerosis depression rating scale. *Expert Review of Neurotherapeutics* 2012; 12: 1053-1055.
 22. Wild, T.C., Hodgins, D., **Patten, S.**, Colman, I., el-Guebaly, N., & Schopflocher, D. (2010). *Measuring addiction and mental health problems in Alberta*. Technical report produced for the Norlien Foundation by the Universities of Alberta and Calgary.
 23. **Patten SB**. Commentary on: "Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review." 2012; 15: 6.
 24. The CAMESA Guideline. Pringsheim TM et al. (**Patten** as member of the CAMESA group). Evidence-Based Recommendations for Monitoring Safety of Second Generation Antipsychotics in Children and Youth. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2011; 20(3): 218–233. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143700/pdf/ccap20_3p218.pdf
 25. The CAMESA Guideline. Ho J. et al. (**Patten** as member of the CAMESA group). Management Recommendations for Metabolic Complications Associated with Second Generation Antipsychotic Use in Children and Youth. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2011; 20(3): 234–241.

¹ <https://www-clinicalkey-com.ezproxy.lib.ucalgary.ca/content/player/stream/1-s2.0-S0140673613602834?fileName=01406736/S0140673613X60167/S0140673613602834/mmc1.pdf>

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143701/pdf/ccap20_3p234.pdf

26. **Patten SB.** (Book Review). Health Measurement Scales: A Practical Guide to their Development and Use. Fourth Edition. Canadian Journal of Psychiatry 2011; 56: 187-88.
27. Arana M, **Patten SB.** Trastornos Musculo-Esqueléticos, Psicopatología. In: Musculoskeletal disorders, psychopathology and pain. Report: Secretary of State for Social and Health Security of the Government of Spain. Online at <http://www.seg-social.es/prdi00/groups/public/documents/binario/143942.pdf>
28. **Patten SB.** (Book Review). The WHO World Mental Health Surveys: Global Perspectives on the Epidemiology of Mental Disorders. Canadian Journal of Psychiatry 2009; 54: 113-114.
29. van Til L, Pranger T, Pedlar D, and the research team: “Workplace reintegration of Veterans with mental disorders” (incl. **Patten SB**). Literature review of work and mental disorders. Research Directorate Research Report, Cat. No. V32-232/2010E-PDF, Veterans Affairs Canada, 2010.
30. Gilmour H, **Patten SB.** Depression at Work. Perspectives on Labour and Income. Statistics Canada. Winter 2007, 57-69.
31. **Patten SB.** MS and Mental Wellness – Most problems are manageable. COMPASS 2007, (8)1:3-4.
32. Gilmour H, **Patten SB.** Depression and Work Impairment. Health Reports 2007, Vol.18(1):9-22.
33. **Patten SB.** (Book Review). International Outcome Measures in Mental Health. Canadian Journal of Psychiatry 2007; Vol 52(1):884.
34. **Patten SB.** Mental Health in MS – How to Recognize and Manage Common Syndromes. Neuro/Transmission 2007;8(1): 4-7.
35. **Patten SB.** Distance Technologies in the Prevention and Treatment of Depression. Sociedad Iberoamericana de Información Científica (SIIC), 2005. <http://www.siicsalud.com/dato/dat041/05106006.htm>
36. Barbui C, **Patten SB.** Commentary: Evidence-based Mental Health. Collaborative care involving pharmacotherapy was cost effective for increasing anxiety free days in panic disorder. Evidence-based Mental Health 2003; 8: 126.
37. Vik S, Maxwell C, Hogan D, **Patten S**, Johnson J, Mitchell C, Romonko-Slack L. Determinants and Health Related Outcomes Associated with Nonadherence to Prescribed Drug Regimens: A Comparison of Rural and Urban Home Care Clients. Institute of Health Economics Working Paper #03-02, 2003.
38. **Patten, Scott B.** Personality and mood adaptivity with aging. Geriatrics and Aging 2002; 5(8): 14-17.
39. el-Guebaly N, Atkinson MJ, **Patten S.** Part III-How stressful is the practice of psychiatry? Canadian Psychiatric Association Bulletin 2002; 34: 43-45.

40. Krupp LB, **Patten SB**, Archibald CJ. Fatigue in multiple sclerosis: clinical significance and impact on patient quality of life. IMAG – Information medicale avant-garde, Inc. 2002.
 41. **Patten, Scott B**. Psychosocial aspects of recovery from stroke. *Geriatrics and Aging* 4(7), Sept. 2001, pp. 16.
 42. **Patten, Scott B**. What is the best approach to treating interferon-induced depression in people with multiple sclerosis? *Journal of Psychiatry and Neuroscience* 2001; 26: 66.
 43. **Patten, Scott**. Depression in Lupus. *Lupus Courier* (Lupus Society of Alberta Newsletter) 2000; 1(2). Spring Edition Cover Story.
 44. **Patten SB**, Love EJ. Drug-induced Depression. *Psychiatry Digest* 1998 (April): 4-5
 45. **Patten SB**, Williams JVA, Love EJ. The Risk of Depressive Symptoms Attributable to Medication Exposures in a Medical Inpatient Population. *Psychiatry Digest* 1997 (August): 28-29.
 46. **Patten SB**. Drug-induced Depression. *Dear Colleague* (Care and Cure Publications) 1996; 6.
 47. **Patten SB**, Lauderdale WM: Disturbo Del Sonno Con Ritardo Di Fase Dopo Lesione Traumatica Cerebrale. *Search Psychiatria* 1993; 1(1): 16-17.
 48. **Patten SB**: Refining the Predictive Value of the Dexamethasone Suppression Test, a Chart Review and Application of Bayes' Theorem. *Jefferson Journal of Psychiatry* 1990; 8(1): 39-45. <http://jdc.jefferson.edu/jeffjpsychiatry/vol8/iss1/9/>
 49. **Patten SB**: The Physical Examination in Psychiatry. *Jefferson Journal of Psychiatry* 1988; 2(6): 12-21. <http://jdc.jefferson.edu/jeffjpsychiatry/vol6/iss2/4/>
- ii) **Peer Reviewed Publications**
1. **Patten S**, Williams J, Lavorato D, Wang J, Jette N, Sajobi T, Fiest K, Bulloch A. Patterns of association of chronic medical conditions and major depression. *Epidemiology and Psychiatric Sciences* 2018; 27(1):42-50.
 2. **Patten SB**, Williams JVA, Lavorato DH, Woolf B, Wang JL, Bulloch AGM, Sajobi T. Major depression and second hand smoke exposure. *Journal of Affective Disorders* 2018; 225:260-264.
 3. Shoimer I, **Patten S**, Mydlarski PR. Burnout in dermatology residents: a Canadian perspective. *British Journal of Dermatology* 2018; 178:270-271. <http://onlinelibrary.wiley.com/doi/10.1111/bjd.15549/epdf> . DOI: 10.1111/bjd.15549 (Research Letter)
 4. Bulloch AGM, Williams JVA, Lavorato DH, **Patten SB**. The depression and marital status relationship is modified by both age and gender. *Journal of Affective Disorders* 2017; 223:65-68.
 5. Kowalec K, McKay KA, Patten SB, Fisk JD, Evans C, Tremlett H, Marrie RA. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study. *Neurology* 2017; 89(24):2455-2461.

6. Josephson CB, Gonzalez-Izquierdo A, Denaxas S, Fitzpatrick NK, Sajobi TT, Engbers JDT, **Patten S**, Jette N, Wiebe S. Serotonin reuptake inhibitor use and mortality in epilepsy: findings from a large contemporary linked electronic health records cohort study. *Epilepsia* 2017; 58(11):2002-2009.
7. Bernstein C, Walker J, Fisk JD, Patten SD, Singer A, Lix L, El-Gabalawy R, Hitchon C, Katz A, Walld R, Sareen J, Bolton J. Increased incidence of psychiatric disorders in Immune-Mediated Inflammatory Disease. *Journal of Psychosomatic Research* 2017; 101:17-23.
8. Vallerand IA, **Patten SB**. Systemic retinoids and psychiatric disorders in patients with skin diseases: a multifactorial relationship (Letter to the Editor). *British Journal of Dermatology* 2017; <http://onlinelibrary.wiley.com/doi/10.1111/bjd.16018/epdf> DOI: 10.1111/bjd.16018.
9. McIntyre L, Kwok C, **Patten SB**. The effect of child hunger on educational attainment and early childbearing outcomes in longitudinal population sample of Canadian youth. *Pediatrics and Child Health* 2017 (1-8); (**E-pub**) <https://academic.oup.com/pch/advance-article/doi/10.1093/pch/pxx177/4772971?questAccessKey=a1b6cf2a-1856-44f1-9bdb-fe2aafbe6c52>
10. Marrie RA, Metz L, Fiest KM, **Patten SB**, Jette N, Greenfield J. Discriminative ability of quality of life measures in Multiple Sclerosis. *Quality of Life Outcomes* 2017; 15:246 (1-9). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740906/pdf/12955_2017_Article_828.pdf (**Open Access**)
11. Vallerand IA, Lewison RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, **Patten SB**. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. *British Journal of Dermatology* 2018; 178(1): 76-857; <http://onlinelibrary.wiley.com/doi/10.1111/bjd.15668/epdf>
12. Khenti AMann R, Sapag J, Bobbili SJ, Lentinello EK, van der Maas M, Agic B, Hamilton H, Stuart H, Patten S, Sanches M, Corrigan P. Protocol: a cluster randomised control trial study exploring stigmatism and recovery-based perspectives regarding mental illness and substance use problems among primary healthcare providers across Toronto, Ontario. *BMJ Open*. 2017 Nov 20;7(11):e017044. doi: 10.1136/bmjopen-2017-017044. (**E-pub**) <http://bmjopen.bmj.com/content/bmjopen/7/11/e017044.full.pdf>
13. Marie RA, Walid R, Bolton JM, Sareen J, Walker JR, **Patten SB**, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN. Rising incidence of psychiatric disorders before diagnosis of Immune-Mediated Inflammatory Disease. *Epidemiology and Psychiatric Sciences* 2017; 1-10 <https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B1A629C7C75368BA935FF018411331FF/S2045796017000579a.pdf/div-class-title-rising-incidence-of-psychiatric-disorders-before-diagnosis-of-immune-mediated-inflammatory-disease-div.pdf> doi:10.1017/S2045796017000579 (**E-pub**)
14. McKay KA, Evans C, Fisk JD, **Patten SB**, Fiest K, Berrigan L, Marrie RA, Tremlett H. Disease-modifying therapies and adherence in multiple sclerosis: comparing patient self-report with pharmacy records. *Neuroepidemiology Journal* 2017; 48(3-4):124-130.
15. Jette N, Pham T, Sauro K, **Patten SB**, Wiebe S, Fiest KM, Bulloch A. The prevalence of anxiety and associated factors in persons with epilepsy. *Epilepsia* 2017; 58(8): E107-E110.

16. **Patten SB**, Marrie RA, Carta MG. Depression in Multiple Sclerosis. *International Journal of Psychiatry* 2017; 29(5):463-472.
17. Fiest KM, Hitchon CA, Bernstein CN, Peschken CA, Walker JR, Graff LA, et al. (including **Patten SB**). Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons with Rheumatoid Arthritis. *Journal of Clinical Rheumatology* 2017; 23(8):425-434.
18. Lukmanji S, Pham T, Blaikie L, Clark C, Jette, N, Wiebe S, Bulloch A, Holroyd-Leduc J, Macrodimitris S, Mackie A, **Patten SB**. Online tools for individuals with depression and neurological conditions: a scoping review. *Neurology Clinical Practice* 2017; 7(4): 344-353.
19. Duffy A, **Patten SB**, Goodday S, Weir A, Heffer N, Cipriani A. Efficacy and tolerability of lithium in treating acute mania in youth with bipolar disorder: Protocol for a systematic review. *International Journal of Bipolar Disorders* 2017; 5:22 (1-6)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468355/pdf/40345_2017_Article_92.pdf
20. Tirmizi S N, Khoja S, **Patten S**, Yousafzai AW, Scott R, Durrani H, Khoja W, Husyin N. Mobile based blended learning for capacity building of health providers in rural Afghanistan. *Mhealth*. 2017 Apr 28;3:14. doi: 10.21037/mhealth.2017.04.01.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427181/pdf/mh-03-2017.04.01.pdf>
21. Knaak S, **Patten SB**, Modgill G, Kassam A, Szeto A, Hamer A. Understanding stigma: A pooled analysis of a national program aimed at healthcare providers to reduce stigma towards patients with a mental illness. *Mental Health and Addiction Nursing Journal* 2017;.E-Pub
<http://jmhan.org/index.php/JMHAN/article/view/19/27>
22. Josephson CB, **Patten SB**, Bulloch A, Williams J, Lavorato D, Fiest K, Secco M, Jette N. The impact of seizures on epilepsy outcomes: a national, community-based survey. *Epilepsia* 2017; 58(5): 764-771.
23. Simoneau G, Levis B, Cuijpers P, Ioannidis JPA, **Patten SB**, Shrier I, Bombardier CH, de Lima Osorio F, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Lowe B, Shaaban J, Stafford L, van Weert H, Whooley MA, Wittkamp KA, Yeung AS, Thombs B, Benedetti A. A comparison of bivariate, multivariate random-effects, and poisson correlated gamma-frailty models to meta-analyze individual patient data of ordinal scale diagnostic tests. *Biometrical Journal* 2017; 59(6): 1317-1338.
24. Levis B, Benedetti A, Levis AW, Cuijpers P, Gilbody S, Ioannidis J, Kloda L, McMillan D, **Patten SB**, Shrier I, Steele R, Ziegelstein R, Bombardier C, Crippa JA, de Lima Osorio F, Fann J, Gjerdingen D, Lamers F, Lotrakul M, Loureiro S, Lowe B, Shaaban J, Stafford L, van Weert H, Whooley M, Williams L, Wittkamp K, Yeung, Thombs B. Selective cutoff reporting in studies of the diagnostic accuracy of the Patient Health Questionnaire-9: A comparison of meta-analysis of published results only versus individual patient data meta-analysis of results from all relevant cutoffs. *American Journal of Epidemiology* 2017; 185(10):954-964.
25. Doktorchik C, Premji S, Slater D, Williamson T, Tough T, **Patten S**. Patterns of Change in anxiety and depression during pregnancy predict preterm birth. *Journal of Affective Disorders* 2017; 227:71-78.

26. Specogna AV, Turin TC, **Patten SB**, Hill MD. Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke. *BMC Neurology* 2017; 17:1-8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553779/pdf/12883_2017_Article_930.pdf
27. Morkem R, **Patten SB**, Queenan J, Barber D. Recent trends in the prescribing of ADHD medications in Canadian primary care. *Pharmacoepidemiology and Drug Safety* 2017; 1-8.
<http://journals.sagepub.com/doi/pdf/10.1177/1087054717720719> **(E-Pub)**
28. Pringsheim TM, Ho J, Sarna JR, Hammer T, **Patten SB**. Feasibility and relevance of antipsychotic safety monitoring in Children with Tourette Syndrome: A prospective longitudinal study. *Journal of Clinical Psychopharmacology* 2017; 37(5):1-7
29. Berzins SA, Bulloch AG, Burton JM, Dobson KS, Fick GH, **Patten SB**. Determinants and incidence of depression in Multiple Sclerosis: A prospective cohort study. *Journal of Psychosomatic Research* 2017; 99(2017):156-176.
30. Morkem R, Williamson T, Patten S, Queenan JA, Wong ST, Manca D, Barber D. Trends in antidepressant prescribing to children and adolescents in Canadian primary care: A time-series analysis. *Pharmacoepidemiology and Drug Safety* 2017; 1-7.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.4240/epdf> **E-pub.**
31. Amoozegar F, **Patten SB**, Becker W, Bulloch AGM, Fiest KM, Davenport J, Carrol C, Jette N. The prevalence of depression and the accuracy of depression screening tools in migraine patients *General Hospital Psychiatry Journal* 2017; 48:25-31.
32. Lang M, **Patten SB**, Giese-Davis J, Campbell D. Does age matter? Comparing post-treatment psychosocial outcomes in young adult and older adult cancer survivors with their cancer-free peers. *Psycho-Oncology* 2017. <http://onlinelibrary.wiley.com/doi/10.1002/pon.4490/epdf> **E-pub**
33. Van der Maas, Stuart H, **Patten SB**, Lentinello EK, Bobbili SJ, Mann RE, Hamilton HA, Corrigan P, Khenti A. Examining the application of the opening minds survey in the Community Health Centre setting. *The Canadian Journal of Psychiatry* 2017;
<http://journals.sagepub.com/doi/pdf/10.1177/0706743717719079>. **E-pub.**
34. Enticott JC, Lin E, Shawyer F, Russell G, Inder B, **Patten S**, Meadows G. Prevalence of psychological distress: How do Australia and Canada compare? *Australian & New Zealand Journal of Psychiatry* 2017. <http://journals.sagepub.com/doi/pdf/10.1177/0004867417708612> **E-pub**
35. McIntyre L, Wu Xiuyun, Kwok C, **Patten SB**. The pervasive effect of youth self-report of hunger on depression over six years of follow-up. *Social Psychiatry and Psychiatric Epidemiology* 2017; 52(5):537-547.
36. Pelletier L, Shanmugasaram S, **Patten SB**, Demers A. Self-management of mood and/or anxiety disorders through physical activity/exercise. *Health Promotion and Chronic Disease Prevention in Canada* 2017; 37(5): 149-159.
37. **Patten SB**, Williams J, Lavorato D, Wang JL, Sajobi T, Bulloch A. Major Depression and Non-

- specific Distress Following Smoking Cessation in the Canadian General Population. *Journal of Affective Disorders* 2017; 218:182-187.
38. Woolf B, Lavorato D, Williams J, Bulloch A, **Patten S**. A Comparison of Recommendations and Received Treatment for Mood and Anxiety Disorders in a Representative National Sample. *BMC Psychiatry* 2017. <https://bmcp psychiatry.biomedcentral.com/articles/10.1186/s12888-017-1316-0> **(E-pub)**
 39. McKay KA, Tremlett H, **Patten SB**, Fisk JD, Evans C, Fiest K, Campbell T, Marrie RA. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. *Multiple Sclerosis (Houdmills, Basingstoke, England)* 2017;23(4):588-96
 40. Crooks RE, Bell M, **Patten SB**, Wiebe S, Holroyd-Leduc J, Bulloch AG, Macrodimitris S, Mackie A, Sauro KM, Federico P, Jette N. Mind the gap: Exploring information gaps for the development of an online resource hub for epilepsy and depression. *Epilepsy & Behaviour* 2017; 70:18-23.
 41. Jorm AF, **Patten SB**, Brugha TS, Mojtabai R. Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the Evidence from four Countries. *World Psychiatry* 2017; 16(1):90-99.
 42. Enticott JC, Meadows GN, Shawyer F, Inder B, **Patten SB**. Mental disorders and distress: associations with demographics, remoteness and socioeconomic deprivation of area of residence across Australia. *Aust NZ J Psychiatry* 2016; 50(12):1169-1179.
 43. Jette N, Amoozegar F, Patten SB. Depression in epilepsy, migraine and multiple sclerosis – epidemiology and how to screen for it. *Neurology Clinical Practice* 2017; 7(2):118-127
 44. Wiens K², **Patten SB**. Is the prevalence of major depression increasing the Canadian adolescent population? Assessing trends from 2000 – 2014. *Journal of Affective Disorders* 2017; 210:22-26.
 45. Lewinson RT, Vallerand IA, Lowerison MW, Parsons LM, Frolkis AD, Kaplan GG, Bulloch AGM, Swain MG, **Patten SB**, Barnabe C. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: A population-based study. *Journal of Investigative Dermatology* 2017;137(4):828-35.
 46. Josephson CB, Lowerison M, Vallerand I, Sajobi TT, Patten S, Jette N, Wiebe S. Association of depression and treated depression with Epilepsy and seizure outcomes. *JAMA Neurology* 2017. <http://jamanetwork.com/journals/jamaneurology/fullarticle/2604239> **(E-pub)**
 47. Marrie RA, **Patten SB**, Tremlett H, Wolfson C, Leung S, Fisk JD. Increased Incidence and Prevalence of Psoriasis in Multiple Sclerosis. *Multiple Sclerosis and Related Disorders* 2017; 13:81-86.
 48. Fiest KM, Sauro KM, Wiebe S, **Patten SB**, Kwon CS, Dykeman J, Pringsheim T, Lorenzetti DL, Jette N. Prevalence and Incidence of Epilepsy: A systematic review & meta-analysis of international studies. *Neurology* 2017; 88(3):296-303.

² MSc student under my supervision at the time of this work. Now a PhD student at the University of Toronto

49. Moll, S., Zanhour, M., Patten, S., Stuart, H. & MacDermid, J. Evaluating mental health literacy in the workplace: Development and psychometric properties of a vignette-based tool. *Journal of Occupational Rehabilitation* 2017; 27:601-611.
50. Gill SJ, Lukmanji S, Fiest KM, Patten SB, Wiebe S, Jette N. Depression screening tools in person with epilepsy: A systematic review of validated tools. *Epilepsia* 2017; <http://onlinelibrary.wiley.com/doi/10.1111/epi.13651/epdf> (E-pub)
51. Moraros J, Nwankwo C, **Patten SB**, Mousseau. The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis. *Depress Anxiety* 2017; 34(3):217-26.
52. **Patten SB**, Williams J, Lavorato D, Fiest K, Wang JL, Bulloch AGM, Sajobi T. Seasonal variation in major depressive episode prevalence in Canada. *Epidemiology and Psychiatric Sciences* 2017; 26(2):169-76.
53. Lister B, Fiest KM, **Patten SB**, Fisk JD, Walker JR, Graff LA, Bolton JM, Sareen J, Marriott JJ, Berrigan LI, Bernstein CN, Zarychanski R. Screening tools for anxiety in person with Multiple Sclerosis: A systematic review. *International Journal of MS Care* 2016; 18(6):273-281.
54. **Patten S**, Williams J, Lavorato D, Bulloch AGM, Charbonneau M, Gautam M, Moss P, Abbey S, Stuart H. Perceived Stigma among Recipients of Mental Health Care in the General Canadian Population. *Canadian Journal of Psychiatry* 2016 Aug; 61(8):480-8.
55. **Patten SB**, Wilkes TCR, Williams JVA, Lavorato DH, el-Guebaly N, Wild TC, Colman I, Bulloch AGM. Childhood Adversity and Subsequent Mental Health Status in Adulthood: Screening for Associations Using Two Linked Surveys. *Epidemiology and Psychiatric Sciences* 2016; 25(2): 160-170.
56. Watterson RA³, Williams JVA, Lavorato DH, **Patten SB**. Descriptive Epidemiology of generalized anxiety disorder in Canada. *Canadian Journal of Psychiatry* 2016: 1-6. <http://journals.sagepub.com/doi/pdf/10.1177/0706743716645304> (E-pub)
57. Wiens K⁴, Williams JVA, Lavorato DH, Bulloch AGM, **Patten SB**. The prevalence of major depressive episodes is higher in urban regions of Canada. *The Canadian Journal of Psychiatry* 2016: 1-5. (e-pub) <http://journals.sagepub.com.ezproxy.lib.ucalgary.ca/doi/pdf/10.1177/0706743716659246>
58. Roseman M, Kloda LA, Saadat N, Riehm KE, Ickowicz A, Baltzer F, Katz LY, **Patten SB**, Rousseau C, Thombs BD. Accuracy of depression screening tools to detect major depression in children and adolescents: a systematic review. *Canadian Journal of Psychiatry* 2016; 61(12):746-757.
59. **Patten SB**, Williams JVA, Lavorato D, Lang JL, McDonald K⁵, Bulloch AGM. Major depression in Canada: What has changed over the past 10 years. *Canadian Journal of Psychiatry* 2016;

³ Psychiatry Resident, supervision during a research elective.

⁴ MSc student under my supervision at the time of this work. Now a PhD student at the University of Toronto.

⁵ MSc student under my supervision. Now a PhD student at Oxford University.

- 61(2):80-85.
60. Erickson J, El-Gabalawy R, Palitsky D, **Patten SB**, Mackenzie CS, Stein MB, Sareen J. Educational attainment as a protective factor for psychiatric disorders: Findings from a nationally-representative longitudinal study. *Depression and Anxiety* 2016; 33(11):1013-1022.
 61. Fiest KM, Bernstein CN, Walker JR, Graff LA, Hitchon CA, Peschken CA, Zarychanski R, Abou-Setta A, **Patten SB**, Sareen J, Bolton J, Singer A, Marrie RA. Systematic review of interventions for depression and anxiety in person with inflammatory bowel disease. *BMC Research Notes* 2016; 9:404. <https://bmccresnotes.biomedcentral.com/articles/10.1186/s13104-016-2204-2>
 62. Wang Haidong and the GBD 2015 HIV Collaborators (including Patten SB). Estimates of global regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. *Lancet HIV* 2016; 3:e361-87. [http://www.thelancet.com/pdfs/journals/lanhiv/PIIS2352-3018\(16\)30087-X.pdf](http://www.thelancet.com/pdfs/journals/lanhiv/PIIS2352-3018(16)30087-X.pdf)
 63. Freiheit EA⁶, Hogan DB, **Patten SB**, Wunsch H, Anderson T, Ghali WA, Knudtson M, Maxwell CJ. Frailty trajectories after treatment for coronary artery disease in older patients. *Circulation: Cardiovascular Quality and Outcomes* 2016; 9(3):230-8.
 64. Ismail Z, Elbayoumi H, Fischer CE, Hogan DB, Millikin CP, Schweizer T, Mortby ME, Smith EE, Patten SB, Fiest KM. Prevalence of depression in patients with mild cognitive impairment – A systematic review and meta-analysis. *JAMA Psychiatry* 2016. <http://jamanetwork.com/journals/jamapsychiatry/fullarticle/2587078>
 65. Goodarzi Z⁷, Mele B, Guo S, Hanson H, Jete N, **Patten S**, Prigsheim T, Holroyd-Leduc J. Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. *BMC Neurology* 2016; 16:244. <https://bmccneurol.biomedcentral.com/articles/10.1186/s12883-016-0754-5>
 66. Global Burden of Disease Pediatrics Collaboration, Kyu H, Pinho C, Wagner JA, et al (including **Patten SB**). Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the Global Burden of Disease 2013 Study. *JAMA Pediatrics* 2016; 170(3):267-87.
 67. Wang JL, **Patten SB**, Lam RW, Attridge M, Ho K, Schmitz N, Marchand A, Lashewicz B. The effects of an E-mental health program and job coaching on the risk of major depression and productivity in Canadian male workers: Protocol for a Randomized controlled trial. *JMIR Research Protocols* 2016 5(4): e218. https://www.jmir.org/article/viewFile/jmir_v18i6e132/2
 68. **Patten SB**, Williams JVA, Lavorato DH, Wang JL, Bulloch AGM. Major depression prevalence increases with latitude in Canada. *The Canadian Journal of Psychiatry* 2016; 62:62-66. <http://cpa.sagepub.com/content/early/2016/10/03/0706743716673323.full.pdf+html>
 69. Maxwell C, Wilcox E, Freiheit E, Faris P, Hogan D, **Patten S**, Anderson T, Ghali W, Knudtson M, Demchuk A. Depressive symptoms and functional decline following coronary interventions

⁶ PhD student at the time of this work. I was her co-supervisor.

⁷ MSc student at the time of this work, I was a member of her supervisory committee.

- in older patients with coronary artery disease: A prospective cohort study. *BMC Psychiatry* 2016; 16: 277 <http://bmcp psychiatry.biomedcentral.com/articles/10.1186/s12888-016-0986-3>
70. Altura KC, **Patten SB**, Fiest KM, Atta C, Bulloch AG, Jette N. Suicidal ideation in persons with neurological conditions – prevalence, associations, and validation of the PHQ-9 for suicidal ideation. *General Hospital Psychiatry* 2016; 42:22-26
71. Knaack S, **Patten S**. A grounded theory model for reducing stigma in health professionals in Canada. *Acta Psychiatrica Scandinavica* 2016; 134(Suppl. 446): 53-62.
72. Marrie RA, **Patten S**, Greenfield J, Svenson L, Jette N, Tremlett H, Wolfson C, Warren S, Profetto-McGrath J, Fisk J. Physical comorbidities increase the risk of psychiatric comorbidity in MS. *Brain and Behavior* 2016. . <http://onlinelibrary.wiley.com/doi/10.1002/brb3.493/epdf> (Open Access June 29)
73. K Sjonnesen⁸, AGM Bulloch, J Williams, D Lavorato, **SB Patten**. Characterization of Disability in Canadians with Mental Disorders Using an Abbreviated Version of a DSM-5 Emerging Measure: The 12-Item WHO Disability Assessment Schedule (WHODAS) 2.0. *The Canadian Journal of Psychiatry* 2016; 61 (4): 227-235.
74. Wang JL, Lam RW, Ho K, Attridge M, Lashewicz BM, **Patten SB**, Marchand A, Aiken A, Schmitz N, Gundu S, Rewari N, Hodgins D, Bulloch A, Merali Z. Preferred features of e-mental health programs for prevention of Major depression male workers: results from a Canadian national survey. *Journal of Medical Internet Research* 2016; 18(6): E132. http://www.jmir.org/article/viewFile/jmir_v18i6e132/2
75. Prisie J⁹, Fiest K, Coutts S, **Patten S**, Atta C, Blaikie L, Bulloch A, Demchuk A, Hill M, Smith D, and Jette N. Validating screening tools for depression in stroke and TIA patients. *The International Journal of Psychiatry in Medicine* 2016; 51(3): 262-277.
76. Fiest KM, Fisk JD, **Patten SB**, Tremlett H, Wolfson C, Warren S, McKay K, Berrigan L, Marrie RA. Fatigue and comorbidities in Multiple Sclerosis. *International Journal of MS Care* 2016; 18(2):96-104.
77. Marrie RA, **Patten S**, Tremlett H, Svenson LW, Wolfson C, Yu BN, Elliott L, Profetto-McGrath J, Warren S, Leung S, Jette N, Bhan V, Fisk JD. Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. *Multiple Sclerosis and Related Disorders* 2016; 8:86-92. [http://www.msard-journal.com/article/S2211-0348\(16\)30061-X/pdf](http://www.msard-journal.com/article/S2211-0348(16)30061-X/pdf)
78. Pelletier L, O'Donnell S, Dykxhoorn J, McRae L, **Patten SB**. Under-diagnosis of mood disorders in Canada. *Epidemiology and Psychiatric Sciences* 2016;. http://journals.cambridge.org/download.php?file=%2F1733_BF321D845188FA9CEBBC32E877F8C586_journals_EPS_S2045796016000329a.pdf&cover=Y&code=f74fca3ff2f9234bb810d4d41529542f
79. Fiest KM, **Patten SB**, Jette N. Screening for depression and anxiety in epilepsy. *Neurol Clin*

⁸ Medical Student, University of Alberta/Summer Student, University of Calgary.

⁹ Medical Student, University of Alberta

- 2016; 34(2): 351-361. <http://www.sciencedirect.com/science/article/pii/S0733861915001176>
80. Frolkis AD¹⁰, de Bruyen J, Jette N, Lowerison M, Engbers J, Ghali W, Lewis JD, Vallerand I, **Patten S**, Eksteen B, Barnabe C, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. The association of smoking and surgery in inflammatory bowel disease is modified by age at diagnosis. *Clinical and Translational Gastroenterology* 2016 (e-pub April) <http://www.nature.com/ctg/journal/v7/n4/pdf/ctg201621a.pdf>
81. Thombs BD, Benedetti A, Kloda L, Levis B, Azar M, Riehm KE, Saadat N, Cuijpers P, Gilbody S, Ioannidis JPA, McMillan D, **Patten SB**, Shrier I, Steele RJ, Ziegelstein RC, Loiselle CG, Henry M, Ismail Z, Mitchell N, Tonelli M. Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. *BMJ Open* 2016;6(4):1-7. <http://bmjopen.bmj.com/content/6/4/e011913.full.pdf+html>
82. McKay K, Tremlett H, Fisk JD, **Patten SB**, Fiest K, Berrigan B, Marrie RA. Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: a prospective multi-site study. *Multiple Sclerosis Journal* 2016; 22(5): 685-93. DOI: 10.1177/1352458515599073. <http://msj.sagepub.com/cgi/reprint/1352458515599073v1.pdf?ijkey=CcjR7su2j2EMtdY&keytype=finite>
83. Marrie RA, Fisk J, Tremlett H, Wolfson C, Warren S, Blanchard J, **Patten SB**, (*CIHR Team in the Epidemiology and Impact of Comorbidity of Multiple Sclerosis*). Differing trends in the incidence of vascular comorbidity in MS and the General population. *Neurology Clinical Practice* 2016. <http://cp.neurology.org/content/6/2/120.full.pdf+html>
84. Cepoiu-Martin M¹¹, Tam-Tham H, **Patten S**, Maxwell CJ, Hogan DB. Predictors of long-term care placement in persons with dementia: a systematic review and meta-analysis. *International Journal of Geriatric Psychiatry* 2016. 31(11):1151-1171. <http://onlinelibrary.wiley.com/doi/10.1002/gps.4449/epdf>
85. Marrie RA, **Patten SB**, Tremlett H, Wolfson C, Warren S, Svenson LW, Jette N, Fisk J. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. *Neurology* 2016; 86(14):1279-1286. <http://www.neurology.org/content/86/14/1279.full.pdf+html>
86. Berrigan L, Fisk J, **Patten SB**, Tremlett H, Wolfson C, Warren S, Fiest K, McKay K, Marrie RA. Health-related quality of life in Multiple Sclerosis: Direct and indirect effects of comorbidity. *Neurology* 2016; 86(15):1417-1424 <http://dx.doi.org/10.1212/WNL.0000000000002564>
87. **Patten SB**, Williams JVA, Lavorato DH, Wang JL, Bulloch AGM, Sajobi T. The association between major depression prevalence and sex becomes weaker with age. *Social Psychiatry and Psychiatric Epidemiology* 2016; 51:203-210 <http://link.springer.com/article/10.1007/s00127-015-1166-3>
88. Colman I, Kingsbury M, Garad Y, Zeng Y, Naicker K, **Patten S**, Jones PB, Wild TC, Thompson AH. Consistency in adult reporting of adverse childhood experiences. *Psychological Medicine* 2016; 46: 543-549.

¹⁰ Medical Student, LIM program, University of Calgary

¹¹ PhD student under my co-supervision

http://journals.cambridge.org/download.php?file=%2FPSM%2FPSM46_03%2FS0033291715002032a.pdf&code=32ff527f732b8e893d961c531b3262e2

89. **Patten SB**, Williams JVA, Lavorato DH, Bulloch AGM, Wiens K, Wang JL. Why is major depression prevalence not changing? *Journal of Affective Disorders* 2016; 189:93-97. <http://www.sciencedirect.com/science/article/pii/S0165032715304742>
90. Fiest KM, Walker JW, Bernstein C, Graff LA, Zarychanski R, Abou-Setta A, **Patten SB**, Sareen J, Bolton JM, Marriott J, & Marrie RA. Systematic Review and Meta-Analysis of Interventions for Depression and Anxiety in Persons with Multiple Sclerosis. *Multiple Sclerosis and Related Disorders* 2016;5:12-26. <http://dx.doi.org/10.1016/j.msard.2015.10.004>
91. Bulloch A, Fiest KM, Williams JV, Lavorato DH, Berzins SA¹², Jette N, Pringsheim TM, **Patten SB**. Depression - a common disorder across a broad spectrum of neurological conditions - a nationally representative survey. *General Hospital Psychiatry* 2015; 37(6):507-12.
92. **Patten SB**. Psychiatric Epidemiology: It is about much more than prevalence. *Canadian Journal of Psychiatry* 2015; 60(12): 529-530.
93. Morkem R, Barber D, Williamson T, Patten SB. A Canadian primary care sentinel surveillance network study evaluating antidepressant prescribing in Canada from 2006 to 2012. *Canadian Journal of Psychiatry* 2015; 60(12): 564-570.
94. Knaak S, **Patten S**, Ungar T. Mental Illness Stigma as a Quality of Care Problem. *The Lancet Psychiatry* 2015; 2(10):863-864.
95. Sajobi TT, Jette N, Fiest KM, **Patten SB**, Engbers J, Lowerison M, Wiebe S. Correlates of patient-reported disability related to seizures in persons with epilepsy. *Epilepsia* 2015; 56(9):1463-9.
96. O'Donnell S, Vanderloo S, McRae L, Onysko J, **Patten SB**, Pelletier L. Comparison of the estimated prevalence of mood and/or anxiety disorders in Canada between self-report and administrative data. *Epidemiology & Psychiatric Sciences* 2015: 1-11. http://journals.cambridge.org/repo_A97eVDxdIF3we2.
97. Moll S, Patten SB, Stuart H, Kirsh B, MacDermid JC. Beyond silence: protocol for a randomized parallel-group trial comparing two approaches to workplace mental health education for healthcare employees. *BMC Medical Education* 2015; 15(78): 1-9. <http://bmcmmededuc.biomedcentral.com/articles/10.1186/s12909-015-0363-9>
98. Raissi A¹³, Bulloch AGM, Fiest KM, McDonald K, Jette N, **Patten SB**. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. *International Journal of MS Care* 2015; 17(6):292-300.

¹² PhD student under my co-supervision

¹³ Medical Student, University of Alberta

99. Roberts JI¹⁴, **Patten SB**, Wiebe S, Hemmelgarn BR, Pringsheim T, Jetté N. Health-related behaviors and comorbidities in people with epilepsy: Changes in the past decade. *Epilepsia* 2015; 56(12):1973-1981 doi:10.1111/epi13207 <http://onlinelibrary.wiley.com/doi/10.1111/epi.13207/epdf> .
100. Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, Tennakoon A, Leung S, **Patten SB**. Differences in the burden of psychiatric comorbidity in MS versus the General population. *Neurology* 2015; 85:1-8. <http://www.neurology.org/content/early/2015/10/30/WNL.0000000000002174>
101. Thombs B, Benedetti A, Kloda LA, Levis B, Riehm KE, Azar M, Cuijpers P, Gilbody S, Ioannidis JPA, McMillan D, **Patten SB**, Shrier I, Steele RJ, Ziegelstein RC, Tonelli M, Nicholas M, Liane C, Schinazi J, Vigod Simone. The Diagnostic Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for Detecting Major Depression in Pregnant and Postnatal Women: Protocol for a Systematic Review and Individual Patient Data Meta-analyses. *BMJ Open* 2015; 5:e009742 (1 -8 pages) doi:10.1136/bmjopen-2015-009742
102. Knaak S, **Patten S**, Ungar T. Mental illness stigma as a quality-of-care problem (comment). *The Lancet Psychiatry* 2015; 2(10): 863-864.
103. Sajobi TT, Jette N, Zhang Y, **Patten SB**, Fiest KM, Engbers JD, Lowerison MW, & Wiebe S. Determinants of Disease Severity in Adults with Epilepsy: Results from the Neurological Diseases and Depression Study. *Epilepsia* 2015; 56(9):1463-1469
104. **Patten SB**. Major depressive disorder: Reification and (maybe) rheostasis. *Epidemiology and Psychiatric Sciences* 2015; 24(6): 473-475. E-Pub: http://journals.cambridge.org/abstract_S2045796015000682
105. **Patten SB**. Medical models and metaphors for depression. *Epidemiology and Psychiatric Sciences* 2015; 24(4): 303-308.
106. Knaak S, Ungar T, **Patten S**. Seeing is believing: Biological information may reduce mental health stigma amongst physicians. *Australian & New Zealand Journal of Psychiatry* 2015; 49(8):751-752. DOI: 10.1177/0004867415584643 <http://anp.sagepub.com/cgi/reprint/49/8/751.pdf?ijkey=g6cVxA87eKo328o&keytype=finite>
107. Fiest KM, Fisk JD, **Patten SB**, Tremlett H, Wolfson C, McKay KA, Berrigan L, Warren S. Comorbidity is Associated with Pain-Related Activity Limitations in Multiple Sclerosis. *Multiple Sclerosis and Related Disorders* 2015;4(5) 470-476. <http://www.msard-journal.com/article/S2211-0348%2815%2900113-3/fulltext>
108. Global Burden of Disease Cancer Collaboration; Fitzmaurice Christina; Dicker Daniel; et al. (incl. **Patten, Scott B**). The Global Burden of Cancer 2013. *JAMA Oncology* 2015; 1(4): 505-527.
109. Konkoly Thege B, Colman I, el-Guebaly N, Hodgins DC, **Patten SB**, Schopflocher D, Wolfe J, Wild TC. Social judgments of behavioral versus substance-related addictions: A population-based study. *Addictive Behaviors* 2015; 42: 24-31

¹⁴ Medical Student, LIM program, University of Calgary

110. Koch M, **Patten SB**, Berzins S, Zhornitzky S, Greenfield J, Wall W, Metz L. Depression in multiple sclerosis: a long-term longitudinal study. *Multiple Sclerosis* 2015; 21: 76-82.
111. **Patten SB**, Burton JM, Fiest KM, Wiebe S, Bulloch A, Koch M, Dobson KS, Metz LM, Maxwell CJ and Jette N. Validity of four screening scales for major depression in MS. *Multiple Sclerosis Journal* 2015; 21(8):1064-1071
112. Knaak S, Szeto A, Fitch K, Modgill G, **Patten SB**. Stigma towards Borderline Personality Disorder: Effectiveness and Generalizability of an Anti-stigma Program for Healthcare Providers. *Borderline Personality Disorder and Emotion Dysregulation* 2015, 2:9
<http://www.bpded.com/content/2/1/9>
113. Zhornitsky S, Greenfield J, Koch MW, **Patten SB**, Harris C, Wall W, Alikhani K, Burton J, Busche K, Costello F, Davenport J, Jarvis SE, Lavarato D, Parpal H, Patry D, Yeung M, Metz L. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year prospective cohort study. *PLOS ONE* 2015; **E-pub**
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123824>
114. **Patten SB**, Williams JVA, Lavorato DH, Fiest KM, Bulloch AGM, Wang JL. Descriptive epidemiology in Canada in 2012. *Can J Psychiatry* 2015; 60(1): 23-30.
115. McDonald KC¹⁵, Bulloch A, Duffy A, Bresee L, Williams J, Lavorato D, **Patten SB**. Prevalence of Bipolar I and II Disorder in Canada. *Can J Psychiatry* 2015; 60(3): 151-156.
116. Patten SB. The Wisdom of Crowds (Vox Populi) and Antidepressant Use. *Clinical Practice & Epidemiology in Mental Health* 2015; 11: 1-3.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321202/>
117. Mura G, Rocha N, Helmich I, Budde H, Machado S, Wegner M, Egidio Nardi A, Arias-Carrión O, Vellante M, Baum A, Guicciardi M, **Patten SB** and Giovanni Carta M. Physical Activity Interventions in Schools for Improving Lifestyle in European Countries. *Clinical Practice and Epidemiology in Mental Health* 2015; 11 (Suppl 1: M5): 77-101.
<http://benthamopen.com/contents/pdf/CPEMH/CPEMH-11-77.pdf>
118. Kassam A, Horton J, Shoimer I, **Patten S**. Predictors of Well-Being in Resident Physicians: A Descriptive Study on Burnout and Work Dissatisfaction. *Journal of Graduate Medical Education*, March 2015; 7(1):70-74. <http://www.jgme.org/doi/pdf/10.4300/JGME-D-14-00022.1>
119. Maxwell C, Amuah J, Hogan D, Cepoiu-Martin M, Gruneir A, **Patten SB**, Soo A, Le Clair K, Wilson K, Hagen L. Elevated hospitalization risk of assisted living residents with dementia in Alberta, Canada. *Journal of the American Medical Directors Association*, July 2015;16(7):568-577. [http://www.jamda.com/article/S1525-8610\(15\)00080-8/pdf](http://www.jamda.com/article/S1525-8610(15)00080-8/pdf)
120. Pringsheim T, Gardiner D, **Patten SB**. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? *British Medical Journal*, March 2015: **E-Pub** <http://www.bmj.com/content/350/bmj.h569>

¹⁵ MSc student under my supervision

121. **Patten SB**, Burton JM, Fiest KM, Wiebe S, Bulloch A, Koch M, Dobson KS, Metz LM, Maxwell CJ and Jette N. Validity of four screening scales for major depression in MS. *Multiple Sclerosis* 2015; 21(8): 1064-1071.
122. **Patten SB**, Williams JVA, Lavorato DH, Fiest KM, Bulloch AGM, Wang JL. The prevalence of major depression is not changing. *Canadian Journal of Psychiatry* 2015; 60(1):31-34.
123. Ismail, Z et al. (incl. **Patten SB**). Medical Comorbidity, Psychosis, Pain and Capacity Predict Hospital Length of Stay in Geriatric Psychiatry Inpatients With and Without Dementia. *International Psychogeriatrics* 2015;27(2):313-321. . doi:[10.1017/S1041610214002002](https://doi.org/10.1017/S1041610214002002)
124. Konkoly Thege B, Colman I, el-Guebaly N, Hodgins D, **Patten S**, Schopflocher D, Wolfe J, Wild TC. Substance-Related and Behavioural Addiction Problems: Two Surveys of Canadian Adults. *Addiction Research & Theory* 2015; 23(1):34-42.
<http://informahealthcare.com/doi/pdf/10.3109/16066359.2014.923408>
125. Murray C, Ortblad C, et al. (incl. **Patten SB**). Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;385:117-171.
doi: 10.1016/S0140-6736(14)60844-8
126. **Patten SB**, Williams JVA, Lavorato DH, Fiest KM, Bulloch AGM, Wang JL. Changing perceptions of mental health in Canada. *Canadian Journal of Psychiatry* 2014; 59(11): 591-597.
127. **Patten SB**, Williams JVA, Lavorato DH, Fiest KM, Bulloch AGM, Wang JL. Antidepressant use in Canada has stopped increasing. *Canadian Journal of Psychiatry* 2014; 59(11): 609-614.
128. Wong S, Manca D, Barber D, Morkem R, Khan S, Kotecha J, Williamson T, Birtwhistle R, and **Patten S**. The diagnosis of depression and its treatment in Canadian primary care practices: an epidemiological study. *CMAJO* 2014;2(4) E337-E342; (published online November 28, 2014, doi:10.9778/cmajo.20140052).
129. Marrie RA, Fisk JD, Stadnyk KJ, Tremlett H, Wolfson C, Warren S, Bhan V, Yu BN, for CIHR Team in the epidemiology and impact of comorbidity in MS (**Patten SB** = member). Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. *Chronic diseases and injuries in Canada* 2014; 34: 145-153.
130. Thombs B, Benedetti A, Kloda LA, Levis B, Nicolau I, Cuijpers P, Gilbody S, Ioannidis J, McMillan D, **Patten S**, Shrier I, Steele R, and Ziegelstein RC. The Diagnostic Accuracy of the Patient Health Questionnaire-2 (PHQ-2) Patient Health Questionnaire-8 (PHQ-8) and Patient Health Questionnaire-9 (PHQ-9) for Detecting Major Depression: Protocol for a Systematic Review and Individual Patient Data Meta-analyses. *Systematic Reviews* 2014, 3:124.
(available at: <http://www.systematicreviewsjournal.com/content/3/1/124>).
131. Stuart H, Chen SP, Christie R, Dobson K, Kirsh B, Knaak S, Koller M, Krupa T, Lauria-Horner B, Luong D, Modgill G, **Patten SB**, Pietrus M, Szeto A, Whitley R. Opening Minds in Canada: Targeting Change. *The Canadian Journal of Psychiatry* 2014; 59(10):S13-S18.

132. Knaak S, Modgill G, **Patten S**. Key Ingredients of Anti-Stigma Programs for Health Care Providers: A Data Synthesis of Evaluative Studies. *The Canadian Journal of Psychiatry* 2014; 59(10):S19-S26.
133. Stuart H, **Patten SB**, Koller M, Modgill G, Liimaa T. Stigma in Canada: Results from a Rapid Response Survey. *The Canadian Journal of Psychiatry* 2014; 59(10):S27-33
134. Fiest KM, Jette N, Quan H, St. Germaine-Smith C, Metcalfe A, **Patten SB**, and Beck C. Systematic Review and Assessment of Validated Case Definitions for Depression in Administrative Data. *BMC Psychiatry* 2014; 14: 289.
<http://www.biomedcentral.com/1471-244X/14/289>
135. Kassebaum N, Bertozzi-Villa A, et al. (incl. **Patten SB**). Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014 ;384(9947):980-1004
[http://dx.doi.org/10.1016/S0140-6736\(14\)60696-6](http://dx.doi.org/10.1016/S0140-6736(14)60696-6)
136. Vu M, Hogan D, **Patten SB**, Jetté N, Bronskill SE, Heckman G, Kergoat MJ, Hirdes JP, Chen J, Zehr M, Maxwell C. A comprehensive profile of the sociodemographic, psychosocial and health characteristics of Ontario home care clients with dementia. *Chronic Diseases in Canada* 2014; 34: 132-144.
137. Wang JL, **Patten SB**, Sareen J, Bolton J, Schmitz N and MacQueen G. Development and Validation of A Prediction Algorithm for Recurrence of Major Depression. *Depression & Anxiety* 2014; 31(5): 451-457.
138. Specogna, A¹⁶, **Patten SB**, Chowdhury T, Hill M. Factors Associated with Early Deterioration after Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. *PLoS One* 2014; 9(5): e96743.
139. **Patten SB**, Wilkes TC, Williams J, Lavorato D, el-Guebaly N, Schopflocher D, Wild C, Colman I, Bulloch A. Retrospective and prospectively assessed childhood adversity in association with major depression, alcohol consumption and painful conditions. *Epidemiology & Psychiatric Sciences* 2014; 24(2): pp 158 - 165
140. Viner R¹⁷, Fiest KM, Bulloch A, Williams J, Lavorato D, Berzins S, Jetté N, Metz L, **Patten SB**. Point Prevalence and Correlates of Depression in a National Community Sample with MS. *General Hospital Psychiatry* 2014;36(3):352-4.
141. Modgill G., **Patten SB.**, Knaak S., Kassam A., Szeto A., Opening minds stigma scale for health care providers (OMS-HC): Examination of psychometric properties and responsiveness, *BMC Psychiatry*. 2014, 14:120 (doi:10.1186/1471-244X-14-120).
142. Mura G, **Patten SB**, Carta M. Exercise as an add-on strategy for the treatment of Major Depressive Disorder. A systematic review. *CNS Spectrums* 2014; 6:496-508.
DOI:10.1017/S1092852913000953.
143. Wiebe N, Fiest KM, Dykeman J, Liu XR, Jette N, **Patten S**, Wiebe S. Patient Satisfaction with

¹⁶ PhD student under my co-supervision

¹⁷ Summer student from Queens University

- Care in Epilepsy: How much do we know? *Epilepsia* 2014; 55(3): 448-455.
144. Yergens D, Dutton D and **Patten SB**. An overview of the statistical methods reported by studies using the Canadian Community Health Survey. *BMC Health Research Methodology* 2014, 14:15. <http://www.biomedcentral.com/content/pdf/1471-2288-14-15.pdf> (doi: 10.1186/1471-2288-14-15)
145. **Patten SB**, Williams VA, Lavorato DH, Currie G, Emery H. Depression and Painful Conditions: Patterns of Association with Health Status and Health Utility Ratings in the General Population. *Quality of Life Research* 2014; 23(1):363–371. (DOI 10.1007/s11136-013-0449-y)
146. Danila O, Hirdes JP, Maxwell C, Marrie RA, **Patten S**, Pringsheim T and Jetté N. Prevalence of Neurological Conditions across the Continuum of Care Based on interRAI Assessments. *BMC Health Services Research* 2014,14: 29. <http://www.biomedcentral.com/content/pdf/1472-6963-14-29.pdf> (doi: 10.1186/1472-6963-14-29)
147. Minden S, Feinstein A, Kalb R, Miller D, Mohr D, **Patten SB**, Bever C, Schiffer R, Gronseth G, Narayanaswami P. Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS. *Neurology* 2014;82(2):174–181.
148. Viner R¹⁸, **Patten S**, Berzins S, Bulloch A, Fiest K. Prevalence and Risk Factors of Suicidal Ideation in the MS Population. *Journal of Psychosomatic Research* 2014, 76(4): 312-316. (Online on January 2, 2014. <http://www.sciencedirect.com/science/article/pii/S0022399913004595>)
149. Wang JL, Manuel D, Williams J, Schmitz N, Gilmour H, **Patten SB**, MacQueen G, Birney A. A Prediction Algorithm for First Onset of Major Depression in the General Population: Development and Validation. *Epidemiology and Community Health* 2014; 68: 418-424.
150. **Patten SB**, Williams J, Lavorato DH, Koch M; Metz L. Depression as a Predictor of Occupational Transitions in a Canadian MS Cohort. *Functional Neurology* 2014; 76(4):312-6.
151. Fiest KM, Pringsheim T, **Patten SB**, Svenson LW, Jetté N . The role of systematic reviews and meta-analyses of incidence and prevalence studies in neuroepidemiology. *Neuroepidemiology* 2014; 42(1): 16-24.
152. Specogna AV¹⁹, **Patten SB**, Chowdhury T, Hill MD. The Cost of Spontaneous Intracerebral Hemorrhage in Canada over One Decade. *Stroke* 2014; 45: 284-286.
153. Bulloch AGM, Williams JVA, Lavorato DH, **Patten SB**. The recurrence of major depressive episodes is strongly dependent on the number of previous episodes *Depression & Anxiety* 2014; 31(1):72-6. Available at: <http://onlinelibrary.wiley.com.ezproxy.lib.ucalgary.ca/doi/10.1002/da.22173/pdf> (doi: 10.1002/da.22173)
154. Fiest KM, **Patten SB**, Altura C, Bulloch AGM, Maxwell C, Wiebe S, Macrodimitris S, Jette N.

¹⁸ Summer student from Queens University

¹⁹ PhD student under my co-supervision

- Patterns and Frequency of the Treatment of Depression in Persons with Epilepsy. *Epilepsy & Behavior* 2014; 39: 59-64.
155. Fiest KM, **Patten SB**, Wiebe S, Bulloch AGM, Maxwell C, Jette N. Validating Screening Tools for Depression in Epilepsy. *Epilepsia* 2014; 55(10):1642–1650.
156. Specogna AV²⁰, **Patten SB**, Chowdhury T, Hill MD. The Reliability and Sensitivity of the National Institutes of Health Stroke Scale for Spontaneous Intracerebral Hemorrhage in an Uncontrolled Setting. *PLoS One* 2013; 8(12): e84702. **10.1371/journal.pone.0084702**
157. Foebel AD, Hirdes JP, Heckman GA, Kergoat MJ, **Patten S**, Marrie RA and on behalf of the ideas PNC research team. Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study *BMC Health Services Research* 2013, 13: 457. Available at: <http://www.biomedcentral.com/1472-6963/13/457>
158. Zhornitsky S, Yong VW, Koch MW, Mackie A, Potvin S, **Patten SB**, Metz L. Quetiapine for the treatment of multiple sclerosis: focus on myelin repair. *CNS Neurosci Ther* 2013; 19(10): 737-44 (epub: <http://onlinelibrary.wiley.com/doi/10.1111/cns.12154/full>).
159. Papish P²¹, Kassam A, Modgill G, Vaz G, Zanussi L and **Patten**. Reducing the stigma of mental illness in undergraduate medical education: A randomized controlled trial. *BMC Medical Education* 2013, **13**:141. <http://www.biomedcentral.com/content/pdf/1472-6920-13-141.pdf>
160. Ferrari AJ, Charlson FJ, Norman R, **Patten SB**, Murray, Vos T and Whiteford HA. Burden of depressive disorders: Findings from the Global Burden of Disease Study 2010. *PLoS Med* 2013; Volume 10(11): e1001547 (*E-pub Nov 5, 2013. 10(11): e1001547. doi:10.1371/journal.pmed.1001547*). <http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001547>
161. Marrie RA, Fisk JD, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Evans C, Wolfson C, Svenson, Tremlett H, Blanchard J, **Patten SB** and for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. *BMC Neurology* 2013;13:457. (Available at: <http://www.biomedcentral.com/1471-2377/13/16>).
162. Bolo C, Sareen J, **Patten SB**, Schmitz N, Currie SR, Wang JL. Receiving workplace mental health accommodations and the outcome of mental disorders in employees with a depressive and/or anxiety disorder. *Journal of Occupational and Environmental Medicine* 2013; 55(11): 1293-1299.
163. Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, **Patten SB**, Svenson LW, Tremlett H, Fisk J, Blanchard JF, for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. *Multiple Sclerosis and Related Disorders* 2013; 2(4):355-361

²⁰ PhD student under my co-supervision

²¹ Psychiatry Resident

164. VanTil LD, Fikretoglu D, Pranger T, **Patten S**, Wang JL, Wong M, Zamorski M, Loisel P, Corbiere M, Shields N, Thompson J, Pedlar D. Work Re-integration for Veterans with Mental Disorders; a Systematic Literature Review to Inform Research. *Physical Therapy* 2013; 93: 1163-1174.
165. MacCarthy D, Weinerman R, Kallstrom L, Hollander M, Kadlec H, **Patten S**. Mental Health Practice and Attitudes can be Changed. *The Permanente Journal* 2013; 17(3): 14-17.
166. Lam D, **Patten S**, Gorman D, Pringsheim T. The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Canadian Children and Adolescents: 2005 to 2009. *Pediatric Drugs* 2013; 15(4): 319-327.
167. Ferrari AJ; Charlson FJ; Norman RE; Flaxman A; **Patten SB**; Vos T; Whiteford HA. The epidemiological modelling of major depressive disorder: Application for the Global Burden of Disease Study 2010. *PLoS One (E-pub: 2013; 8(7): e69637. doi:10.1371/journal.pone.0069637. <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0069637>*
168. McIntyre L, Williams JVA, Lavorato DH, **Patten S**. Depression and suicide ideation in late adolescence and early adulthood are and outcome of child hunger. *Journal of Affective Disorders* 2013; 150: 123-129.
169. Ganesh A²², Campbell D, Hurley J, **Patten**. High Positive Screening Rates Displace the Value of Screening in a Homeless Population. *Canadian Journal of Psychiatry* 2013; 58(6):353–36.
170. Addington DE, **Patten SB**, McKenzie E, Addington J. Relationship Between Relapse and Hospitalization in First-Episode Psychosis. *Psychiatric Services* 2013; 64(8): 796-799.
171. Maxwell C, Vu M, Hogan DB, **Patten SB**, Jantzi M, Kergoat MJ, Jetté N, Bronskill S, Heckman G, Hirdes JP. Patterns of dementia pharmacotherapy in a population-based cohort of home care clients. (*Drugs and Ageing* 2013; 30: 569-585. (E-pub available April 23, 2013).
172. **Patten SB**, Williams JV, Lavorato DH, Bulloch AGM. Recreational Physical Activity Ameliorates Some of the Negative Impact of Major Depression on Health Related Quality of Life. *Frontiers in Psychiatry* 2013; 4:22. Available at: http://www.frontiersin.org/Journal/Abstract.aspx?s=15&name= affective_disorders_and_psychosomatic_research&ART_DOI=10.3389/fpsy.2013.00022.
173. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, **Patten SB**, Vos T, Whiteford HA. Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature. *Psychological Medicine* 2013; 43(3): 471-481.
174. Ganesh A²³, Apel S, Metz L, **Patten S**. The case for vitamin D supplementation in multiple sclerosis. *Multiple Sclerosis and Related Disorders* 2013; 4(2): 281-306. Epub: <http://www.sciencedirect.com/science/article/pii/S2211034813000023>.
175. Colman I, Garad Y, Zeng Y, Naicker K, Weeks M, **Patten SB**, Jones PB, Thompson AH, Wild TC. Stress and development of depression and heavy drinking in adulthood: moderating effects

²² Medical student/neurology resident (later awarded a Rhodes scholarship)

²³ Medical student/neurology resident (later awarded a Rhodes scholarship)

- of childhood trauma. *Social Psychiatry and Psychiatric Epidemiology* 2013;48:265-74.
176. **Patten SB**. Major Depression Epidemiology from a Diathesis-Stress-Threshold Conceptualization. *BMC Psychiatry* 2013, **13**:19. <http://www.biomedcentral.com/1471-244X/13/19>.
177. Fiest KM²⁴, Dykeman J, **Patten S**, Wiebe S, Kaplan G, Maxwell C, Bulloch A, Jette N. Depression in Epilepsy: A Systematic Review & Meta-Analysis. *Neurology* 2013;80(6):590-9
178. **Patten SB**. Childhood and adult stressors and major depression risk: interpreting interactions with the sufficient-component cause model. *Social Psychiatry and Psychiatric Epidemiology* 2013; 48(6): 927-933.
179. **Patten SB**. Recurrence risk in major depression. *Depression Anxiety* 2013;30(1):1-4.
180. Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, **Patten SB**, Svenson LW, Tremlett H, Fisk J, Blanchard JF, for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. *Neuroepidemiology* 2013; 40: 85-92.
181. Wang JL, Manuel D, Williams J,; et al. (incl. **Patten S**). Development and validation of prediction algorithms for major depressive episode in the general population *Journal of Affective Disorders* 2013; 151(1): 39-45.
182. **Patten SB**, Lin E, Martens PJ, Stiff D, Adair CE. Synthesis through Simulation: Insights on the Epidemiology of Mood and Anxiety Disorders in Canada. *Canadian Journal of Psychiatry* 2012; 57(12):765-71
183. Sjonnesen K²⁵, Berzins S, Fiest KM et al. (incl. **Patten SB**). Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. *Postgrad Med* 2012;124:69-77.
184. Vos T, Flaxman AD, Naghavi M, et al. (incl. **Patten SB**). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2163-2196.
185. Murray CJ, Vos T, Lozano R, et al. (incl. **Patten SB**). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2197-2223.
186. **Patten SB**, Remillard A, Phillips L, Modgill G, Szeto A, Kassam A, Gardner DM. Effectiveness of contact-based strategies for reducing mental illness-related stigma in pharmacy students. *BMC Medical Education* 2012, 12:120.
187. Bulloch A, Lavorato D, Williams J, **Patten S**. Alcohol Consumption and Major Depression in the General Population: the Critical Importance of Dependence. *Depression and Anxiety* 2012; 29:1058–1064.

²⁴ Research conducted while Ms. Fiest was a PhD student under my co-supervision.

²⁵ Research conducted while Ms. Sjonnesen was a Summer Student under my supervision.

188. Marrie RA, Yu, BN, Leung S, et al. (incl. **Patten S**). Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. *Multiple Sclerosis* 2012; 18: 1310-1319.
189. Hogan DB, Freiheit EA, Strain LA, **Patten SB**, Schmaltz HN, Rolfson D and Maxwell CM. Comparing frailty measures in their ability to predict adverse outcomes among older residents of assisted living. *BMC Geriatrics* 2012, 12: 56.
190. Khaled S²⁶, Bulloch AGM, Williams JVA, Lavorato DH, **Patten SB**. Persistent heavy smoking as risk factor for major depression (MD) incidence - Evidence from a longitudinal Canadian cohort of the National Population Health Survey. *Journal of Psychiatric Research* 2012; 46: 436-433.
191. Wang JL, **Patten SB**, Currie S, Sareen J, Schmitz N. A Population-Based Longitudinal Study on Work Environmental Factors and the Risk of Major Depressive Disorder. *American Journal of Epidemiology* 2012; 176: 52-59.
192. Terriff DL, **Patten SB**, Williams J, Lavorato DH, Bulloch AGM. Patterns of Disability, Care Needs, and Quality of Life of People with Parkinson's Disease in a General Population Sample. *Parkinsonism and Related Disorders* 2012; 18: 828-32.
193. Leavens A, **Patten SB**, Hudson M, Baron M, Thombs BD, Canadian Scleroderma Research Group. Influence of somatic symptoms on PHQ-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. *Arthritis Care and Research* 2012; 64: 1195-1201.
194. Wang JL, **Patten SB**, Currie S, Sareen J, Schmitz N. Business Mergers and Acquisitions and Mental Disorders: A Population-Based Study. *Occupational and Environmental Medicine* 2012; 69: 569-573.
195. Kassam A, Papish A, Modgill G and **Patten S**. Psychometric properties of a new scale to evaluate mental illness related anti-stigma/anti-discrimination programs targeted at health care providers: The Opening Minds Scale for Health Care Providers (OMS-HC). *BMC Psychiatry* 2012; 12: 62. <http://www.biomedcentral.com/1471-244X/12/62>
196. Simpson K, Meadows G, Frances A, **Patten SB**. Is the mental health of the Canadian population changing over time? *Canadian Journal of Psychiatry* 2012; 57(5):324-31.
197. **Patten SB**, Williams JA, Lavorato DA, Terriff D, Metz L, Berzins S, and Bulloch AGM (2012) Perceived Met and Unmet Health-Care Needs in a Community Population with Multiple Sclerosis. *International Journal of MS Care: Spring* 2012, Vol. 14, No. 1, pp. 2-8. <http://dx.doi.org/10.7224/1537-2073-14.1.2>
198. **Patten SB**, Williams JVA, Lavorato DH, Metz LM, Bulloch AGM. Disability in a Community Population with MS with and without Mental Disorders. *International Journal of Psychiatry in Medicine* 2012; 43(1): 51-65.
199. **Patten SB**, Williams JVA, Lavorato DH, Bulloch AGM, D'Arcy C, Streiner DL. Recall of recent

²⁶ Research conducted while Ms. Khaled was a PhD student under my supervision.

- and more remote depressive episodes in a prospective cohort study. *Social Psychiatry and Psychiatric Epidemiology* 2012; 47:691–696.
200. Bulloch AGM, Bresee LC, Beck CA, **Patten SB**. Substantial changes in prescription recommendations for bipolar disorder in Canada: 2002-2010. *Canadian Journal of Psychiatry* 2012; 57: 263-268.
201. Modgill G²⁷, Jette N, Wang JL, Becker WJ, **Patten SB**. A Population-Based Longitudinal Community Study of Major Depression and Migraine. *Headache* 2012; 52: 422-432.
202. Bresee LC, Majumdar SR, **Patten SB**, Johnson JA. Utilization of general and specialized cardiac care by people with schizophrenia. *Psychiatric Services* 2012;63:237-242.
203. Thombs B, Coyne J, Cuijpers P, de Jonge P, Gilbody S, Ioannidis J, Johnson B, **Patten SB**, Turner EH, Ziegelstein R. Rethinking Recommendations for Depression Screening in Primary Care. *CMAJ* 2012; 184: 413-418. (epub ahead of print, September 19, 2011)
204. **Patten SB**, Williams J, Lavorato D, Bulloch A, MacQueen GM. Depressive Episode Characteristics and Subsequent Recurrence Risk. *Journal of Affective Disorders* 2012; 140(3): 277–284.
205. Freiheit EA, Hogan DB, Eliasziw M, **Patten SB**, Demchuk AM, Faris P, Anderson T, Galbraith D, Parboosingh JS, Ghali WA, Knudtson M, Maxwell C. A dynamic view of depressive symptoms and neurocognitive change among patients with coronary artery disease. *Archives of General Psychiatry* 2012; 69(3): 244-255.
206. **Patten SB**, Williams JVA, Lavorato DH, Berzins S, Metz LM, Bulloch AGM. Health Status, Stress and Life Satisfaction in a Community Population with MS. *Canadian Journal of Neurological Sciences* 2012; 39: 206-212.
207. **Patten SB**. The National Population Health Survey's Assessment of Depression Risk Factors. A Simulation Study Assessing Vulnerability to Bias. *Chronic Diseases in Canada* 2012; 32(2):70-75.
208. Kassam A, Williams JVA, **Patten SB**. Experienced discrimination among people with mental illness in a population-based sample of Canadians reporting a disability. *Canadian Journal of Psychiatry* 2012; 57(2): 52-60.
209. Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, **Patten S**, Rodin G, Schaffer A, Beaulieu S, McIntyre R. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. *Annals of Clinical Psychiatry* 2012;24(1):91-109

²⁷ Research conducted while Ms. Modgill was an MSc student under my supervision.

210. Reid A, Metcalfe A, **Patten S**, Wiebe S, Macrodimitris S, Jette N. Epilepsy is associated with unmet health care needs compared to the general population despite higher health resource utilization – A national population-based study. *Epilepsia* 2012
211. Wang JL, Smailes E, Sareen J, Schmitz N, Fick G, **Patten S**. Three job-related stress models and depression: a population-based study. *Social Psychiatry and Psychiatric Epidemiology* 2012; 47: 185-193.
212. Wang JL, **Patten SB**, Currie S, Sareen J, Schmitz N. Work environment characteristics, depression and health-related presenteeism in a general population sample. *Psychological Medicine* 2012; 42: 327-334.
213. **Patten SB**, Williams JV, Lavorato D, Li WJ, Khaled S, Bulloch AG. Mortality associated with major depression in a canadian community cohort. *Can J Psychiatry* 2011; 56: 658-666.
214. Pringsheim T, Lam D, **Patten S**. The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents, 2005-2009. *Journal of Child and Adolescent Psychopharmacology* 2011; 21(6): 537-543.
215. Colman I, Naicker K, Zeng Y, Atallahjan A, Senthilselvan A, **Patten SB**. Predictors of long-term prognosis in adult depression: six-year follow-up in a national Canadian cohort. *Canadian Medical Association Journal* 2011; 183:1969-76.
216. White W; Currie S; Crockford D; **Patten S**; El-guebaly N. A prospective single-arm open-label pilot study of baclofen and bupropion SR combination therapy for smoking cessation. *Addictive Disorders and Their Treatment* 2011; 10(5): 101-104.
217. Pringsheim T, Doja A, Belanger S, **Patten S**. The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guidelines group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. *Paediatric and Child Health* 2011; 16(9): 590-598.
218. Pringsheim T, Lam D, Tano D, and **Patten SB**. The Pharmacoepidemiology of Antipsychotic Medications for Adults with Schizophrenia in Canada, 2005 to 2009. *Canadian Journal of Psychiatry* 2011; 56: 630-634.
219. **Patten SB**, Williams JVA, Lavorato DH, Khaled S²⁸, Bulloch AGM. Weight Gain in Relation to Major Depression and Antidepressant Medication Use. *Journal of Affective Disorders* 2011; 134: 288-293.
220. Mudry TE, Hodgins DC, el-Guebaly N, Wild TC, Colman I, **Patten SB**, Schopflocher D. (2011). Conceptualizing excessive behaviour syndromes: A systematic review. *Current Psychiatry Reviews* 2011; 7: 138-151
221. Khaled S²⁹, Bulloch A, Williams J, Lavorato D, **Patten SB**. Major Depression is a risk factor for Shorter Time to First Cigarette Irrespective of the Number of Cigarettes Smoked Per Day:

²⁸ Research conducted while Ms. Khaled was a PhD student under my supervision.

²⁹ Research conducted while Ms. Khaled was a PhD student under my supervision.

- Evidence from a National Population Health Survey. *Nicotine and Tobacco Research* 2011;13(1): 1059-1067.
222. Bresee L³⁰, Majumdar SR, **Patten S**, Johnson J. Diabetes, Cardiovascular Disease, and Health Care Use in People with and without Schizophrenia. *European Psychiatry* 2011; 26: 327-332.
223. Pringsheim T, Lam D, Ching H, **Patten S**. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. *Drug Safety* 2011; 34(8): 651-658
224. Colman I, Zeng Y, Atallahjan A, Senthilselvan A, **Patten SB**. The association between antidepressant use and depression eight years later: a national cohort study. *Journal of Psychiatric Research* 2011; 45:1012-18
225. Bulloch AGM, Currie S, Guyn L, Williams JV, Lavorato DH, **Patten SB**. Estimates of the treated prevalence of bipolar disorders by psychiatrists in the general population: comparison of results from administrative and health survey data. *Chronic Diseases in Canada* 2011; 31: 129-134.
226. **Patten S**, Grigoriadis S, Beaulieu S. Clinical Effectiveness, Construct and Assessment. *Journal of Affective Disorders* 2011; 132(Suppl. 1): S3-S8.
227. Freiheit E, Hogan D, Strain L, Schmaltz H, **Patten SB**, Eliasziw M, Maxwell C. Operationalizing frailty among older residents of assisted living facilities. *BMC Geriatrics* 2011; 11: 23. <http://www.biomedcentral.com/1471-2318/11/23><http://www.biomedcentral.com/1471-2318/11/23>.
228. Sloka S, Silva C, Pryse-Phillips W, **Patten SB**, Metz L, Wee Yong V. A Quantitative Analysis of Suspected Environmental Causes of Multiple Sclerosis. *Canadian Journal of Neurological Sciences* 2011; 38: 98-105.
229. Wang JL, **Patten SB**, Schmitz N, Currie SR, Sareen J. Perceived needs for and use of workplace mental health accommodations by individuals with a depressive and/or anxiety disorder. *Journal of Occupational and Environmental Medicine*. 2011 Nov; 53(11):1268-72.
230. Tamburrini AL, Woolcott CG, Boyd NF, Yaffe MJ, Terry T, Yasui Y, Jones CA, **Patten SB**, Courneya KS, Friedenreich CM. Associations between mammographic density and serum and dietary cholesterol. *Breast Cancer Research and Treatment* 2011; 125: 181-189.
231. **Patten SB**, Williams JVA, Lavorato DH, Kassam A, Sabapathy CD. Pharmacoepidemiology of Benzodiazepine and Sedative-Hypnotic Use in a Canadian General Population Cohort During 12 Years of Follow-up. *Can J Psychiatry* 2010; 55: 792-799.
232. **Patten SB**, Williams JVA, Lavorato DH, Bulloch AGM. Reciprocal Effects of Social Support in Major Depression Epidemiology. *Clinical Practice and Epidemiology in Mental Health* 2010; 6: 126-131. <http://benthamscience.com/open/cpemh/articles/V006/126CPEMH.pdf>
233. Wang JL, Schmitz N, Smailes E, Sareen J, **Patten S**. Workplace characteristics, depression and health-related presenteeism in a general population sample. *Journal of Occupational and*

³⁰ Research conducted while Dr. Bresee was a PhD student, I was a member of her supervisory committee.

- Environmental Medicine 2010; 52: 836-842.
234. **Patten SB**, Berzins S, Metz LM. Challenges in screening for depression in multiple sclerosis. *Multiple Sclerosis* 2010; 16: 1406-1411.
<http://msj.sagepub.com/content/early/2010/07/29/1352458510377770>
235. **Patten SB**, Wang JL, Williams JV, Lavorato DH, Khaled SM, Bulloch AG. Predictors of the Longitudinal Course of Major Depression in a Canadian Population Sample. *Can J Psychiatry* 2010; 55(10):669–676.
236. **Patten SB**, Gordon-Brown L, Meadows G. Simulation Studies of Age-Specific Lifetime Major Depression Prevalence. *BMC Psychiatry* 2010, 10:85.
237. Metcalfe A, Williams J, McChesney J, **Patten SB**, Jetté N. Use of Complementary and Alternative Medicine by those with a Chronic Disease and the General Population – Results of a National Population Based Survey. *BMC Complementary and Alternative Medicine* 2010, 10:58
238. **Patten SB**. Diagnosing depression in MS in the face of overlapping symptoms. *The International MS Journal* 2010; 17: 3–5
239. Wang JL, Smailes E, Sareen J, Schmitz N, Fick G, **Patten S**. The prevalence of mental disorders in the working population over the period of global economic crisis. *Can J Psychiatry* 2010; 55: 598-605.
240. **Patten S**, Wang JL, Williams J, Lavorato DH, Beck CA, Bulloch AHM. Frequency of Antidepressant Use in Relation to Recent and Past Major Depressive Episodes. *Can J Psychiatry* 2010; 55(8): 532-535.
241. **Patten SB**. Problems encountered with the use of simulation in an attempt to enhance interpretation of a secondary data source in epidemiologic mental health research. *BMC Research Notes* 2010; 3: 231.
242. **Patten SB**, Williams JA, Lavorato DH, Eliasziw E. A population-based longitudinal study of major depression and injury risk. *Can J Psychiatry* 2010; 55: 315-318.
243. Hinnell C, Williams J, Metcalfe A, **Patten SB**, Parker R, Wiebe S and Jetté N. Health status and health-related behaviors in epilepsy compared to other chronic conditions - a national population-based study. *Epilepsia* 2010;51(5):853-861.
244. Bulloch AG, **Patten SB**. Non-adherence to psychotropic medications in the general population. *Social Psychiatry and Psychiatric Epidemiology* 2010; 45:47-56.
245. Wang J, Williams J, Lavorato D, Schmitz N, Dewa C, **Patten SB**. The incidence of major depression in Canada: The National Population Health Survey. *Journal of Affective Disorders* 2010; 123: 158-163.
246. Bresee LC, Majumdar SR, **Patten SB**, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. *Schizophrenia Research* 2010: 117; 75-82.

247. Nabalamba A, **Patten SB**. Prevalence of mental disorders in a Canadian household population with dementias. *Canadian Journal of Neurological Sciences* 2010; 37: 186-194.
248. **Patten SB**, Williams JVA, Lavorato DH, Eliasziw M. Major Depression as a Risk Factor for an Inactive Lifestyle – A Prospective, Community-based Study. *General Hospital Psychiatry* 2009; 31: 571-575.
249. **Patten SB**. Antidepressant treatment for major depression in multiple sclerosis: the evolving literature. *International Journal of MS Care* 2009;11:174–179.
250. Streiner DL, **Patten SB**, Anthony JC, et al. Has 'lifetime prevalence' reached the end of its life? An examination of the concept. *International Journal of Methods in Psychiatric Research* 2009; 18(4): 221-228
251. **Patten SB**, Wang JL, Williams JVA, Lavorato DH, Bulloch A, Eliasziw M. Prospective Evaluation of the Effect of Major Depression on Working Status in a Population Sample. *Can J Psychiatry* 2009; 54:841-845.
252. Bulloch AG, Williams JV, Lavorato DH, **Patten SB**. The relationship between major depression and marital disruption is bidirectional. *Depression and Anxiety* 2009; 26:1172-1177.
253. Neutel CI, **Patten SB**. Sleep medication use in the elderly. *Canadian Journal of Clinical Pharmacology* 2009; 16(3):e442-52.
254. **Patten SB**, Meadows GM. Population-based service planning for implementation of MBCT: Linking epidemiologic data to practice. *Psychiatric Services* 2009; 60(11):1540-1542.
255. Esposito E, Barbui C, **Patten SB**. Patterns of benzodiazepine use in a Canadian population sample. *Epidemiologia et Psichiatria Sociale* 2009;18(3):248-254.
256. Kennedy SH, Milev R, Giacobbe P, Ramasubbu R, Lam RW, Parikh SV, **Patten SB**, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. *Journal of Affective Disorders* 2009; 117:S44-53.
257. Ravindran AV, Lam RW, Filteau MJ, Lesperance F, Kennedy SH, Parikh SV, **Patten SB**. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. *Journal of Affective Disorders* 2009; 117:S54-64.
258. Kennedy SH, Lam RW, Parikh SV, **Patten SB**, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. *Journal of Affective Disorders* 2009; 117:S1-2.
259. Parikh SV, Segal ZV, Grigoriadis S, Ravindran AV, Kennedy SH, Lam RW, **Patten SB**. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *Journal of Affective Disorders* 2009; 117:S15-25.

260. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, **Patten SB**, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *Journal of Affective Disorders* 2009; 117:S26-43.
261. Wang JL, Keown L, **Patten SB**, Williams JA, Currie SR, Beck C, Maxwell CJ, El-Guebaly NA. A population-based study on ways of dealing with daily stress: Comparisons among individuals with mental disorders, with long-term general medical conditions and healthy people. *Social Psychiatry and Psychiatric Epidemiology* 2009; 44:666-674.
262. Jones CA, **Patten SB**. Major depression and health related quality of life in Parkinson Disease. *General Hospital Psychiatry* 2009;31:334-340.
263. Block R, Slomp M, **Patten S**, Jacobs P, Ohinmaa A, Dewa, C. Disability Payments for Persons With Severe Mental Illness in Alberta, Canada. *Psychiatric Services* 2009; 60: 686-688.
264. **Patten SB**. Accumulation of major depressive episodes over time in a community cohort indicates that retrospectively assessed lifetime prevalence estimates are too low. *BMC Psychiatry* 2009, **9**:19
265. Mitton C, Adair CE, McKenzie E, **Patten S**, Perry BW, Smith N. Designing a knowledge transfer and exchange strategy for the Alberta Depression Initiative: Contributions of qualitative research with key stakeholders. *International Journal of Mental Health Systems* 2009, **3**:11
266. **Patten SB**, Williams J, Lavorato DH, Campbell N, Eliasziw M, Campbell T. Major Depression as a Risk Factor for High Blood Pressure: Epidemiologic Evidence from a National Longitudinal Study. *Psychosomatic Medicine* 2009; 71:273-279.
267. **Patten SB**, Williams JVA, Lavorato DH, Brown L, McLaren L, Eliasziw M. Major depression, antidepressant medication and the risk of obesity. *Psychotherapy and Psychosomatics* 2009; 78:182-186.
268. **Patten SB**, Williams JVA, Lavorato DH, Eliasziw M. A longitudinal community study of major depression and physical activity. *General Hospital Psychiatry* 2009; 31: 571-575.
269. **Patten SB**, Williams JVA, Lavorato DH, Eliasziw M. The effect of major depression on participation in preventive activities. *BMC Public Health* 2009; 9:87.
270. Khaled S, **Patten SB**. Cigarette Smoking “Stages of Change” and Major Depression in the Canadian Population. *Canadian Journal of Psychiatry* 2009; 54(3):204-208.
271. **Patten SB**, Williams JV, Lavorato DH, Eliasziw M. Allergies and Major Depression: A Longitudinal Community Study. *Biopsychosocial Medicine* 2009; 3:3.
272. **Patten SB**, Schopflocher D. Longitudinal Epidemiology of Major Depression As Assessed by the Patient Health Questionnaire (PHQ-9). *Comprehensive Psychiatry* 2009; 50: 26-33.
273. **Patten SB**, Paris J. The Bipolar spectrum – A bridge too far? *The Canadian Journal of Psychiatry*, 2008; 53(11):762-768.

274. Cohen JS, Leung Y, Fahey M, Hoyt L, Sinha R, Cailler L, Ramchandar K, Martin J and **Patten S**. The happy docs study: a Canadian Association of Interns and Residents well-being survey examining resident physician satisfaction within and outside of residency training in Canada. BMC Research Notes 2008; <http://www.biomedcentral.com/1756-0500/1/105>.
275. **Patten SB**. Sensitization: the *Sine Qua Non* of the Depressive Disorders? Medical Hypotheses 2008;71:872-875.
276. **Patten SB**, Bilsker D, Goldner E. The evolving understanding of major depression epidemiology: Implications for practice and policy. The Canadian Journal of Psychiatry 2008;53(10):689-695.
277. **Patten SB**, Williams JVA, Lavorato DH, Modgill G, Jette N, Eliasziw M. Major Depression as a Risk Factor for Chronic Disease Incidence: Longitudinal Analyses in a General Population Cohort. General Hospital Psychiatry 2008;30:407-413.
278. **Patten SB**. Confounding by Severity and Indication in Observational Studies of Antidepressant Effectiveness. Canadian Journal of Clinical Pharmacology 2008; 15(2):e367-e371.
279. **Patten SB**. Major depression prevalence is very high, but the syndrome is a poor proxy for community populations' clinical treatment needs. Canadian Journal of Psychiatry 2008; 53(7):411-419.
280. Maxwell CJ, Dalby DM, Slater M, **Patten SB**, Hogan DB, Eliasziw M. The prevalence and management of persistent pain among older home care residents. Pain 2008; 138:208-216.
281. Dalby DM, Hirdes JP, Hogan DB, **Patten SB**, Beck CA, Rabinowitz T, Maxwell CJ. Potentially inappropriate management of depressive symptoms among Ontario home care clients. International Journal of Geriatric Psychiatry 2008;23:650-659.
282. **Patten SB**, Williams JVA, Mitton C. Costs Associated with Mood and Anxiety Disorders as evaluated by Telephone Survey. Chronic Diseases in Canada 2008; 28(4):155-162.
283. Jette N, Williams JVA, **Patten SB**, Weibe S, Becker W. Comorbidity of Migraine and Psychiatric Disorders – A National Population-Based Study. Headache 2008;48:501-516.
284. **Patten SB**. Still No Evidence that Benzodiazepines Cause Depression. International Journal of Psychiatry in Clinical Practice 2008; 12(1):85-88.
285. **Patten SB**, Williams JVA, Metz LM. Antidepressant Use in Association with Interferon and Glatiramer Acetate Treatment in Multiple Sclerosis. Multiple Sclerosis 2008 14:406-411.
286. Chuang H, Mansell C, **Patten SB**. Lifestyle Characteristics of Psychiatric Outpatients. Canadian Journal of Psychiatry 2008; 53(4):260-265.
287. Fitzgerald C³¹, **Patten S**. Assessing depression in multiple sclerosis. Current Psychiatry 2008;

³¹ Research conducted while Dr. Fitzgerald was a Resident in Psychiatry.

- 4(4):79-86.
288. McLaren L, Beck C³², **Patten SB**, Adair CE. The relationship between body mass index and mental health: a population-based study of the effects of the definition of mental health. *Social Psychiatry and Psychiatric Epidemiology* 2008; 43: 63-71.
289. Bulloch A, **Patten SB**. Non-remission of depression in the general population as assessed by the HAM-D-7 scale. *Depression and Anxiety* 2008; 25:393-397.
290. **Patten SB**, Newman SC, Becker M, Riddell C, Metz LM. Disease Management for Depression in Multiple Sclerosis. *International Journal of Psychiatry in Medicine* 2007; 37(4):459-473.
291. Tellez-Zenteno JF, **Patten SB**, Jette N, Williams J, Wiebe S. Psychiatric Comorbidity in Epilepsy: A Population-based Analysis. *Epilepsia* 2007; 48: 2336-2344.
292. Esposito E³³, Wang JL, Adair CE, Williams JVA, Dobson K, Schopflocher D, Mitton C, Newman S, Beck C, Barbui C, **Patten SB**. Frequency and Adequacy of Depression Treatment in a Canadian Population Sample. *Canadian Journal of Psychiatry* 2007; 52(12) 780-789.
293. **Patten SB** and Williams JVA. Chronic Obstructive Lung Diseases and Prevalence of Mood, Anxiety and Substance-use Disorders in a Large Population Sample. *Psychosomatics* 2007; 48(6):496-501.
294. Mitton C, Adair CE, McKenzie E, **Patten S**, Waye-Perry B. Knowledge Transfer and Exchange: Review and Synthesis of the Literature. *Milbank Quarterly* 2007;45(4):729-768.
295. Esposito E³⁴, Wang JI, Williams JVA, **Patten SB**. The Impact of Mood and Anxiety Disorders on Presenteeism in Employed Members of a General Population Sample. *Psichiatria e Epidemiologia Sociale* 2007;16(3):231-237.
296. el-Guebaly N., Currie S, **Patten SB**, Williams J, Wang JL, Beck CA³⁵, Maxwell C. Association of Mood, Anxiety and Substance use Disorders with Labor Force Participation in a Community Sample. *Psychiatric Services* 2007; 58: 657-659.
297. Cohen J, Adams S, **Patten S**. No Association Between Patients Receiving Isotretinoin for Acne and the Development of Depression in a Canadian Prospective Cohort. *Canadian Journal of Clinical Pharmacology* 2007; 14: e227-e233
298. **Patten SB**, Liu MF. Anxiety Disorders and Chronic Disease Determinants in a Population Sample. *Internet Journal of Mental Health* 2007: 4; 1.
299. **Patten SB**, Esposito E³⁶, Carter BC. Reasons for Antidepressant Prescription in Canada. *Pharmacoepidemiology and Drug Safety* 2007; 16: 746-52.

³² Research conducted while Dr. Beck was a PhD student under my supervision.

³³ Research conducted while Dr. Esposito was a visiting postgraduate student from the University of Verona, Italy.

³⁴ Research conducted while Dr. Esposito was a visiting postgraduate student from the University of Verona, Italy.

³⁵ Research conducted while Dr. Beck was a PhD student under my supervision.

³⁶ Research conducted while Dr. Esposito was a visiting postgraduate student from the University of Verona, Italy.

300. **Patten SB**. An Animated Depiction of Major Depression Epidemiology. *BMC Psychiatry* 2007;7:23.
301. Addington D, Addington J, McKenzie E, **Patten SB**. Application of Essential Performance Measures for Evaluating Services for People with a First Episode Psychosis. *Early Intervention in Psychiatry* 2007;1:157-167.
302. **Patten SB**, Williams JVA. Assessment of physical etiologies for mood and anxiety disorders in structured diagnostic interviews. *Social Psychiatry and Psychiatric Epidemiology* 2007; 42(6): 462-466.
303. Svenson LW, Warren S, Warren KG, Metz LM, **Patten SB**, Schopflocher DP. Prevalence of Multiple Sclerosis in First Nations People of Alberta. *Canadian Journal of Neurological Sciences* 2007; 34: 175-180.
304. Supina AL³⁷, Johnson JA, **Patten SB**, Williams JV, Maxwell CJ. The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety. *Quality of Life Research*. 2007; 16(5): 749-754.
305. Wang, JL and **Patten SB**. Perceived effectiveness of mental health care provided by primary care physicians and mental health specialists. *Psychosomatics* 2007; 48(2):123-127.
306. **Patten SB**, Williams JVA. Self-reported Allergies and Their Relationship to Several Axis I Disorders in a Community Sample. *International Journal of Psychiatry in Medicine* 2007; 37(1):11-22.
307. Addington D, Addington J, **Patten SB**. Relapse Rates in an Early Psychosis Treatment Services. *Acta Psychiatrica Scandinavica* 2007; 115:126-131.
308. **Patten SB**, Svenson LW, White CM, Khaled SM³⁸, Metz LM. Affective Disorders in Motor Neuron Disease: a Population-based Study. *Neuroepidemiology* 2007;28:1-7
309. **Patten SB**, Adair CE, Williams JVA, Brant R, Wang, JL, Casebeer A, Beauséjour P. Assessment of Mental Health and Illness by Telephone Survey: Experience with an Alberta Mental Health Survey. *Chronic Diseases in Canada* 2006; 27(3):99-109.
310. Kassam A³⁹, **Patten SB**. Hypnotic use in a population-based sample of over 35 thousand interviewed Canadians. *Population Health Metrics* 2006, 4:15.
311. **Patten SB**, Williams JVA, Esposito E⁴⁰, Beck CA. Self-reported thyroid disease and mental disorder prevalence. *General Hospital Psychiatry* 2006; 28:504-508.
312. Pierson K, Addington D, Addington J, **Patten S**. Serum Monitoring of Antipsychotic Drug Levels during Concomitant Administration of Sertraline and Antipsychotic Medication. *Canadian*

³⁷ Research conducted while I was a member of Dr. Supina's PhD supervisory committee.

³⁸ Research conducted while Ms. Khaled was a PhD student under my supervision.

³⁹ Research conducted while Ms. Kassam was an MSc student under my supervision.

⁴⁰ Research conducted while Dr. Esposito was a visiting postgraduate student from the University of Verona, Italy.

- Journal of Psychiatry 2006; 51(11):715-718.
313. Thurston WE, **Patten SB**, Lagendyk LE. Prevalence of Violence Against Women Reported in a Rural Health Region. *Canadian Journal of Rural Medicine* 2006;11(4):259-267.
 314. el-Guebaly N, **Patten SB**, Currie S, Williams JVA, Beck CA, Maxwell CJ, Wang JL. Epidemiological Associations between Gambling Behavior, Substance Use & Mood and Anxiety Disorders. *Journal of Gambling Studies* 2006 Fall; 22(3):275-87.
 315. Bulloch AG, Adair CE, **Patten SB**. Forgetfulness: A role in non-compliance with antidepressant treatment. *Canadian Journal of Psychiatry* 2006; 51(11): 719-722.
 316. **Patten SB**. A major depression prognosis calculator. *Clinical Practice and Epidemiology in Mental Health* 2006; 2: 13.
 317. Wang JL, Adair CE, **Patten SB**. Mental Health and Related Disability among Workers: A Population-based Study. *American Journal of Industrial Medicine* 2006; 49: 514-522.
 318. Vik S⁴¹, Hogan D, **Patten SB**, Johnson JA, Romonko-Slack L, Maxwell CJ. Medication Nonadherence and Subsequent Risk of Hospitalization and Mortality among Older Adults. *Drugs and Aging* 2006; 23: 345-356.
 319. Supina AL, **Patten SB**. Self-reported diagnoses of schizophrenia and psychotic disorders may be valuable for monitoring and surveillance. *Canadian Journal of Psychiatry* 2006; 51: 256-259.
 320. Kassam A⁴², **Patten SB**. Canadian Trends in Benzodiazepine & Similar Sedative-Hypnotic Use. *Canadian Journal of Clinical Pharmacology* 2006; 13: e121-e127.
 321. **Patten SB**. Psychiatric Side Effects of Interferon Treatment. *Current Drug Safety* 2006; 1: 143-150.
 322. **Patten SB**, Williams JVA, Wang JL. Mental Disorders in a Population Sample with Musculoskeletal Disorders. *BMC Musculoskeletal Disorders* 2006; 7: 37.
 323. Kassam A⁴³, Carter B, **Patten SB**. Sedative Hypnotic Use in Alberta. *Canadian Journal of Psychiatry* 2006; 51; 287-294.
 324. **Patten SB**, Wang JL, Williams JV, Currie S, Beck CA, Maxwell CJ, el-Guebaly N. Descriptive epidemiology of Major Depression in Canada. *Canadian Journal of Psychiatry* 2006; 51: 84-90.
 325. Kassam A⁴⁴, **Patten SB**. Major Depression, Fibromyalgia and labour force participation: A population-based cross-sectional Study. *BMC Musculoskeletal Disorders* 2006; 7: 4.

⁴¹ Research conducted while I was a member of Dr. Vik's PhD supervisory committee.

⁴² Research conducted while Ms. Kassam was a Masters student under my supervision.

⁴³ Research conducted while Ms. Kassam was a Masters student under my supervision.

⁴⁴ Research conducted while Ms. Kassam was a Masters student under my supervision.

326. **Patten SB**. Does Almost Everybody Suffer from a Bipolar Disorder? *Canadian Journal of Psychiatry* 2006; 51: 6-8.
327. **Patten SB**, Lee RC. Describing Major Depression Incidence and Recurrence Patterns Using Markov Models: Data Integration Across 3 National Surveys. *Population Health Metrics* 2005; 3: 11
328. **Patten SB**, Wang JL, Beck CA⁴⁵, Maxwell CJ. Measurement issues related to the evaluation and monitoring of mood disorder prevalence in Canada. *Chronic Diseases in Canada* 2005; 26: 100-106.
329. Addington D, McKenzie E, Addington J, **Patten S**, Smith H, Adair C. Performance Measures for Application in Early Psychosis Programs. *Psychiatric Services* 2005; 56: 1570-1582.
330. Molgat CV⁴⁶, **Patten SB**. Comorbidity of Major Depression and Migraine-A Canadian Population-based Study. *Canadian Journal of Psychiatry* 2005; 50: 832-837.
331. **Patten SB**, Williams JVA, Wang JL, Adair C, Brant R, Casebeer A, Barbui C. Antidepressant Pharmacoepidemiology in a General Population Sample. *Journal of Clinical Psychopharmacology* 2005; 25(3):285-286.
332. Beck CA⁴⁷, **Patten SB**, Williams J, Wang JL, Currie S, Maxwell C, El Guebaly. Antidepressant utilization in Canada. *Social Psychiatry and Psychiatric Epidemiology* 2005; 40(10):799-807.
333. **Patten SB**, Lavorato DH, Metz LM. Clinical Correlates of CES-D Depressive Symptom Ratings in an MS Population. *General Hospital Psychiatry* 2005;27:439-445.
334. Barbui C, Nosè M, Rambaldelli G, Bonetto C, Levi D, **Patten SB**, Tansella M. Development of a registry for monitoring psychotropic drug prescriptions : aims, methods and implications for ordinary practice and research. *International Journal of Methods in Psychiatric Research* 2005; 14: 151-157.
335. **Patten SB**, Svenson LW, Metz LM. Psychotic Disorders in MS. Population-based Evidence of an Association. *Neurology* 2005; 65: 1123-1125.
336. White WD⁴⁸, Crockford D, **Patten SB**, El-guebaly N. Randomized, Open-label Comparison of Gabapentin and Bupropion SR for Smoking Cessation. *Nicotine & Tobacco Research* 2005; 7(5):809-813.
337. Currie SR, **Patten SB**, Williams JVA, Wang JL, Beck CA⁴⁹, El-Guebaly N, Maxwell CJ. Comorbidity of major depression with substance use disorders. *Canadian Journal of Psychiatry* 2005; 50(10):660-666.

⁴⁵ Research conducted while Dr. Beck was a PhD student under my supervision.

⁴⁶ This research was conducted when Dr. Molgat was a post-graduate clinical trainee (resident) in psychiatry.

⁴⁷ Research conducted while Dr. Beck was a PhD student under my supervision.

⁴⁸ Research conducted while Dr. White was a Psychiatry Resident.

⁴⁹ Research conducted while Dr. Beck was a PhD student under my supervision.

338. Wang JL, **Patten B**, Williams J VA, Currie S, Beck CA⁵⁰, Maxwell CJ, el-Guebaly N. Help-seeking behaviours of individuals with mood disorders. *Canadian Journal of Psychiatry* 2005; 50(10):652-659.
339. Beck CA⁵¹, Williams JVA, Wang JL, Kassam A, El-Guebaly N, Currie SR, Maxwell CJ, and **Patten SB**. Psychotropic medication use in Canada. *Canadian Journal of Psychiatry* 2005; 50(10):605-613.
340. Beck CA⁵², Metz LM, Svenson LW, **Patten SB**. Regional variation of multiple sclerosis prevalence in Canada. *Multiple Sclerosis* 2005; 11(5):516-519.
341. Cohen J⁵³, **Patten SB**. The Happy Doc Study: a Canadian pilot study examining resident physician health and well-being, stressors and resources. *BMC Medical Education* 2005, 5: 21.
342. Schiffer RB, Goldman Consensus Conference Members (including **Patten SB**). The Goldman Consensus Statement on Depression in Multiple Sclerosis. *Multiple Sclerosis* 2005; 11:328-337.
343. **Patten SB**. Modeling major depression epidemiology and the impact of antidepressants on population health. *International Review of Psychiatry* 2005; 17(3):205-211.
344. **Patten SB**, Svenson LW, Metz LM. Descriptive Epidemiology of Affective Disorder in Multiple Sclerosis. *CNS Spectrums* May 2005; 10(5):365-71.
345. Vik S, Maxwell C, Hogan DB, **Patten SB**, Johnson JA, Romonko-Slack L. Assessing Medication Adherence among Older Persons in Community Settings. *Canadian Journal of Clinical Pharmacology* 2005; 12: e152-64.
346. **Patten SB**. Markov models of major depression for linking psychiatric epidemiology to clinical practice. *BMC Clinical Practice and Epidemiology in Mental Health* 2005; 1: 2. <http://www.cpementalhealth.com/content/1/1/2>.
347. Pandya R⁵⁴, Metz LM, **Patten SB**. Predictive Value of the Center for Epidemiological Studies Depression Rating Scale in Disease-modifying Treatment Candidates with multiple sclerosis. *Psychosomatics* 2005; 46: 131-134.
348. **Patten SB**. Treatment of Neuropsychiatric Syndromes in MS. *Expert Review of Neurotherapeutics* 2005; 5: 413-420.
349. Barbui C, Ciuna A, Nosè M, Levi D, Andretta M, **Patten SB**, Amaddeo F, and Tansella M. Drug treatment modalities in psychiatric inpatient practice. A 20-year comparison. *European Archives of Psychiatry and Clinical Neuroscience* 2005; 255:136-142.
350. **Patten SB**, Beck CA⁵⁵, Kassam A, Williams JVA, Barbui C, Metz L. Long-term medical

⁵⁰ Research conducted while Dr. Beck was a PhD student under my supervision.

⁵¹ Research conducted while Dr. Beck was a PhD student under my supervision.

⁵² Research conducted while Dr. Beck was a PhD student under my supervision.

⁵³ Research conducted while Dr. Cohen was a Psychiatry Resident.

⁵⁴ Research conducted while Dr. Pandya was a Psychiatry Resident.

⁵⁵ Research conducted while Dr. Beck was a PhD student under my supervision.

- conditions and major depression: Strength of association for specific conditions in the general population. *Canadian Journal of Psychiatry* 2005; 50(4):195-202.
351. **Patten SB.** An analysis of data from two general health surveys found that increased incidence and duration contributed to elevated prevalence of major depression in persons with chronic medical conditions. *Journal of Clinical Epidemiology* 2005; 58: 184-189.
352. Zabad R, Metz LM, **Patten SB.** The Association of Depression with Disease Course in Multiple Sclerosis. *Neurology* 2005; 64:359-360.
353. **Patten SB,** Cipriani A, Brambilla P, Nosè M, Barbui C. International dose differences in fluoxetine clinical trials conducted in patients with depression. *Canadian Journal of Psychiatry* 2005; 50(1): 31-38.
354. **Patten SB,** Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The Relationship between Depression and Interferon beta-1a therapy in patients with multiple sclerosis. *Multiple Sclerosis* 2005; 11: 175-181.
355. **Patten SB.** The Impact of Antidepressant Treatment on Population Health. Synthesis of Data from Two National Data Sources in Canada. *Population Health Metrics* 2004; 2: 9.
<http://www.pophealthmetrics.com/content/2/1/9>
356. **Patten SB,** Lee RC. Epidemiological theory, decision theory and health services research. *Social Psychiatry and Psychiatric Epidemiology* 2004; 39: 893-898.
357. **Patten SB,** Arboleda-Florez J, Epidemic theory and group violence. *Social Psychiatry & Psychiatric Epidemiology* 2004; 39; 853-856
358. Barbui C, Ciuna A, Nosé M, Levi D, **Patten S,** Amadeo F, Tansella M The changing pattern of inpatient antipsychotic drug use in Italy. *Journal of Clinical Psychopharmacology* 2004; 24: 559-561.
359. **Patten SB,** Lee RC. Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov Model. *Medical Decision Making* 2004; 24; 4: 351-358.
360. Beck CA⁵⁶, **Patten SB.** Adjustment of antidepressant utilization rates to account for major depression in remission. *Comprehensive Psychiatry* 2004; 45: 268-274.
361. Metz LM, **Patten SB,** Archibald CJ, Bakker JI, Harris CJ, Patry DP, Bell RB, Yeung M, Power C, Murphy WF, Pederson C, Stoian C, Rose S, Billesberger K, Tillotson L, Peters S, McGowan D. The effect of immunomodulatory therapy on multiple sclerosis fatigue. *Journal of Neurology, Neurosurgery and Psychiatry* 2004; 75: 1045-1047.
362. **Patten SB,** Barbui C. Drug-induced depression. A systematic review to inform clinical practice. *Psychotherapy and Psychosomatics* 2004; 73:207-215.
-

⁵⁶ Research conducted while Dr. Beck was a PhD student under my supervision.

363. **Patten SB**, Beck CA⁵⁷. Major Depression and Mental Health Care Utilization in Canada, 1994-2000. *Canadian Journal of Psychiatry* 2004; 49: 303-309. (reviewed by *Evidenced-based Mental Health* 2005; 8:26)
364. **Patten SB**, Lee RC. Towards a dynamic description of major depression epidemiology. *Epidemiologia Psychiatria Sociale* 2004; 13: 21-28.
365. Barbui C, Ciuna A, Nosè M, **Patten SB**, Stegagno M, Burti L, Amaddeo F, Tansella M. Off-label and non-classical prescriptions of antipsychotic agents in ordinary practice in Italy. *Acta Psychiatria Scandinavia* 2004; 109: 275-278.
366. Neutel CI, Walop W, **Patten SB**. Can continuing benzodiazepine use be predicted? *Canadian Journal of Clinical Pharmacology* 2003; 10: 202-206.
367. **Patten SB**, Fridhandler S⁵⁸, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort. *Multiple Sclerosis* 2003; 9: 616-620.
368. **S.B. Patten**, C.A. Beck⁵⁹, J.V.A. Williams, C. Barbui, and L.M. Metz. Major depression in multiple sclerosis: A population-based perspective. *Neurology* 2003; 61: 1524-1527.
369. Szádóczy E, Rózsa S, **Patten S**, Arató M and Füredi J. Lifetime patterns of depressive symptoms in the community and among primary care attenders: an application of grade of membership analysis. *Journal of Affective Disorders* 2003; 77: 31-39.
370. **Patten SB**, Holley HL, Russell ML, Maxwell CJ, Arboleda-Florez J. The Epidemiology of Major Depression in a Predominantly Rural Health Region. *Social Psychiatry and Psychiatric Epidemiology* 2003; 38:360-365.
371. **Patten SB**. International differences in major depression prevalence, what do they mean? *Journal of Clinical Epidemiology* 2003; 56: 711-716.
372. Fengxiao L, Hilsden RJ, **Patten SB**, Sutherland LR. Irritable bowel syndrome and health-related quality of life. *Canadian Journal of Gastroenterology* 2003; 56: 256-261.
373. **Patten SB**. Recall bias and major depression lifetime prevalence. *Social Psychiatry and Psychiatric Epidemiology* 2003; 38: 290-296.
374. **Patten SB**, Li FX, Cook T, Hilsden RJ, Sutherland LR. Irritable bowel syndrome: are incentives useful for improving survey response rates? *Journal of Clinical Epidemiology* 2003; 56: 256-261.
375. Wang JL, Langille DB, **Patten SB**. Mental Health Services Received by Depressed Persons who Visited General Practitioners and Family Doctors. *Psychiatric Services* 2003; 54: 878-883.

⁵⁷ Research conducted while Dr. Beck was a PhD student under my supervision.

⁵⁸ Research conducted while Ms. Fridhandler was an undergraduate student.

⁵⁹ Research conducted while Dr. Beck was a PhD student under my supervision.

376. **Patten SB.** Prevention of Depressive Symptoms Using Distance Technologies, A Randomized-Controlled Trial. *Psychiatric Services* 2003; 54: 396-398.
377. Ramasubbu R, **Patten SB.** Effects of depression on stroke morbidity and mortality. *Canadian Journal of Psychiatry* 2003; 48: 250-257.
378. **Patten SB.** A Framework for Simulating the Impact of Antidepressant Medications on Population Health Status. *Pharmacoepidemiology and Drug Safety* 2002; 11: 549 – 559.
379. **Patten SB.** Progress against major depression in Canada. *Canadian Journal of Psychiatry* 2002; 47: 775-780.
380. **Patten SB.** Major depressive episodes and diet pills. *Expert Opinion in Pharmacotherapy* 2002; 3: 1405-1409.
381. **Patten SB,** Metz LM. Hopelessness Ratings in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. *The International Journal of Psychiatry in Medicine* 2002; 32: 155-166.
382. **Patten SB,** Jacobs P, Petcu R, Reimer MA, Metz LM. Major Depressive Disorder as a Direct Cost Determinant in Multiple Sclerosis. *The International Journal of Psychiatry in Medicine* 2002; 32: 167-178.
383. **Patten SB,** Metz LM. Interferon β -1a and Depression in Secondary Progressive MS: Data from the SPECTRIMS Trial. *Neurology* 2002; 59: 744-746.
384. Bristow K⁶⁰, **Patten SB.** Treatment-seeking rates and Associated Mediating Factors Among Individuals with Depression. *Canadian Journal of Psychiatry* 2002; 47: 660-665.
385. Simpson S, Carlson L, Beck C⁶¹, **Patten SB.** Effects of a Brief Intervention on Social Support and Psychiatric Morbidity in Breast Cancer Patients. *Psycho-Oncology* 2002; 11: 282 – 294.
386. **Patten SB,** Lee RC. Modeling Methods for Facilitating Decisions in Pharmaceutical Policy and Population Therapeutics. *Pharmacoepidemiology and Drug Safety* 2002; 11: 165-168.
387. Wang JL, **Patten SB.** The moderating effects of coping strategies on major depression in the general population. *Canadian Journal of Psychiatry* 2002; 47: 167-173.
388. ⁶²Gagnon LM, **Patten SB.** Major depression and its association with long-term medical conditions. *Canadian Journal of Psychiatry* 2002; 47: 149-152.
389. Addington D, Addington J, **Patten S,** Remington G, Moamai J, LaBelle A, Beauclair L. A double blind, placebo-controlled comparison of sertraline for major depression in patients with remitted schizophrenia. *Journal of Clinical Psychopharmacology* 2002; 22: 20-25.

³⁸ Research conducted under my supervision while Dr. Bristow was a medical student, and subsequently a psychiatry resident.

⁶¹ Research conducted while Dr. Beck was a Psychiatry Resident.

⁶² Research conducted under my supervision while Dr. Gagnon was a Medical Student.

390. Wang JL⁶³, **Patten SB**. Prospective study of frequent heavy alcohol use and the risk of major depression in the Canadian general population. *Depression and Anxiety* 2002; 15: 42-45.
391. **Patten SB**. Descriptive Epidemiology of a Depressive Syndrome in a Western Canadian Community Population. *Canadian Journal of Public Health* 2001; 92: 392-395.
392. Wang JL⁶⁴, **Patten SB**. Perceived work stress and major depression in the Canadian employed population. *Journal of Occupational Health Psychology* 2001; 6: 283-289.
393. **Patten SB**, Sedmak B, Russell ML. Major Depression Prevalence, Treatment Utilization and Age in Canada. *Canadian Journal of Clinical Pharmacology* 2001; 8: 133-138.
394. Wang JL⁶⁵, **Patten SB**. Alcohol consumption and major depression: findings from a follow-up study. *Canadian Journal of Psychiatry* 2001; 46: 632-638.
395. **Patten SB**, Metz LM. Interferon -1a and Depression in Relapsing/Remitting Multiple Sclerosis: An Analysis of Depression Data from the PRISMS Clinical Trial. *Multiple Sclerosis* 2001; 7: 243-248.
396. Wang JL, **Patten SB**, Russell ML. Alternative medicine use by individuals with major depression. *Canadian Journal of Psychiatry* 2001; 46: 528-533.
397. **Patten SB**. "Diet Pills" and Major Depression in the Canadian Population. *Canadian Journal of Psychiatry* 2001; 46: 438-440.
398. ⁶⁶Wang JL, **Patten SB**. A prospective study of sex-specific effects of major depression on alcohol consumption. *Canadian Journal of Psychiatry* 2001; 46: 422-425.
399. **Patten SB**. The duration of major depression in the Canadian population. *Chronic Diseases in Canada* 2001; 22: 6-11.
400. **Patten SB**, Williams JVA, Petcu R, Oldfield R. Delirium in Psychiatric Inpatients: A Case-control Study. *Canadian Journal of Psychiatry* 2001; 46: 162-166.
401. **Patten SB**. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. *Journal of Affective Disorders* 2001; 63(1-3):35-41.
402. **Patten SB**, Lavorato DH. Medication Use and Major Depressive Syndrome in a Community Population. *Comprehensive Psychiatry* 2001; 42: 124-131.
403. ⁶⁷Oster A, Bernbaum S, **Patten S**. Determinants of violence in the psychiatric emergency service. *Canadian Medical Association Journal* 2001; 164: 32-33.
404. **Patten SB**. Major Depression Prevalence in Calgary. *Canadian Journal of Psychiatry* 2000; 45:

⁶³ Research conducted while Dr. Wang was a PhD Student under my co-supervision.

⁶⁴ Research conducted while Dr. Wang was a PhD Student under my co-supervision

⁶⁵ Research conducted while Dr. Wang was a PhD Student under my co-supervision

⁶⁶ Research conducted under my supervision while Dr. Wang was a PhD student.

⁶⁷ Research conducted under my supervision while Dr. Oster was a Medical Student.

- 923-926.
405. ⁶⁸Wang JL, Reimer M, Metz LM, **Patten SB**. Major depression and quality of life in individuals with multiple sclerosis. *International Journal of Psychiatry in Medicine* 2000; 30: 305-313.
406. **Patten SB**. Exogenous Corticosteroids and Major Depression in the General Population. *Journal of Psychosomatic Research* 2000; 49: 447-449.
407. **Patten SB**. Major Depression Incidence in Canada. *Canadian Medical Association Journal* 2000;163:714-5.
408. **Patten SB**, Brandon-Christie J, Devji J, Sedmak B. Performance of the Composite International Diagnostic Interview Short Form for Major Depression in a Community Sample. *Chronic Diseases in Canada* 2000; 21: 68-72.
409. **Patten SB**. Selection Bias in Studies of Major Depression Using Clinical Subjects. *Journal of Clinical Epidemiology* 2000; 53: 351-357.
410. **Patten SB**. Psychiatric Epidemiology, A Review of New Developments. *International Medical Journal* 2000; 7: 7-12.
411. **Patten SB**, Metz LM, Reimer MA. Biopsychosocial Correlates of Major Depression in a Multiple Sclerosis Population. *Multiple Sclerosis* 2000; 6: 115-120.
412. **Patten SB**. The Specificity of Epidemiological Correlates of Major Depression. *Comprehensive Psychiatry* 2000; 41: 92-96.
413. ⁶⁹Baranowski SL, **Patten SB**. The Predictive Value of Dysgraphia and Constructional Apraxia in Psychiatric Inpatients. *Canadian Journal of Psychiatry* 2000; 45: 75-78.
414. **Patten SB**, Neutel CI. Corticosteroid-Induced Adverse Psychiatric Effects; Incidence, Diagnosis and Management. *Drug Safety* 2000; 22: 111-122.
415. Metz LM, **Patten SB**, McGowan DM. Symptomatic Therapies in Multiple Sclerosis. *Biomedicine & Pharmacotherapy* 1999; 53: 371-379.
416. ⁷⁰Lavorato DH, **Patten SB**. Antihypertensive Medications and Depression, an Historical Perspective. *Journal of Pharmacoepidemiology and Drug Safety* 1999; 8: 355-359.
417. **Patten SB**. Depressive Symptoms and Disorders, Levels of Functioning and Psychosocial Stress: an Integrative Hypothesis. *Medical Hypotheses* 1999; 53: 210-216.
418. **Patten SB**. Epidemics of Violence. *Medical Hypotheses* 1999; 53: 217-220.
419. **Patten SB**. Exogenous Corticosteroid Exposures are Associated with Increased Recollection of Traumatic Events. *Journal of Affective Disorders* 1999; 53: 123-128.

⁶⁸ Research conducted under my supervision while Dr. Wang was a PhD student.

⁶⁹ Research conducted under my supervision while Ms. Baranowski was a Medical Student.

⁷⁰ Research conducted under my supervision while Ms. Lavorato was a Master's student.

420. **Patten SB.** Long Term Medical Conditions and Major Depression in the Canadian Population. *Canadian Journal of Psychiatry* 1999; 44: 151-157.
421. **Patten SB.** Integrating Data from Clinical and Administrative Databases in Pharmacoepidemiological Research. *Canadian Journal of Clinical Pharmacology* 1998; 5(2): 92-97.
422. **Patten SB, Charney DA.** Alcohol Consumption and Major Depression in the Canadian General Population. *The Canadian Journal of Psychiatry. Canadian Journal of Psychiatry* 1998; 43: 502-506
423. Addington D, Addington J, **Patten S.** Depression in first episode schizophrenia. *British Journal of Psychiatry* 1998; 172(suppl. 33): 89-91.
424. Neutel CI, **Patten SB.** Risk of suicide attempts after benzodiazepine and/or antidepressant use. *Annals of Epidemiology* 1997; 7: 568-574.
425. **Patten SB, Williams JVA, Love EJ.** Case-control Studies of Cardiovascular Medications as Risk Factors for Clinically Diagnosed Depressive Disorders in a Hospitalized Population. *Canadian Journal of Psychiatry* 1996; 41: 469-476.
426. **Patten SB, Metz LM.** Depression in Multiple Sclerosis. *Psychotherapy and Psychosomatics* 1997; 66: 286-292.
427. **Patten SB.** Performance of the CIDI Short Form in Clinical and Community Samples. *Chronic Disease in Canada* 1997; 18(3): 109-112.
428. **Patten SB, Williams JVA, Haynes L, McCrudden J, Arboleda-Florez J.** The Incidence of Delirium in Psychiatric Inpatient Units. *Canadian Journal of Psychiatry* 1997; 42(8): 858-863.
429. **Patten SB, Love EJ.** Drug-induced Depression (Invited Manuscript). *Psychotherapy and Psychosomatics* 1997; 66: 63-73.
430. Neutel CI, Hirdes JP, Maxwell CJ, **Patten SB.** New Evidence of Benzodiazepine Use and Falls: The Time Factor. *Age and Ageing* 1996; 25: 273-278.
431. Addington D, Addington J, **Patten SB.** Gender and Affect in Schizophrenia. *Canadian Journal of Psychiatry* 1996; 41: 263 - 268.
432. **Patten SB, Williams JVA, Love EJ.** Depressive Symptoms Attributable to Medication Exposures in a Medical Inpatient Population. *Canadian Journal of Psychiatry* 1996; 41(10): 651-654.
433. **Patten SB, Williams JVA, Love EJ.** Self-reported Depressive Symptoms Following Treatment with Corticosteroids and Sedative-hypnotics. *The International Journal of Psychiatry in Medicine* 1996; 26 (1); 15-24.
434. **Patten SB, Williams JVA, Love EJ.** A Case-Control Study of Corticosteroid Exposure as a Risk Factor for Clinically Diagnosed Depressive Disorders in a Hospitalized Population. *Canadian*

- Journal of Psychiatry 1995; 40: 396-400.
435. **Patten SB**, Williams JVA, Love EJ. Self-Reported Depressive Symptoms in Association with Medication Exposures Among Medical Inpatients: A Cross-Sectional Study. *Canadian Journal of Psychiatry* 1995; 40, 264-269.
 436. **Patten SB**, Love EJ. Neuropsychiatric Adverse Drug Reactions: Passive Reports to Health and Welfare Canada's Adverse Drug Reaction Program. *International Journal of Psychiatry in Medicine* 1994; 24, 45-62.
 437. Lamarre CJ, **Patten SB**. A Clinical Evaluation of the Neuro-Behavioral Cognitive Status Examination in a General Psychiatric Inpatient Population. *Journal of Psychiatry and Neuroscience* 1994; 19(2): 103-108.
 438. **Patten SB**, Love EJ. Drug-Induced Depression, Incidence, Avoidance and Management. (Invited Manuscript). *Drug Safety* 1994; 10(3): 208-219.
 439. **Patten SB**, Fick GH. Clinical Interpretation of the Mini-Mental Status Examination. *Journal of General Hospital Psychiatry* 1993; 15(4): 254-259.
 440. **Patten SB**, Love EJ: Can Drugs Cause Depression? A Review of the Evidence. *Journal of Psychiatry and Neuroscience* 1993; 18(3): 92-102.
 441. **Patten SB**. The Comparative Efficacy of Trazodone and Imipramine in the Treatment of Depression. *Canadian Medical Association Journal* 1992; 146(7): 1177-1182.
 442. **Patten SB**, Lupin D, Boucher SA, Lamarre CJ. The Pharmacologic Management of Refractory Depression. *Canadian Medical Association Journal* 1992; 146(4): 483-485.
 443. **Patten SB**. Can Drug Induced Depression be Identified by Their Clinical Features? *Canadian Journal of Psychiatry* 1992; 37: 213-215.
 444. **Patten SB**, Lauderdale WM. Delayed Sleep Phase Disorder After Traumatic Brain Injury. *Journal of the American Academy of Child and Adolescent Psychiatry* 1992; 31: 100-102
 445. **Patten SB**. Are the Brown and Harris "Vulnerability" Factors Risk Factors for Depression? *Journal of Psychiatry and Neuroscience* 1991; 16: 267-271.
 446. **Patten SB**. Early Parental Loss as a Risk Factor for Depression. *Canadian Journal of Psychiatry* 1991; 36: 706-711.
 447. Lamarre CJ, **Patten SB**. A Clinical Evaluation of the Modified Mini-Mental Status Examination. *Canadian Journal of Psychiatry* 1991; 36: 507-511.
 448. **Patten SB**: Non-Psychiatric Therapeutic Medications in the Etiology of Organic Depression. *Psychiatric Journal of the University of Ottawa* 1990; 15: 150-155.
 449. **Patten SB**: Propranolol and Depression, Evidence from the Antihypertensive Trials. *Canadian Journal of Psychiatry* 1990; 35: 257-259.

450. **Patten SB**, Klein GM, Lussier C, Sawa R: Organic Mania Induced by Phenytoin, A Case Report. Canadian Journal of Psychiatry 1989; 34(8): 827-828.
451. **Patten SB**, Lamarre CJ. The face-hand test: a useful addition to the psychiatric physical examination. Psychiatric Journal of the University of Ottawa 1989; 14: 554-556.

In Press:

1. Bernstein C, Marie RA, Fisk JD, Walker J, Bolton J, Lix L, Graff L, **Patten SB**. The validity and reliability of screening measures for depression and anxiety disorders in inflammatory bowel disease. (Inflammatory Bowel Diseases).
2. Marrie RA, Graff L, Walker JR, Fiske JD, **Patten SB**, Hitchon CA, Lix LM, Bolton JM, Sareen J, Katz A, Berrigan LI, Marriott JJ, Singer A, El-Gabalawy R, Peschken A, Zarychanski R. A prospective study of the effects of psychiatric comorbidity in immune-mediated inflammatory disease: rationale, protocol and participation. (JMIR Research Protocols) (*possible title change*)
3. Marrie RA, Walid R, Bolton J, Sareen J, Walker J, **Patten SB**, Singer A, Lix L, Hitchon C, El-Gabalawy, Katz A, Fisk J, Bernstein C. Physical comorbidities increase the risk of psychiatric comorbidity in immune-medicated inflammatory disease. (General Hospital Psychiatry)
4. Lister B, Bernstein CN, Graff LA, Walker JR, Fisk JD, **Patten SB**, Bolton JM, Sareen J, El-Gabalawy R, Marrie RA. Validation of the PHQ-9 for suicidal ideation in persons with inflammatory bowel disease. (Inflammatory Bowel Diseases)
5. Marrie RA, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, **Patten SB**, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Berstein C. The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis and related disorders. (Multiple Sclerosis and Related Disorders)
6. Marrie RA, Walld R, Bolton J, Sareen J, Walker JR, **Patten SB**, Singer A, Lix LM, Hitchon CA, EL-Gabalawy R, Katz A, Fisk JD, Bernstein CN. Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. (BMC Research Notes).
7. Vallerand IA, Lewinson RT, Parsons LM, Lowerison MW, Frolkis AD, Kaplan GG, Barnabe C, Bulloch AGM, **Patten SB**. Risk of depression among patients with acne in the United Kingdom: a population-based cohort study. (British Journal of Dermatology).

Under Editorial Review:

1. De Vos S, Patten S, Wit E, Berzins S, Wardenaar K, De Jonge P. Networks of depressive symptoms in patients with Multiple Sclerosis and matched controls. (Journal of Psychosomatic Research).
2. Pham T, Jette N, Bulloch AGM, Burton J, Wiebe S, **Patten SB**. The prevalence of anxiety and associated factors in persons with Multiple Sclerosis. (Multiple Sclerosis).
3. Diaz RL, Bulloch AGM, Sajobi TT, Thomas BD, Williams JVA, Lavorato DH, **Patten SB**. The healthy immigrant effect on major depression in Canada disappears with age. (Social Psychiatry)

and Psychiatric Epidemiology)

4. Altura KCC, Jette N, **Patten SB**, Williams J, Fiest KM. Medical and psychosocial outcomes in migraine – a national community-based study. (Headache)
5. Levis B, Levis AW, Sanchez T, et al “including” **Patten SB**. Differences in probability of major depression diagnostic classification between semi-structured and fully structured diagnostic interviews: an individual participant data meta-analysis. (JAMA Psychiatry)
6. Josephson CB, Engbers JDT, Jette N, **Patten SB**, Sajobi TT, Marshall D, Lowerison M, Wiebe S. Psychiatric symptoms after prescription of eight common antiepileptic drugs in general practice. (Epilepsia)
7. Fiest KM, Greenfield J, Metz LM, **Patten SB**, Jette N, Marrie RA. Concordance of Quality of Life Measures in Multiple Sclerosis. (Health and Quality of Life Outcomes).
8. Thurston W.E., **Patten S.B.**, Williams K., Amaratunga C. The impact of BSE in Canada: Results of a survey of the mental health of farmers post-BSE. (Canadian Journal of Rural Medicine).
9. Roy A, **Patten S**, Thurston W, Beran T, Crowshoe L, Tough S. Race as a determinant of prenatal depressive symptoms: Analysis of data from the "All Our Babies" study. (BMC Pregnancy and Childbirth). Submitted March 2014.

iii. Letters

1. Jette N, Fiest KM, Sauro KM, Wiebe S, **Patten SB**. Author Response: Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology* 2017; 89(6):641-642 .
2. Jorm AF, **Patten SB**, Brugha TS, Mojtabi R. Scaling-up of treatment of depression and anxiety. *The Lancet Psychiatry* 2016; 3(7):603.
3. Thombs DB, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, **Patten SB**, Turner EH, and Ziegelstein RC. Re: Re-rethinking the article by Thombs and colleagues. *CMAJ* March 6, 2012; 184:438-439.
4. Wang JL, **Patten SB**. Re: “Job strain and the risk of depression: is reporting biased? *American Journal of Epidemiology* 2011; 1250: 174: 125-126.
5. **Patten SB**. Context Dependency of Major Depression. *Psychological Medicine* 2010; 40: 1757-1758.
6. **Patten SB**. Effectiveness of Antidepressants. *The Canadian Journal of Psychiatry* 2007; 52(11): 750.
7. **Patten SB**, Barbui C. Interferon-alpha-induced depression: When a randomized trial is not a randomized controlled trial. (Reply). *Psychotherapy & Psychosomatics* 2005; 74: 387-388.
8. Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, **Patten SB**, Duquette

- P, Antel JP, Mitchell JR. Minocycline Reduces Gadolinium-enhancing MRI Lesions in Multiple Sclerosis. *Annals of Neurology* 2004; 55: 756.
9. **Patten SB**. International differences in major depression prevalence estimates. *Journal of Clinical Epidemiology* 2004; 57: 762.
 10. **Patten SB**, Beck CA. Antidepressant utilization in the general population. *American Journal of Psychiatry* 2003; 160: 189-190.
 11. **Patten SB**, Russell ML. Treatment utilization for major depression. *Canadian Journal of Clinical Pharmacology* 2002; 9: 214 & 231.
 12. Pandya R⁷¹, **Patten S**. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). *Canadian Journal of Psychiatry* 2002; 47: 686.
 13. **Patten SB**, Ramasubbu R, Simpson S. The association between stroke and depressed affect in institutionalized Canadians. *Canadian Journal of Psychiatry* 2002; 47: 343.
 14. Bristow K⁷², **Patten SB**. Using databases to prevent inpatient morbidity. *Canadian Journal of Psychiatry* 2001; 46: 455.
 15. **Patten SB**, Metz LM. Fatigue and Depression in Multiple Sclerosis. *Canadian Journal of Psychiatry* 2000; 45: 84-85.
 16. **Patten SB**. Bias in Studies Using Electronic Administrative Data Sources. *Canadian Journal of Psychiatry* 1999; 44: 188-189.
 17. Simpson S, **Patten S**. Psychosocial morbidity following stroke. *Canadian Medical Association Journal* 1999; 160(6): 780-781.
 18. **Patten SB**. Hospital Separations for Delirium in Psychiatric Patients in Canada: 1985-1994. *Canadian Journal of Psychiatry* 1998; 43: 644.
 19. **Patten SB**, Williams JVA, Love EJ. H-2 Blocker Exposure as a Risk Factor for Depression. *Canadian Journal of Psychiatry* 1996; 41: 537-538.
 20. **Patten SB**, Thompson J. Organic Depression Associated with Flunarizine (letter). *Canadian Journal of Psychiatry* 1995; 40:111-2.
 21. **Patten SB**, Fick GH. Centre Effects and Statistical Heterogeneity in Clinical Trials of Alprazolam. *Canadian Journal of Psychiatry* 1994; 39: 316-317.
 22. **Patten SB**, Lamarre CJ. Dysgraphia in Psychiatric Subjects (letter). *Canadian Journal of Psychiatry* 1989; 34(7): 746.
 23. **Patten SB**, Brager N, Sanders S: Manic Symptoms Associated With the Use of Captopril (letter). *Canadian Journal of Psychiatry* 1991; 36: 314-315.

⁷¹ Research conducted under my supervision while Dr. Pandya was a psychiatry resident.

⁷² Research conducted under my supervision while Ms. Bristow was an undergraduate student.

24. **Patten SB:** Phenytoin and Mania (letter). *Canadian Journal of Psychiatry* 1990; 35(5): 457.

iv. Books

1. **Patten SB.** *Epidemiology for Canadian Students: Principles, Methods and Tools for Critical Appraisal*, 1st Edition. Edmonton: Brush Education, 2015.

v. Book Chapters

1. Bresee LC, Sveson LW, **Patten SB.** Chapter 10: Diabetes and Mental Health Disorders in Canada. In Johnson, JA, Editors: *Alberta Diabetes Atlas 2011*. Edmonton: Institute of Health Economics; 2011; pp.163-175.
2. **Patten SB.** Chapter 6. Affective Disorders in Canada. In: *Mental Disorder in Canada, an Epidemiological Perspective*. Editors: John Cairney & David Streiner. University of Toronto Press 2010; pp. 107-125.
3. Neutel CI., **Patten SB.** Chapter 32: Epidemiology of sleep medication use in the elderly. *Principles and Practice of Geriatric Sleep Medicine*. Editors: S.R. Pandi-Perumal, Jaime M. Monti, Andrew A. Monjan. Cambridge University Press 2010; pp 332-343.
4. Bresee LC, Svenson LW, **Patten SB.** Diabetes and Mental Health Disorders in Alberta. *Alberta Diabetes Atlas 2009*. Editor: Johnson JA. Published by Institute of Health Economics, 2009; pp 176-187.
5. **Patten SB.** Chapter IX - Epidemiological Determinants of the Elevated Prevalence of Major Depression in Women. *Major Depression in Women*. Editors: Pauline R Bancroft & Leli Adley. Nova Science Publishers, 2008; pp 165-175
6. **Patten SB.** Major Depression, Age and Antidepressant Utilization in the General Population. *Trends in Depression Research*. Maurice J. Henri (ed.); Nova Science Publishers; 2006; pp 53-60.

vi. Published Abstracts

1. Fiest KM, Fisk J, **Patten SB**, Tremlett H, Wolfson C, Warren S, McKay K, Berrigan L & Marrie, RA for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECOMS). Comorbidity is associated with Pain and Fatigue in Multiple Sclerosis. American Academy of Neurology Annual Meeting, Washington, DC, April 18- 25, 2015. Abstract published in *Neurology* 2015; 84(14) Supplement:P1.114
2. Maxwell CJ, Leah J, Bronskill SE, Hogan DB, Jetté N, **Patten SB**, Jantzi M, Heckman G, Hirdes JP. The burden and correlates of persistent depressive symptoms among older home care clients with dementia. Poster presentation, Alzheimer's Association International Conference, Copenhagen, Denmark, July 12-17, 2014. Abstract published in *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* 2014 Vol. 10, Issue 4, Supplement, P602.
3. Roy A, **Patten S**, Thurston W, Tough S. Psychosocial stress partially mediates the association

- between race and prenatal depressive symptoms in a sample of pregnant women in Alberta [Abstract]. *Journal of Epidemiology & Community Health*; 2015;**69**:A4 doi:10.1136/jech-2014-205217.11 (abstract published since it was rated in the top 25 at the 2014 CSEB Student Conference).
4. Marrie R, Metz L, Alikhani K, Blevins G, Bakker J, Svenson L, Jette N, Suchowersky O, Myles ML, wall W, Newsome J, Greenfield J, Koch M, **Patten S**, Kraft S, Emery D, Goyaf M. CCSVI Treatment and comorbidity: A province wide study of Multiple Sclerosis. *International Journal of MS Care* 2013; 15(S3):99. Presented at the 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers, May 29 – June 1 2013, Orlando Florida.
 5. Maxwell CJ, Zehr M, Vu M, Hogan DB, Patten SB, Jettè N, Bronskill SE, Kergoat MJ, Heckman G, Danilla OM, Hirdes JP. Neuropsychiatric symptoms in dementia: Variation by care setting and gender.. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* 2013Vol. 9, Issue 4, Supplement, Page P758. Poster presentation, Alzheimer's Association International Conference, Boston MA, July 15-18, 2013
 6. Fiest KM, **Patten SB**, Dykeman J, Wiebe S, Lowerison M, Bulloch AGM, Atta C, Blaikie L, Carroll C & Jette N. The Neurological Disease and Depression Study (NEEDS): Epilepsy Recruitment and Methodology. 2013. *International Epilepsy Congress*, Montreal, June 2013 (poster presentation), June 23-27, 2013. *Epilepsia* 2013;54(Suppl 3):108-109
 7. Metz L, Marrie RA, Alikhani K, Blevins G, Bakker J, Svenson L, Jette N, Myles LM, Wall W, Newsome J, Greenfield J, Koch M, **Patten S**, Kraft S, Emery D, Goyal M, Suchowersky O. Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: Changes in Treatment Patterns and Opinions in a Province-wide Study. (Poster) *American Academy of Neurology 65th Annual Meeting*, March 16–23 2013. San Diego California. *Neurology* 2013;80(Suppl. S):PO5183.
 8. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. Prenatal depression in Aboriginal women: The “Voices and PHACES” Study. (Abstract). *Clinical and Investigative Medicine* 2012; 35 (6S): E10. Presented (by Amrita Roy) at the 2012 CSCI/CITAC Young Investigators Forum, September 20, 2012, Ottawa.
 9. Thege BK, Colman I, El-Guebaly N, Hodgins DC, **Patten S**, Schopflocher D, Wolfe J, Wild TC. Prevalence of behavioural and substance-related addictions: A preliminary study from Canada. *Journal of Behavioral Addictions* 2013; 2(Suppl), pp. 18. Presented at the 1st International Conference on Behavioral Addictions, March 11-12 (2013), Budapest, Hungary.
 10. Wild C, Wolfe J, Thege BK, Schopflocher D, Colman I, El-Guebaly N, Hodgins D, **Patten S**. Social judgments of behavioural versus substance-related addictions. *Journal of Behavioral Addictions* 2013; 2(Suppl), pp. 36. Presented at the 1st International Conference on Behavioral Addictions, March 11-12 (2013), Budapest, Hungary.
 11. Specogna AV, **Patten SB**, Hill MD. Factors associated with economic cost after spontaneous intracerebral hemorrhage: a Canadian example. 2012 *Canadian Stroke Congress*, September 29 – October 2, Calgary, Alberta. *Stroke* 2012; 43(11): E115-E115.

12. Specogna AV, **Patten SB**, Hill MD. The economic cost of spontaneous intracerebral hemorrhage over one decade in a Canadian centre. 2012 Canadian Stroke Congress, September 29 – October 2, Calgary, Alberta Stroke 2012; 43(11): E117.
13. Maxwell CJ, Amuah JE, Cepoiu-Martin M, Soo A, Gruneir A, Hogan DB, **Patten SB**, LeClair K, Wilson K, Strain LA. Resident and facility predictors of hospitalization among older adults with dementia residing in assisted living facilities. Oral presentation, Alzheimer's Association International Conference, Vancouver, BC, July 14-19, 2012. Abstract published in *Alzheimer's & Dementia* 2012;8(4) Suppl. P429.
14. Cepoiu-Martin M, Soo A, Strain LA, Hogan DB, **Patten SB**, Gruneir A, LeClair K, Wilson K, Amuah JE, Maxwell CJ. Resident and facility determinants of long-term care placement among older adults with dementia residing in assisted living facilities. Oral presentation, Alzheimer's Association International Conference, Vancouver, BC, July 14-19, 2012. Abstract published in *Alzheimer's & Dementia* 2012;8(4) Suppl. P251.
15. Fiest K, Dykeman J, **Patten S**; et al. The Relationship between Depression & Epilepsy: A Systematic Review and Meta-Analysis. 64th Annual Meeting of the American-Academy-of-Neurology (AAN), New Orleans, LA, April 21-28, 2012.. *Neurology* 2012; Volume: 78 (Apr), P01.042
16. Specogna A, Turin T, **Patten S**, et al. Factors Associated with Early Neurologic Deterioration after Primary Intracerebral Hemorrhage: A Systematic Review of the Literature. . 64th Annual Meeting of the American-Academy-of-Neurology (AAN), New Orleans, LA, April 21-28, 2012. *Neurology* 2012; Volume: 78 (Apr). P02.204
17. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. Methods for measuring oppression: A scoping literature review of Aboriginal population health research. 2011 CSCI/CITAC Young Investigators Forum, September 13, 2011., Ottawa, Ontario. *Clinical and Investigative Medicine* 2011; 34(6S): 1-40.
18. **Patten S**, Williams JVA, Lavorato D, Bulloch A. Disability in MS with and without mental disorders. American Academy of Neurology Annual Meeting. Honolulu, Hawaii. April 14th, 2011. Abstract published in *Neurology* 2011; 76(9), Suppl. 4: A470-A471.
19. Colman I, Naicker K, Zeng Y, Atallahjan A, Senthilselvan A, **Patten SB**. Predictors of six-year trajectories of depression in a national Canadian Sample. 3rd North American Congress of Epidemiology, Montreal, June 21-24, 2010. *American Journal of Epidemiology* 2011; 173: S62.
20. Pringsheim T, Lam D, Ching H, **PattenSB**. Neurological complications of second generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Fifteenth International Congress of Parkinson's Disease and Movement Disorders, Toronto, June 4 - 9, 2011. *Movement Disorders* 2011; 26 (Supplement 2): S45-S45
21. Roy A, Thurston WE, Tough S, **Patten SB**, Crowshoe L. Measuring oppression and other determinants of depression among pregnant Aboriginal women in the Calgary area : study design. 2010 CSCI/CITAC Young Investigators Forum, September 20-23rd, 2010, Ottawa, Ontario. *Clinical and Investigative Medicine*. 2010;33(4S):16.
22. Jette N, Pow J, McChesney J, **Patten S**, Williams J, Weibe S. A Population-Based Study of

- Health Related Quality-of-Life in Migraine and Epilepsy Compared to Asthma and Diabetes. 62nd Annual Meeting of the American Academy of Neurology, Toronto, April 10-17, 2010. *Neurology* 2010; 74 (suppl. 2): A42-A43.
23. Modgill G, **Patten SB**, Wang JL. Migraine increased the risk for major depressive episodes: national population based study. 14th International Headache Congress, Philadelphia, PA *Cephalalgia* 2009; 29(12):1355.
 24. Sloka S, Silva C, Pryse-Phillips W, Wang J, Metz L, **Patten S**, Yong VW. Environmental risks for multiple sclerosis: quantitative analyses and biological mechanisms. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Dusseldorf, Germany, September 09-12, 2009. *Multiple Sclerosis* 2009;15(9):S158.
 25. Bresee LC, Majumdar SR, **Patten SB**, Johnson, JA. Prevalence of cardiovascular disease in people with diabetes with and without schizophrenia: a population-based cohort study. from 45th Annual Meeting of the European Association for the Study of Diabetes. Vienna, Austria, September 30-October 02, 2009. *Diabetologia* 2009; 52(Suppl. 1):307.
 26. Supina AL, Hogan DB, **Patten SB**, Manns BJ, Downey W, Beck P, Maxwell CJ. The risk of institutionalization with the concurrent use of cholinesterase inhibitors (ChEIs) and potentially contraindicated medications in Alzheimer's disease (Poster Presentation). Presented at the 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI, Aug 16-19, 2009. *Pharmacoepidemiology and Drug Safety* 2009;18: S86.
 27. Metcalfe A, Williams J, **Patten S**, et al. Use of complementary and alternative medicine by people with chronic diseases: a national population-based study. 42nd Annual Meeting of the Society for Epidemiologic-Research, Anaheim, CA, June 23-26, 2009. *American Journal of Epidemiology* 2009;169(SS11):S8.
 28. Metcalfe A, Williams J, **Patten SB**, et al. Perceived unmet health care needs in those with chronic diseases despite high resource use: a national population-based study. 42nd Annual Meeting of the Society for Epidemiologic-Research, Anaheim, CA, June 23-26, 2009. *American Journal of Epidemiology* 2009;169(S11):S8.
 29. Specogna AV, Hill MD, **Patten SB**. The cost of intracerebral hemorrhage: A Canadian example. American College of Epidemiology Annual Meeting, Sept 15-18, 2007, Ft. Lauderdale, Florida. *Ann Epidemiol* 2008;17(9):735-736.
 30. Reid AY, Metcalfe A, Williams J, et al. (incl. **Patten SB**). Epilepsy is associated with greater unmet health care needs compared to asthma, diabetes or migraine despite higher health resource use - a large national population-based study. Conference Information: 62nd Annual Meeting of the American-Epilepsy-Society, DEC 05-09, 2008 Seattle, WA. *Epilepsia* 2008; 49(7):162-163.
 31. Hinnell C, Williams J, Metcalfe A, et al. (incl. **Patten SB**) Health related behaviours and health status in epilepsy compared to migraine or diabetes - a large national population-based study. 62nd Annual Meeting of the American-Epilepsy-Society, December 05-09, 2008 Seattle, WA. *Epilepsia* 2008;49(7):273.
 32. Supina AL, Hogan DB, **Patten SB**, Manns BJ, Downey W, Beck P, Maxwell CJ. The Impact on

- Prevalence of Various Definitions for Co-Medication Use of Cholinesterase Inhibitors and Potentially Contraindicated Medications in Alzheimer's Disease. *Pharmacoepidemiology and Drug Safety* 2008;17:S54 . Poster presented at the 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Copenhagen, Denmark, Aug 17-20, 2008.
33. Metz LM, Duquette P, Lavorato D, Wall W, Roger E, **Patten SB**. Survival analysis predicts that nearly half of people with MS become unemployed within 15 years of MS onset. 12th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, Washington, DC, MAY 30 - June 02, 2007. *Multiple Sclerosis* 2007, 13(9):1227.
 34. Tamburrini A-L, Friedenreich CM, Courneya KS, Jones C, **Patten S**, Yasui Y. The relation between serum cholesterol and mammographic density as a risk factor for breast cancer. The Society for Epidemiologic Research Conference, June 19 - June 22, Boston, USA. *Am J Epidemiol* 2007;165:S146
 35. Addington DE, **Patten SB**, McKenzie E, Adair C, Smith H, Addington JM. Evaluating early psychosis treatment services with performance measures. 5th International Conference on Early Psychosis, Birmingham, England, October 04-06, 2006. *Schizophrenia Bulletin* 2007, 33 (2): 481.
 36. Vik SA, Hanley DA, **Patten SB**, Verhoef M, Brasher P, Hopman W, Anatassiades T, Towheed TE. Correlates of Natural Health Product Use for Osteoporosis. *Journal of Complementary and Integrative Medicine* 2006; 1:7. Presented at the Third Annual IN-CAM Research Symposium, Calgary, Alberta, November 4 – 5, 2006.
 37. Tellez-Zenteno JF, **Patten SB**, Weibe S. Psychiatric comorbidity in epilepsy: A population-based analysis. *Epilepsia* 2005, 46(8):264-265.
 38. Svenson LW, Warren SA, Metz LM, Schopflocher DP, **Patten SB**. The incidence of multiple sclerosis among First Nations people in Alberta, Canada. *J Neurol Sci* 2005; 238 (Suppl. 1): S251. Presented at the 18th World Congress of Neurology meeting held Nov 5-11 in Sydney, Australia.
 39. Supina AL, Johnson JA, Maxwell CM, **Patten SB**, MD, Williams JVA. The Usefulness of the EQ-5D in Differentiating Among Persons with Major Depressive Episode and Anxiety. *Value in Health*, May-June 2005; 8(3):396. Presented at: EuroQoL Plenary Meeting. Oslo, Norway. September 2005.
 40. Supina AL, Maxwell CJ, Johnson JA, **Patten SB**, Williams J. The Usefulness of the EQ-5D in Differentiating Persons with and without Major Depressive Episode and, by Treatment Adequacy. *Can J Clin Pharmacol*, Winter 2005 Vol 12(1):e103. Presented at the Second Canadian Therapeutics Congress Joint Scientific Meeting of Canadian Society for Clinical Pharmacology/Canadian Association for Population Therapeutics. Vancouver, April 13-19, 2005.
 41. Beck CA, **Patten SB**, Williams JVA, Wang J, El Guebaly N, Currie S, Maxwell C. Psychotropic drug utilization in Canada. *Can J Clin Pharmacol*, Winter 2005 Vol 12(1):e93. Presented at the Second Canadian Therapeutics Congress Joint Scientific Meeting of Canadian Society for Clinical Pharmacology/Canadian Association for Population Therapeutics. Vancouver, April 13-19, 2005.

42. Beck CA, **Patten SB**. Thyroid disease and its treatment in relation to major depression in Canada. Presented at: Can J Clin Pharmacol, Spring 2004. Vol 11(1):e127 Presented at: First Canadian Therapeutics Congress/Canadian Association for Population Therapeutics. Winnipeg, June 6-8, 2004.
43. Victorino C, Vik SA, Maxwell CJ, Hogan DB, **Patten SB**. Pain management among older home care clients. Can J Clin Pharmacol, Spring 2004. Vol 11(1):e116. Presented at: First Canadian Therapeutics Congress/Canadian Association for Population Therapeutics. Winnipeg, June 6-8, 2004.
44. Metz LM, Stoian CA, Duquette P, Roger E, Svenson LW, **Patten SB**. The odds of having diabetes is reduced in people with multiple sclerosis. Canadian Congress of Neurological Sciences. Abstract Published: Canadian Journal of Neurological Sciences 2004; 31(Suppl. 1): S42.
45. Beck CA, Metz LM, **SB Patten**. Multiple sclerosis prevalence in Canada: a population-based regional comparison. Canadian Congress of Neurological Sciences. Abstract Published: Canadian Journal of Neurological Sciences 2004; 31(Suppl. 1): S40.
46. LM Metz, Stoian CA, Currie GR, Svenson LW, Myles ML, Heinrichs I, Rodgers J, Harris CJ, **Patten SB**. Indicators of quality health care: the impact of population-based MS clinic care on the use of disease modifying therapy in multiple sclerosis. Canadian Congress of Neurological Sciences. Abstract Published: Canadian Journal of Neurological Sciences 2004; 31(Suppl. 1): S15.
47. Metz LM, Yong VW, Yeung M, Patry DG, Bell RB, Zhand Y, **Patten SB**, Duquette P, Wallace C, Sevick R, Antel J, Bar-Or A, Mitchell RB. Open-Label Trial of Minocycline in Active Relapsing-Remitting Multiple Sclerosis. (Platform) Presented at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, Hawaii, March 29 – April 5, 2003. J Neurology (2003 Mar) 60 (Suppl 1): A251
48. Victorino C, Vik SA, Maxwell CJ, Hogan DB, **Patten SB**. The prevalence and management of pain among elderly home care clients. Canadian Association for Population Therapeutics Annual Forum, Quebec, March 30 – April 1, 2003. Abstract published in the Canadian Journal of Clinical Pharmacology 2003; 10: 49.
49. Vik SA, Maxwell CJ, Hogan DB, **Patten SB**, Johnson JA, Mitchell C, Romonko-Slack L. Potentially inappropriate medication use and adverse health outcomes among elderly home care clients. Canadian Association for Population Therapeutics Annual Forum, Quebec, March 30 – April 1, 2003. Abstract published in the Canadian Journal of Clinical Pharmacology 2003; 10: 49.
50. Vik SA, Maxwell CJ, Hogan DB, **Patten SB**, Johnson JA, Mitchell C, Romonko-Slack L. Medication adherence and health outcomes among elderly home care clients. Canadian Association for Population Therapeutics Annual Forum, Quebec, March 30 – April 1, 2003. Abstract published in the Canadian Journal of Clinical Pharmacology 2003; 10: 46.
51. Beck CA, **Patten SB**. Methodological issues in the estimation of antidepressant treatment rates in major depression. Canadian Association for Population Therapeutics Annual Forum, Quebec, March 30 – April 1, 2003. Abstract published in the Canadian Journal of Clinical Pharmacology 2003; 10: 43.

52. Beck CA, **Patten SB**. Getting the best data on antidepressant use in population health surveys: is asking subjects whether they are taking an antidepressant “good enough.” Canadian Association for Population Therapeutics Annual Forum, Quebec, March 30 – April 1, 2003. Abstract: *Can J Clin Pharm* 2003; 10: 39.
53. Hirdes JP, Dalby D, Maxwell CJ, **Patten SB**, Hogan DB, Beck C, Rabinowitz T. The prevalence and management of depression among elderly home care clients in Ontario. Canadian Association for Population Therapeutics Annual Forum, Quebec, March 30 – April 1, 2003. Abstract published in the *Canadian Journal of Clinical Pharmacology* 2003; 10: 28.
54. **Patten SB**, Metz LM. Hopelessness in MS. ACTRIMS/ECTRIMS (Joint meeting of the American and European Committees for Treatment and Research in Multiple Sclerosis). Baltimore, MD. September 18-21, 2002. Abstract published in *Multiple Sclerosis* 2002; 8: S110.
55. **Patten SB**, Lee RC. Use of Markov models for assessing the impact of antidepressants on population health. Canadian Association for Population Therapeutics Annual Form. Toronto, April 14-16, 2002. Abstract published in the *Canadian Journal of Clinical Pharmacology* 2002; 8: 50.
56. Vik SA, Maxwell CJ, Hogan DB, **Patten SB**, Johnson JA, Mitchel C, Romonko-Slack, Copeland M, Couchman S, Matson B, Harbridge T. Assessment of medication adherence in the real world: is pill count data useful? Canadian Association for Population Therapeutics Annual Form. Toronto, April 14-16, 2002. Abstract published in the *Canadian Journal of Clinical Pharmacology* 2002; 8: 28.
57. **Patten SB**. Antidepressant Utilization in Canada (Poster). Canadian Association for Population Therapeutics Annual Form. Toronto, April 14-16, 2002. Abstract published in the *Canadian Journal of Clinical Pharmacology* 2002; 8: 27.
58. Hilsden RJ, Li FX, **Patten SB**, Sutherland LR. Irritable bowel syndrome (IBS): Prevalence and frequency of health-related visitation. Canadian Association of Gastroenterology Annual Meeting. Montreal, Feb 2-5, 2002. Abstract published in *Canadian Journal of Gastroenterology* 2002; 16(Suppl. A): 102A
59. Hilsden RJ, Li FX, **Patten SB**, Sutherland LR. A population survey of health-related quality of life in irritable bowel syndrome. Canadian Association of Gastroenterology Annual Meeting. Montreal, Feb 2-5, 2002. Abstract published in *Canadian Journal of Gastroenterology* 2002; 16(Suppl. A): 102A.
60. **Patten SB**. What is the impact of antidepressant treatment on population mental health? 17th International Conference on Pharmacoepidemiology. Toronto, August 23-26, 2001. Abstract published in, *Pharmacoepidemiology and Drug Safety* 2001; 10(Suppl.1): S134.
61. Neutel CI, Walop W, **Patten SB**. Predicting continuing benzodiazepine use. 17th International Conference on Pharmacoepidemiology. Toronto, August 23-26, 2001. Abstract published in, *Pharmacoepidemiology and Drug Safety* 2001; 10(Suppl.1): S77.
62. Metz LM, **Patten SB**, Rose SM, McGuinness SD, Harris CJ, Bakker JI, Lagendyk L, Patry D, Yeung M, Bell RB, Power C, Murphy WF, McGowan D, Pederson C. Multiple sclerosis fatigue is decreased at 6 months by glatiramer acetate (Copaxone). European Neurological Association Meeting, Paris, April 2001. Abstract published in *J Neurology* (2001) 248 (Suppl 2):II/115.

63. Mitchell C, Johnson JA, Maxwell CJ, Vik SA, Hogan DB, Romonko-Slack L, **Patten SB**, Copeland M, Couchman S, Matson B, Harbridge T. Reliability of Likert-type versus dichotomous response options for a standardized self-report measure of medication compliance behaviour. Abstract Published in: Canadian Journal of Clinical Pharmacology 2001; 8(1): pp. 36.
64. **Patten SB**. Evaluating the impact of antidepressant medications at the population level. Abstract Published in: Canadian Journal of Clinical Pharmacology 2001; 8(1): pp. 30.
65. Vik SA, Maxwell CJ, Hogan DB, **Patten SB**, Johnson JA, Mitchell C, Romonko-Stack L, Copeland M, Couchman S, Matson B, Harbridge T. Drug adherence among older urban and rural home care clients. Abstract Published in: Canadian Journal of Clinical Pharmacology 2001; 8(1): pp. 29.
66. **Patten SB**, Metz LM. Is treatment with interferon beta-1a (Rebif) associated with depression in multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Toulouse, France. September 6-9, 2000. Abstract published in: Revue Neurologique 2000 (Suppl. 3); pp. 123.
67. **Patten SB**, Maxwell C, Thurston WE, Casebeer A, Russell ML. Major depression and antidepressant use in relation to age in a predominantly rural Alberta health region. The 2000 Canadian Population Therapeutics Forum, Montreal. Abstract Published in: Canadian Journal of Clinical Pharmacology 2000; 7(1): 67.
68. **Patten SB**, Lavorato DH. Medication use and major depressive syndrome in a community population. The 2000 Canadian Population Therapeutics Forum, Montreal. Abstract Published in: Canadian Journal of Clinical Pharmacology 2000; 7(1): 67.
69. Maxwell C, Hogan DB, Howard MI, Eby EM, **Patten SB**. Antihypertensives and depression risk in the elderly. The 2000 Canadian Population Therapeutics Forum, Montreal. Abstract Published in: Canadian Journal of Clinical Pharmacology 2000; 7(1): 65.
70. Russell ML, **Patten S**, Maxwell C, Thurston WE, Casebeer A, Vollman AR, Verhoef M.. Depression and the use of alternative therapy providers in rural Alberta. The 2000 Canadian Population Therapeutics Forum, Montreal. Abstract Published in: Canadian Journal of Clinical Pharmacology 2000; 7(1): 69.
71. Ilkiw M, Hogan DB, Verhoef M, **Patten S**. Attitudes and beliefs about insomnia management among older adults with chronic insomnia. *Clinical and Investigative Medicine* 1999;22(4):S19.
72. **Patten SB**, Williams JVA, Petcu R, Oldfield R. Determinants of delirium in psychiatric inpatients: A pharmacoepidemiological study. The 1999 Canadian Population Therapeutics Forum, Halifax. Abstract Published in: Canadian Journal of Clinical Pharmacology 1999; 6(1): 49.
73. **Patten SB**, Charney DA. Alcohol consumption and major depression in the Canadian population. *Alcohol Research* 1998; 3(5): 195.
74. **Patten SB**. Delirium in Canadian psychiatric inpatients, 1985-94. The 1998 Canadian

- Pharmacoepidemiology Forum, Ottawa. Abstract Published in: Canadian Journal of Clinical Pharmacology 1998; 5: 64.
75. **Patten SB**, Williams JVA. Diagnosing delirium by chart review, a pilot study. The 1998 Canadian Pharmacoepidemiology Forum. Abstract Published in: Canadian Journal of Clinical Pharmacology 1998; 5: 64
76. Lavorato D, **Patten SB**. Oral contraceptives and major depression in the Canadian population. The 1998 Canadian Pharmacoepidemiology Forum. Abstract Published in: Canadian Journal of Clinical Pharmacology 1998; 5: 64.
77. **Patten SB**, Lavorato D. An association between corticosteroid exposure and recollection of traumatic events in the Canadian population. The 1998 Canadian Pharmacoepidemiology Forum. Abstract Published in: Canadian Journal of Clinical Pharmacology 1998; 5: 60.
78. **Patten SB**, Williams JVA, Haynes L, McCrudden J, Arboleda-Florez J. The Period Prevalence and Cumulative Incidence of Delirium in a General Hospital Psychiatric Inpatient Population. The International Society for Pharmacoepidemiology. Abstract Published in: Pharmacoepidemiology and Drug Safety 1997; 6(Suppl 2): S9.
79. **Patten SB**. Integrating Research Data and Administrative Data to Evaluate the Impact of Selection Bias on a Period Prevalence Estimate. The International Society for Epidemiology Annual Meeting, Abstract Published in: Orlando, Florida. Pharmacoepidemiology and Drug Safety 1997; 6(Suppl 2): S9.
80. **Patten SB**, Williams JVA, Haynes L, McCrudden J, Arboleda-Florez J. The cumulative incidence of delirium in a psychiatric inpatient population. The 1997 Canadian Pharmacoepidemiology Forum. Abstract Published in: The Canadian Journal of Clinical Pharmacology 1997; 4(1): 51.
81. **Patten SB**. Integration of Research and Administrative Data for the Enhancement of Internal Validity. The 1997 Canadian Pharmacoepidemiology Forum. Abstract Published in: The Canadian Journal of Clinical Pharmacology 1997; 4(1): 51.
82. Addington D, Addington J, **Patten S**. The Two Year Course of Depression in Schizophrenia. Schizophrenia Research 1997; 26: 82.
83. Addington D, Addington J, **Patten S**. The Relationship Between Negative Symptoms and Depression in Schizophrenia. European Neuropsychopharmacology 1996; 6 (Suppl 3): 62.
84. Addington D, Addington J, **Patten S**. Course, Correlates & Predictors of Depression in Schizophrenia. Biennial Winter Workshop on Schizophrenia. Schizophrenia Research 1996; 15: 117.
85. Neutel CE, **Patten SB**: Risk of Suicide Attempts After Benzodiazepine use. International Society for Pharmacoepidemiology Annual Meeting. Montreal, August, 1995. (Abstract published in the Journal of Pharmacoepidemiology and Drug Safety, 1995; 4 (Suppl. 1), s80.

vii. Presentations (without journal publication of abstracts)

1. Williams K, **Patten SB**, Jette N. Validity of the patient health Questionnaire-9 in neurological populations. Canadian Psychiatric Association 67th Annual Conference. Ottawa, Ontario, Sept 14 – 16, 2017.
2. Josephson C, Gonzalez-Izquierdo, Denaxas S, Fitzpatrick N, Sajobi T, Engbers J, **Patten S**, Jette N, Wiebe S. Serotonin reuptake inhibitor use and mortality in epilepsy: findings from a contemporary linked electronic health records cohort study (POSTER). 32nd International Epilepsy Congress (IEC). Barcelona, Spain. Sept 3, 2017
3. Christie R, Stuart H, **Patten S**, Knaak SJ, Szeto AC, Dobson K, Best practices in stigma reduction impacting youth – the Canadian context. The 22nd International Association for Child and Adolescent Psychiatry and Allied Professions World Congress (IACAPAP). Calgary, Alberta. September 18 – 22, 2016.
4. Rush B, Goldner E, **Patten S**, Tremblay J. Population-based estimates of need for mental health and substance use services: Examples and challenges (POSTER). Canadian Academy of Psychiatric Epidemiology (CAPE) Annual Scientific Symposium. Toronto, Ontario. September 21, 2016.
5. Diaz RL⁷³, Bulloch AGM, Sajobi T, Chomas BC, Williams JVA, Lavorato DH, **Patten SB**. The healthy immigrant effect on major depression in Canada Varies with age (POSTER). Canadian Academy of Psychiatric Epidemiology (CAPE) Annual Scientific Symposium. Toronto, Ontario. September 21, 2016.
6. Lukmanji S, Gill SJ, Fiest KM, **Patten SB**, Wiebe S, Jette N. Systematic review of validated depression screening tools in person with epilepsy. American Epilepsy Society: Working Toward a World without Epilepsy Houston, TX, December 2 – 6, 2016.
7. Crooks R, Bell M **Patten SB**, Wiebe S, Holroyd-Leduc J, Bulloch AG, Macrondimitris S, Mackie A, Jette N. Mind the gap! Filling the depression in epilepsy knowledge gap. . American Epilepsy Society: Working Toward a World without Epilepsy. Houston, TX, December 2 – 6, 2016.
8. Knaak S, **Patten SB**, Szeto A. Five ways to improve mental health care in your organization. National Health Leadership Conference. Ottawa, ON, June 6 – 7, 2016.
9. Lunney M, Sauro K, Atkinson MJ, Josephson C, Girgis F, Singh S, **Patten SB**, Jette N, Sajobi T, Harder W, Wiebe S. Identification of Themes Relevant to Patients' Evaluation of their Satisfaction with Epilepsy Surgery Through Focus Group Discussions. (Poster Presentation) American Epilepsy Society 69th Annual Meeting, Philadelphia PA, December 4 – 8, 2015.
10. Lauria-Horner B, **Patten P**. Skill-Based Approaches, Effective in Reducing Stigma in Health Professionals. Canadian Psychiatric Association Annual Conference, Vancouver, October 1-3, 2015.

⁷³ MSc student under my supervision at the time this research was conducted.

11. Ismail Z, Elbayoumi H, Smith EE, Fischer C, Schweizer T, Millikin C, Hogan D, **Patten S**, Fiest K. A Systematic Review and Meta-Analysis for the Prevalence of Depression in Mild Cognitive Impairment, Alzheimer's Association International Conference, July 24-28, 2015, Washington D.C.
12. Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, **Patten SB**. CIHR Team in the Epidemiology and Impact of Comorbidity in Multiple Sclerosis. Generalized increase in the burden of psychiatric comorbidity in multiple sclerosis as compared to the general population: a population-based Canadian study. ECRIMS 2015, October 7-10, Barcelona, Spain.
13. Morkem R, Barber D, Williamson T, **Patten S**. Antidepressant Prescribing to Children and Adolescents in Canadian Primary Care. North American Primary Care Research Group Annual Meeting, October 24-28 2015, Cancun, Mexico.
14. Wiens K⁷⁴, Williams JVA, Lavorato DH, Bulloch AGM & **Patten SB**. Data synthesis settles inconsistencies in urban-rural differences in prevalence of Major Depression. "Innovation + Collaboration = Transformation" CDRIN Annual Conference, Feb 24 & 25th, 2015, Ottawa.
15. Vallerand I⁷⁵, Engbers J, Lowerison M, Bulloch A, **Patten S**. Deaths among people with depression in primary care: a cohort study using The Health Improvement Network (THIN) database. "Innovation + Collaboration = Transformation" CDRIN Annual Conference, Feb 24 & 25th, 2015, Ottawa.
16. Maxwell CJ, Bronskill SE, Diong C, Hogan DB, **Patten SB**, Jetté N, Marrie RA. Depressive symptom trajectories in older adults with dementia and associated risk of functional decline. Alzheimer's Association International Conference. Washington DC, United States. July 18-23, 2015.
17. Vallerand IA⁷⁶, Engbers J, Lowerison M, Wiebe S, Kaplan GG, Bulloch AG & **Patten SB**. (Accepted). Comparison of methods to address survival bias associated with the diagnosis of depression and risk of mortality using a large population n-based cohort. Proceedings of the Society for Epidemiologic Research (SER) 48th Annual Meeting. Denver, CO., June 18, 2015. (POSTER) (**Note: possible abstract publication**)
18. Knaak S, **Patten S**. A model for successful anti-stigma programming for healthcare providers: results of a qualitative study. The World Psychiatric Association 7th International TAS: Each Mind Matters Conference. San Francisco February, 18th – 20th 2015.
19. **Patten S**, Modgill G, Knaak S. Reducing Stigma in Health Care Providers: Key Program Ingredients. The World Psychiatric Association 7th International TAS: Each Mind Matters Conference. San Francisco February, 18th – 20th 2015.

⁷⁴ MSc student under my supervision when this research was conducted.

⁷⁵ PhD student under my supervision when this research was conducted, now a medical student in the Leaders in Medicine program at the University of Calgary.

⁷⁶ PhD student under my supervision when this research was conducted, now a medical student in the Leaders in Medicine program at the University of Calgary.

20. Modgill G, Knaak S, Szeto A, **Patten S**. Interventions to Reduce Stigma in Health Providers: Systematic Review Protocol. The World Psychiatric Association 7th International TAS: Each Mind Matters Conference. San Francisco, CA. February 18 – 20, 2015.
21. Knaak S, Modgill G, **Patten S**. Key ingredients for combating stigma among healthcare providers (Oral presentation). Canadian Mental Health Association National Conference. Calgary, October 22-24. 2014.
22. Ismail Z, Elbayoumi H, Fischer C, Hogan D, Millikin C, Schweizer T, Smith E, **Patten S**, Fiest K. A systematic review and meta-analysis of the prevalence of depression and depressive symptoms in Mild Cognitive Impairment. 2014 CMHA Nation-Wide Conference, Calgary, Alberta, Canada, Oct 22-24 2014.
23. Isabelle Vallerand⁷⁷, Andrew Bulloch, **Scott B. Patten**. Mental disorders in primary care. 2014 CMHA Nation-Wide Conference, Calgary, Alberta, Canada, Oct 22-24 2014.
24. Berzins S⁷⁸, Bulloch AGM, Burton JM, Dobson K, Fick GH, **Patten SB**. Recruitment and retention in long-term studies. 2014 CMHA Nation-Wide Conference, Calgary, Alberta, Canada, Oct 22-24 2014.
25. Sjonnesen K⁷⁹, Bulloch AGM, Williams J, Lavorato D, **Patten S**. Mental disorder, disability and interacting comorbidities: Characterizing disability using the WHO Disability Assessment Schedule (WHODAS) 2.0. 2014 CMHA Nation-Wide Conference, Calgary, Alberta, Canada, Oct 22-24 2014.
26. McIntyre L, Fleisch VC, **Patten S**. Are long-term education and early pregnancy outcomes associated with child hunger distinct from other poverty outcomes? (poster). 142nd APHA Annual Meeting and Exposition New Orleans, LA, November 15-19, 2014.
27. Campbell H, **Patten S**, Knaak S, Stretch J, Groves N, Hall S, Weinerman R. Training reduces mental illness related stigma among healthcare providers. Cognitive Behavioural Interpersonal Skills. Canadian Psychiatric Association Annual Meeting. Toronto, September 11-13, 2014.
28. Campbell H, **Patten S**, Knaak S, Stretch J, Groves N, Hall S, Weinerman R. Training reduces mental illness related stigma among healthcare providers. cognitive Behavioural Interpersonal Skills. Canadian Collaborative Mental Health Care conference. Toronto, June 19 2014.
29. McDonald K⁸⁰, Bulloch A, Bresee L, Duffy A, Williams J, Lavorato D, **Patten S**. Estimating the Prevalence of Bipolar Disorder in the General Population: Challenges and New Directions (Poster). Canadian Academy of Psychiatric Epidemiology (CAPE) 2014 Symposium, Toronto, September 10, 2014.

⁷⁷ PhD student under my supervision when this research was conducted, now a medical student in the Leaders in Medicine program at the University of Calgary.

⁷⁸ PhD student under my supervision when this research was conducted, now Director of Research at the Calgary Counselling Centre.

⁷⁹ Medical student at the time this research was conducted (under my supervision, supported by an AIHS Summer Studentship), now a Neurology resident at the University of Calgary.

⁸⁰ MSc student under my supervision at the time this research was conducted. Now a PhD student at Oxford University.

30. Jette N, **Patten SB**, Altura C, Bulloch AGM, Maxwell CJ, Wiebe S, Macrodimitris S, Fiest KM. Quality of Life in Persons with Epilepsy (Poster). Annual Meeting of the American Epilepsy Society, Seattle WA, December 5-9 2014.
31. Fiest KM, **Patten SB**, Altura C, Bulloch AGM, Maxwell CJ, Wiebe S, Macrodimitris S, Jette N. Patterns and Frequency of the Treatment of Depression in Persons with Epilepsy (Poster). Annual Meeting of the American Epilepsy Society, Seattle WA, December 5-9 2014.
32. Prisdie JC, Fiest KM, **Patten SB**, Atta C, Blaikie L, Bulloch AGM, Coutts SB, Demchuk A, Hill MD, Smith EE, Jette N. Validating Screening Tools for Depression in Stroke. Campus Alberta Student Conference on Health (Banff, Canada) September 6, 2014.
33. Atta C, Blaikie L, Fiest KM, **Patten SB**, Wiebe S, Bulloch AGM, Dobson K, Jette N. Correlates of suicidal ideation in persons with epilepsy. Canadian Neurological Sciences Federation Meeting (Banff, Canada) June 3-6, 2014.
34. Minden S, Feinstein A, Kalb R, Miller D, Mohr D, **Patten SB**, Bever C, Schiffer R, Gronseth G, Narayanaswami P. Clinical Practice Guideline on Assessment and Management of Psychiatric Disorders in Individuals with Multiple Sclerosis. 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Dallas, Texas. May 28 -31, 2014.
35. Roy A, **Patten S**, Thurston W, Tough S. Race as a determinant of prenatal depressive symptoms: Analysis of data from the "All Our Babies" longitudinal pregnancy cohort study. (Poster presentation by A Roy). Canadian National Perinatal Research Meeting; Banff (AB); February 12-15, 2014.
36. Jette N, Fiest KM, Bulloch AGM, Blaikie L, Atta C, Carroll C, Wiebe S, Dobson K, Macrodimitris S, **Patten SB**. The Best Tool to Screen for Depression in Persons with Epilepsy. American Epilepsy Society Annual General Meeting, December 6-10, 2013. Washington D.C
37. Jette N, Fiest KM, Bulloch AGM, Blaikie L, Atta C, Carroll C, Wiebe S, Dobson K, Macrodimitris S, **Patten SB**. The NEurological Disease and Depression Study (NEEDS) – Epilepsy Cohort: A study of the burden, course and impact of depressive disorders in persons with epilepsy. American Epilepsy Society Annual General Meeting, December 6-10, 2013. Washington D.C.
38. Kassam A, Horton J, Shoimer I, **Patten, S**. Predictors of Well-Being in Residents: A Descriptive Study on Burnout and Work Dissatisfaction. Canadian Conference on Medical Education, Quebec City, Canada. April 20-23, 2013.
39. Zhornitsky S, Koch MW, Cerchiaro G, Makci A, **Patten SB**, Metz LM. A dose-finding, safety and tolerability trial of extended-release quetiapine fumarate in relapsing-remitting and progressive MS. EndMS Annual Retreat, Banff, September 13-14, 2013.
40. Berzins S⁸¹, Bulloch A, Burton J, Dobson K, Fick G, **Patten S**. Psychosocial coping and depression in MS. EndMS Annual Retreat, Banff, September 13-14, 2013.

⁸¹ PhD student under my supervision at the time this research was conducted.

41. Berzins S⁸², Bulloch A, Burton J, Dobson K, Fick G, **Patten S**. Psychosocial coping in MS. Canadian Academy of Psychiatric Epidemiology Scientific Symposium, Ottawa, September 25th, 2013.
42. Viner R⁸³, **Patten S**, Berzins S & Fiest K. Prevalence and risk factors of suicidal ideation in the MS population. Canadian Academy of Psychiatric Epidemiology Scientific Symposium, Ottawa, September 25th, 2013.
43. Maxwell CJ, Hogan DB, **Patten SB**, Jette N, Bronskill S, Kergoat MJ, Heckman G, Hirdes J. Correlates of neuropsychiatric symptoms among older women and men with dementia across continuing care settings. 7th Canadian Conference on Dementia. Vancouver, B.C. October 3-5, 2013.
44. Oswald T, Wang Y, Bolton J, Enns M, **Patten S**, Sareen J. Correlates of depressive episode duration in a nationally representative sample. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium, Ottawa, October 25th 2013.
45. Berzins S⁸⁴, Lavorato D, Williams J, Bolo C, Bulloch A, **Patten S**. Mixed mode data collection in a prospective cohort study: lessons learned for recruitment & retention. Poster Presentation. International Federation of Psychiatric Epidemiology Conference, Leipzig, Germany, June 5-8, 2013.
46. Wang JL, Schmitz N, Sareen J, **Patten S**, Currie S. A population-based longitudinal study on work environment and major depressive disorder. International Federation of Psychiatric Epidemiology Conference, Leipzig, Germany, June 5-8, 2013.
47. Berzins S⁸⁵, Bulloch A, Burton J, Fick G, Dobson K, **Patten S**. Determinants of Depression in Multiple Sclerosis. . International Federation of Psychiatric Epidemiology Conference, Leipzig, Germany, June 5-8, 2013.
48. Fiest K, Jette N, Quan H, **Patten S**, St. Germaine-Smith C, Metcalfe A, Beck C. Validation of depression coding in administrative data and recommendations for case ascertainment. Poster. International Federation of Psychiatric Epidemiology Conference, Leipzig, Germany, June 5-8, 2013.
49. Reyes RR⁸⁶, **Patten S**. Estimates of residual depressive symptoms in the Canadian Population. Poster. International Federation of Psychiatric Epidemiology Conference, Leipzig, Germany, June 5-8, 2013.
50. Khoja S, Scott R, Durrani H, Mohbatali F, **Patten S**, Palacios M. Improving Mental Health Care in Afghanistan, Badakshan Province through e-Health-Phase 0. Med-e-Tel April 10-12, 2013,

⁸² PhD student under my supervision at the time this research was conducted.

⁸³ Research conducted while Ms. Viner was a Summer Student funded by EndMS. Ms. Berzins and Ms. Feist were PhD candidates under my supervision (co-supervision for KM Fiest) while this research was conducted.

⁸⁴ PhD student under my supervision at the time this research was conducted.

⁸⁵ PhD student under my supervision at the time this research was conducted.

⁸⁶ MSc student under my supervision at the time this research was conducted. Now an analyst at the Alberta Health Quality Council.

Luxembourg, G.D. of Luxembourg.

51. Ganesh A⁸⁷, Campbell DJT, Hurley J, **Patten SB**. High Positive Psychiatric Screening Rates in an Urban Homeless Population. American Psychiatric Association Annual Meeting, San Francisco, May 18-22, 2013.
52. Konkoly-Thege B, Colman I, el-Guebaly N, Hodgins D, **Patten S**, Schopflocher D, Wolfe J, & Wild TC. (March 11, 2013). Prevalence of behavioural and substance-related addictions: A preliminary study from Canada. Paper presented at the 1st International Conference on Behavioral Addictions, Budapest, Hungary.
53. Wild TC, Wolfe J, Konkoly-Thege B, Schopflocher D, Colman I, el-Guebaly N, Hodgins D, **Patten S**. (March, 2013). *Social judgements of behavioral versus substance-related addictions*. Paper presented at the 1st International Conference on Behavioral Addictions, Budapest, Hungary.
54. Maxwell CJ, Vu M, Hogan DB, **Patten SB**, Zehr M, Jetté N, Bronskill S, Kergoat MJ, Heckman G, Danila OM, Hirdes JP, on behalf of the ideas PNC team. Neuropsychiatric symptoms in dementia: Variation by care setting and sex (Poster Presentation). Alzheimer's Association International Conference. July 13-18, 2013, Boston, MA.
55. McIntyre L, Wu X, **Patten SB**. The pervasive effect of youth self-report of hunger on depression over six years of follow up. Canadian Society for Epidemiology and Biostatistics Conference, June 22 – 23, 2013, St. John's, Newfoundland.
56. Fiest KM, **Patten SB**, Dykeman J, Wiebe S, Lowerison M, Bulloch AGM, Atta C, Blaikie L, Carroll C & Jette N. (Poster) The Neurological Disease and Depression Study (NEEDS): Epilepsy Recruitment and Methodology. 30th International Epilepsy Congress, June 23-27, 2013, Montreal.
57. Ganesh A⁸⁸, Campbell D, **Patten SB**. High Positive Psychiatric Screening Rates in an Urban Homeless Population (Poster: Abstract Number 3345). 166th APA Annual Meeting to be held in San Francisco, CA, May 18-22, 2013
58. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. Gender and intersectionality lenses in a study on prenatal depression among Aboriginal women. (Poster presentation by A. Roy). *Advancing Excellence in Gender, Sex and Health Research (Conference of the CIHR Institute of Gender and Health)*, Montreal (QC), October 29-31, 2012.
59. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. Understanding depression among pregnant Aboriginal women: a constructivist grounded theory study. (Poster presentation by A. Roy). *Canadian Public Health Association (CPHA) Annual Conference*. Edmonton (AB), June 11-14, 2012.
60. **Patten SB**. Reducing stigma in health professionals. Mental Health Commission of Canada Leadership Assembly. Ottawa, October 16-17th, 2012.
61. Sjonnesen K⁸⁹, Fiest K, Berzins S, Williams J, Bulloch A and **Patten SB**. Assessing the PHQ-9 to screen for major depression in multiple sclerosis (Poster). Canadian Academy of Psychiatric

⁸⁷ Medical student at the time, subsequently awarded a Rhodes Scholarship.

⁸⁸ Medical student at the time, subsequently awarded a Rhodes Scholarship.

⁸⁹ Pre-medical student at the time this research was conducted (under my supervision, supported by an AIHS

- Epidemiology, Montreal, September 27, 2012. This Poster received an award for the Best Poster Presentation at the CAPE meeting.
62. Fiest K, Sjonnesen K, Berzins S, Williams J, Bulloch A and **Patten S**. Depressive symptoms in multiple sclerosis patients versus the general population. Canadian Academy of Psychiatric Epidemiology, Montreal, September 27, 2012.
 63. Oswald T, Wang Y, Bolton J, Enns M, **Patten S**, Sareen J. Correlates of duration of depressive episodes in a nationally representative sample (Poster). Canadian Academy of Psychiatric Epidemiology, Montreal, September 27, 2012.
 64. Vu M, Hogan D, Jetté N, Bronskill S, Heckman G, **Patten SB**, Chen J, Hirdes J, Maxwell C on behalf of ideas PNC research team. A Population-based Study of Home Care Clients with Dementia in Ontario. CCSMH & CAGP Joint Conference. Celebrating the Past, Present & Future of Seniors' Mental Health. Banff, Alberta. Sept 21-22, 2012.
 65. Pietrus M, Christie R, **Patten S**, Stuart H. Symposium: Mental Health Commission of Canada. Opening Minds: Changing How We See Mental Illness. Together Against Stigma. Changing How We See Mental Illness. 5th International Stigma Conference, Ottawa, ON. June 4-6, 2012.
 66. **Patten SB**. Agent-based modeling of Stigma. Together Against Stigma. Changing How We See Mental Illness. 5th International Stigma Conference, Ottawa, ON. June 4-6, 2012.
 67. Szeto ACH, Kassam A, Modgill G, Phillips L, Remillard A, **Patten S**, Gardner DM. Reducing Stigma about Mental Illness in Pharmacy Students. Together Against Stigma. Changing How We See Mental Illness. 5th International Stigma Conference, Ottawa, ON. June 4-6, 2012.
 68. **Patten SB**. Epidemiology of Depression and Work Impairment. Symposium Presentation in Symposium 114: New Insights in Treating Depressed Workers: Focus on Early Identification and Intervention. American Psychiatric Association Annual Meeting, May 5-9, 2012, Philadelphia PA.
 69. Roberts J, et al. (including **Patten SB**). The Incidence and Prevalence of Spinal Cord Injury: A Systematic Review and Meta-Analysis. Poster presentation at the 47th Congress of the Canadian Neurological Sciences Federation, June 5 -8, 2012, Ottawa, Ontario
 70. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. A scoping review of the measurement of oppression in the literature on Aboriginal population health: review methodology. (Poster presentation by A Roy). *Canadian Society of Epidemiology and Biostatistics National Student Conference*, Montreal (QC), June 19-20, 2011.
 71. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. The measurement of oppression in Aboriginal population health research: methods and preliminary findings of a scoping literature review. (Poster presentation by A Roy). *Native Health Research Conference*, Niagara Falls (NY), June 27-30, 2011.
 72. Maxwell CJ, Soo A, Strain LA, Hogan DB, **Patten SB**, Cepoiu-Martin M, Gruneir A, Le Clair K, Wilson K, Amuah JE, on behalf of the ACCES-Mental Health Research Group. Factors associated with long term care placement among older adults with dementia residing in Assisted Living facilities. Poster presented at the 6th Canadian Conference on Dementia, Montreal QC, Oct 27-29, 2011.

Summer Studentship), now a Neurology resident at the University of Calgary.

73. VanTil LD, Pranger T, Thompson J, Corbiere M, Shields N, Wong M, Fikretoglu D, **Patten S**, Wang JL, Zamorski M, Loisel P, Pedlar D. Work Re-integration for Veterans with Mental Disorders. The Military and Veteran health Research Forum, Kingston (ON) November 15-16, 2011
74. Papish A, Kassam A, Modgill G, Zanussi L, **Patten S**. The University of Calgary's Psychiatry Course Improves Medical Student Attitudes Towards Help-Seeking and Mental Illness. Canadian Psychiatric Association Annual Meeting. October 13-15th, 2011.
75. **Patten SB**. Epidemiology of depression and work impairment in Canada. Annual Meeting of the Canadian Psychiatric Association. Vancouver, October 13-15th 2011.
76. **Patten SB**. "Tipping points" in anti-stigma intervention – An examination using agent-based modelling. Canadian Academy of Psychiatric Epidemiology. Vancouver, October 13, 2011.
77. JianLi Wang, **Scott Patten**, Norbert Smitz, Shawn Currie, Jitender Sareen, Elizabeth Smailes. Results of a population-based longitudinal study on work and health in Alberta. Canadian Academy of Psychiatric Epidemiology. Vancouver, October 13, 2011.
78. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. Methods for measuring oppression: A scoping literature review of Aboriginal population health research. [Poster presentation by A Roy]. Joint Meeting and Young Investigators Forum, CSCI (Canadian Society for Clinical Investigation) and CITAC (Clinician Investigator Trainee Association of Canada), Ottawa (ON), September 12-14, 2011.
79. Freiheit EA, Hogan DB, Strain LA, Schmaltz HN, **Patten SB**, Eliasziw M, Maxwell CJ. Operationalizing frailty among older residents of assisted living facilities. Oral Presentation at the Canadian Geriatrics Society 31st Annual Scientific Meeting, Vancouver, BC, April 14-16. 2011.
80. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. A scoping review of the measurement of oppression in the literature on Aboriginal population health: review methodology. (Poster presentation by A Roy). Canadian Society of Epidemiology and Biostatistics National Student Conference, Montreal (QC), June 19-20, 2011.
81. Roy A, Thurston WE, **Patten SB**, Tough S, Crowshoe L, Beran T. The measurement of oppression in Aboriginal population health research: methods and preliminary findings of a scoping literature review. (Poster presentation by A Roy). Native Health Research Conference, Niagara Falls (NY), June 27-29, 2011.
82. **Patten S**, Williams JVA, Lavorato D, Metz LM, Bulloch A. Disability in a Community Population with MS with and without Mental Disorders. Found in Translation. Sharing Alberta Research for Mental Wellness in Seniors and Persons with Disabilities. Edmonton, Alberta, April 18th, 2011. Poster available online at:
http://www.mentalhealthresearch.ca/KeyInitiatives/ResearchGrants/Seniors_PwD/Documents/found%20in%20translation/S.%20Patten.pdf
83. Lam D, **Patten S**, Tano D, Pringsheim TM. The Pharmacoepidemiology of Antipsychotic Medications for Adults with Schizophrenia in Canada, 2005 to 2009. American Psychiatric Association Annual Meeting. Honolulu, Hawaii. May 14-18th, 2011.

84. Pringsheim TM, Lam D, **Patten S**. The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitor Medications for Canadian Children, 2005 to 2009. American Psychiatric Association Annual Meeting. Honolulu, Hawaii. May 14-18th, 2011.
85. el-Guebaly N, Hodgins D, Casey D, Mudry T, Martin C, Wild C, **Patten S**, Colman I, Schopflocher D, Smith G, Williams R. Defining behavioral addictions: research dimensions. Opening lecture, International Society Addiction Medicine, Milan, Oct 2010.
86. el-Guebaly N, Hodgins D, Casey D, Mudry T, Martin C, Wild C, **Patten S**, Colman I, Schopflocher D, Smith G, Williams R. Strategies for defining behavioral addictions. Plenary, Canadian Society Addiction Medicine, Charlottetown, PEI, Oct 2010
87. Roy A, Thurston WE, Tough S, **Patten SB**. Measuring oppression and other determinants of depression among pregnant Aboriginal women in the Calgary area: a research proposal. Canadian Society of Epidemiology and Biostatistics National Student Conference, Kingston, Ontario, May 27-28, 2010.
88. Maxwell CJ, Freiheit E, Hogan DB, Strain LA, Schmaltz HN, **Patten SB**, Eliasziw M. Operationalizing frailty among older residents of assisted living facilities. 2010 Canadian inter-RAI Conference, Toronto, Ontario, October 6th, 2010.
89. **Patten SB**. Epidemiology of major depression: Implications for policy and practice. In: Symposium entitled: Current Controversies in the definition, epidemiology, identification, and care of depression. Canadian Psychiatric Association Annual Meeting, Toronto, September 23-26, 2010.
90. **Patten SB**. Epidemiology of the major mental disorders. In CAPE Course. Psychiatric Epidemiology in Canada. Canadian Psychiatric Association Annual Meeting, Toronto, September 23-26, 2010.
91. **Patten SB**. Epidemiological evidence of synergistic interactions between traumatic experiences during childhood and adult stressors in major depression etiology. Canadian Academy of Psychiatric Epidemiology Annual Meeting, Toronto, September 23, 2010.
92. Pringsheim T, Lam D, **Patten SB**. The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children: 2005 to 2009. (Poster presentation) Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in New York, NY, October 26-31 2010.
93. Roy A, Thurston WE, Tough S, **Patten SB**. Measuring oppression and other determinants of depression among pregnant Aboriginal women in the Calgary area: a research proposal (Oral presentation by A Roy). Canadian Society of Epidemiology and Biostatistics National Student Conference, Kingston (ON), May 27-28, 2010.
94. Modgill G, Jette N, Wang J, **Patten S**. Migraine as a risk factor for major depressive episodes: A longitudinal community study.(Poster) CAPE 2009 Annual Scientific Symposium, St. John's, Newfoundland, August 27, 2009.
95. **Patten S**. Canadian network of mood and anxiety treatments clinical guidelines for the management of major depressive disorder in adults II: Neurostimulation and alternative therapies. Canadian Psychiatric Association, 59th Annual Conference, St. John's, Newfoundland, August 27 – 29, 2009.

96. Alison L Supina, David B Hogan, **Scott B Patten**, Braden J Manns, Winanne Downey, Patty Beck, Colleen J Maxwell. The Risk of Institutionalization with the Concurrent Use of Cholinesterase Inhibitors (ChEIs) and Potentially Contraindicated Medications in Alzheimer's Disease (AD). (Poster Presentation). International Society for Pharmacoepidemiology. International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Rhode Island, August 16 – 19, 2009
97. Khaled S, Bulloch A, Lavorato D, Williams J, **Patten S**. Major depression as risk factor of nicotine dependence development in the Canadian population: A longitudinal population-based study. XII International Congress of International Federation of Psychiatric Epidemiology (IFPE) Vienna, Austria, April 16 – 19, 2009.
98. Brown L, Majumdar S, **Patten S**, Johnson J. Cardiovascular risk factors, burden of disease, and access to care for people with schizophrenia in Alberta, Canada. XII International Congress of International Federation of Psychiatric Epidemiology (IFPE) Vienna, Austria, April 16 – 19, 2009.
99. Bulloch A, Brown L, **Patten S**. Increasing frequency and heterogeneity of treatment for bipolar 1 disorder in the general population. XII International Congress of International Federation of Psychiatric Epidemiology (IFPE) Vienna, Austria, April 16 – 19, 2009.
100. Specogna AV, **Patten SB**, Hill MD. Age and hemorrhage location do not predict worsening neurologic or disability status in survivors of primary intracerebral hemorrhage. (Poster). Alberta Stroke Conference, Canmore, Alberta, October 30 – November 1, 2008.
101. Jette N. et al. (incl. **Patten SB**). Health related behaviours and health status in epilepsy compared to migraine or diabetes ? A large national population-based study.(Poster). 2008 AES Annual Meeting. Seattle, Washington, Dec 5 – 7, 2008.
102. Jette N. et al. (incl. **Patten SB**). Epilepsy is associated with greater unmet health care needs compared to asthma, diabetes or migraine despite higher health resource use - A large national population-based study? A large national population-based study.(Poster). 2008 AES Annual Meeting. Seattle, Washington, Dec 5 – 7, 2008.
103. Brown L. et al (incl. **Patten SB**). Cardiovascular Risk, Burden of Disease, and access to Care for People with Schizophrenia in Alberta. 4th Annual Mental Health Research Showcase, Banff, Alberta, November 19 – 21, 2008.
104. Berzins S. et al (incl. **Patten SB**). Patterns of Care for Transition from Youth to Adult Mental Health Services in the Calgary Health Region. 4th Annual Mental Health Research Showcase, Banff, Alberta, November 19 – 21, 2008.
105. Berzins S. et al (incl. **Patten SB**). Evaluation of the Development of the Calgary Health Region Mental Health Outreach Redesign Process. 4th Annual Mental Health Research Showcase, Banff, Alberta, November 19 – 21, 2008
106. Specogna A, Hill M. **Patten S**. Age and Hemorrhage Location Do Not Predict Change in Functional Status in Patients Who Survive Primary Intracerebral hemorrhage (Poster). Alberta Stroke Conference, Canmore, Alberta, October 30 – November 1, 2008.
107. **Patten S.B**. Cumulative Prevalence of Major Depression in the National Population Health

- Survey. CAPE 2008 Annual Scientific symposium, Vancouver, BC, September 4, 2008.
108. Bulloch AGM, **Patten SB**. The relationship between major depression and marital status is bidirectional. CAPE 2008 Annual Scientific symposium, Vancouver, BC, September 4, 2008.
 109. **Patten SB**. Major Depression and Hypertension Incidence (Poster) World Psychiatric Association. Section of Epidemiology and Public Health Meeting, Saskatoon, May 11th – 14th, 2008.
 110. **Patten SB** Major Depression and Chronic Disease Incidence (Poster) World Psychiatric Association. Section of Epidemiology and Public Health Meeting, Saskatoon, May 11th – 14th, 2008.
 111. **Patten SB**. The Patient Health Questionnaire as a Screening Instrument: A Longitudinal Study and Simulation Model World Psychiatric Association. Section of Epidemiology and Public Health Meeting, Saskatoon, May 11th – 14th, 2008.
 112. Khaled SM⁹⁰ & **Patten SB**. Cigarette Smoking, and Major Depression in the Canadian Population. Mental Health Research Showcase, Banff, Alberta, November 21 to 23, 2007
 113. Khaled SM, Mitchell RT, Kavanagh KM, Ramadan D, Aggarwal SG, Noulett C, **Patten SB**, Van Schaik A, & Exner DV. Impact of Depression Status On Relapse & Quitting In Smokers Post-MI. Canadian Cardiovascular Congress, Quebec City, October 21 to 24, 2007.
 114. Addington D, Addington J, **Patten S**. Relapse rates in an early psychosis treatment service. Canadian Psychiatric Association Annual Meeting, Montreal, Sept 15-19, 2007.
 115. **Patten S**. Depression in Multiple Sclerosis. As part of a symposium: Mind, Brain and Body: Examining the Relationship Between Mental and Physical Illness (co-presenters: James Bolton, Daniel Rasic, Gregory Ratcliffe, Norbert Schmitz). Canadian Psychiatric Association Annual Meeting, Montreal, Sept 15-19, 2007.
 116. Specogna AV, Hill MD, **Patten SB**. The Cost of Intracerebral Haemorrhage: A Canadian Example. American College of Epidemiology Conference. Ft Lauderdale, FL September 15-18, 2007.
 117. Shiffer RB, Goldman Consensus Conference Members (including **Patten SB**). The Goldman Algorithm. CMSC/ACTRIMS. Challenges of Care and Research in Multiple Sclerosis. Washington DC, May 30th to June 2nd 2007.
 118. Bulloch A, **Patten S**. F-3: Non-remission of major depression in the general population: Assessment via the HAMD-7 scale. Canadian Society for Epidemiology and Biostatistics Conference, Calgary, May 28 - 31, 2007
 119. **Patten S**. J-1: A simulation study of the effect of recall bias on estimates of “lifetime” major depression prevalence. Canadian Society for Epidemiology and Biostatistics Conference, Calgary, May 28 - 31, 2007.
 120. Tamburrini AL, Friedenreich C, Courneya K, Jones C, **Patten S**, Yasui Y. The relation between

⁹⁰ PhD student under my supervision at the time this research was conducted.

serum cholesterol and mammographic density as a risk factor for breast cancer. Canadian Society for Epidemiology and Biostatistics Conference, Calgary, May 28 - 31, 2007

121. Supina AL, Hogan DB, **Patten SB**, Amuah JE, Downey W, Beck P, Maxwell CJ. New Prescription of Hypnotic and Anticholinergic Medications after Initiation of Cholinesterase Inhibitors in Alzheimer's Disease: An Example of Interpretative Bias in Pharmacoepidemiology. Canadian Society for Epidemiology and Biostatistics Student Conference, Calgary, May 28 - 31, 2007.
122. Supina AL, Hogan DB, **Patten SB**, Amuah JE, Downey W, Beck P, Maxwell CJ. The Use of Hypnotics and Anticholinergic Agents after Initiation of Cholinesterase Inhibitor Therapy for Alzheimer's Disease. Canadian Society for Epidemiology and Biostatistics Student Conference, Calgary, May 28-31, 2007.
123. Metz LM, Duquette P, Lavorato D, Wall W, Roger E² and **Patten SB**, Survival Analysis Predicts That Nearly Half of People with MS Become Unemployed Within 15 Years of MS Onset. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 12th Annual Meeting. Washington, DC, June 2, 2007.
124. Mitton C, Adair C, McKenzie EJC, **Patten SB**, Waye-Perry B. KT2: Linking Researchers and Decision-makers – What Have We Learned? Canadian Association for Health Services and Policy Research (CAHSPR) Leadership Conference. Toronto, Ontario, June 12-14, 2007
125. Ronksley PE, **Patten SB**, Tsai WH. Prevalence of Depression Among Patients Referred for Sleep Assessment. American Psychiatric Association Annual Meeting, San Diego, CA, May 19-24, 2007.
126. **Patten SB**, Esposito E, Wang JL, Adair CE, Williams JVA, Dobson K, Schopflocher D, Mitton C, Newman S, Beck C, Barbui C. Frequency and Adequacy of Depression Treatment in the General Population in Calgary, Alberta. International Federation of Psychiatric Epidemiology. XI Congress. Gothenburg, Sweden, May 3-6, 2007.
127. **Patten SB**. Visual Depiction of Major Depression Epidemiology. International Federation of Psychiatric Epidemiology. XI Congress. Gothenburg, Sweden, May 3-6, 2007.
128. Jetté N, **Patten S**, Williams J, Weibe S, Becker W. Comorbidity of Migraine and Psychiatric Disorders – A National Population-Based Study. American Headache Society 49th Annual Scientific Meeting. Chicago, Illinois, June 7 – 10, 2007.
129. Mitton C, Adair C, McKenzie E, **Patten S** and Waye-Perry B. Knowledge Transfer and Exchange: findings from a systematic review and key informant interviews. 2007 Canadian Association for Health Services and Policy Research (CAHSPR) Conference. Toronto, Ontario, June 12-14, 2007.
130. Orpana H, Gilmour H, Wilkins K, **Patten SB**. Determinants and consequences of mental health problems in Canada: Evidence from national data source. 68th Canadian Psychological Association Annual Convention, Ottawa, Ontario, June 2007.
131. Esposito E, Wang JL, Adair CE, Williams J, Dobson K, Mitton C, Newman S, Beck C, Barbui C,

- Patten SB.** Frequency and adequacy of depression treatment in Alberta, Canada. Alberta Mental Health Showcase, Banff, Alberta, October 30 – November 1, 2006.
132. McLaren L, Beck CA, **Patten SB**, Adair CE. The relationship between body mass index and mental health: A population-based study of the effects of the definition of mental health. Alberta Mental Health Showcase, Banff, Alberta, Oct. 30 – Nov. 1, 2006.
133. Addington DE, **Patten SB**, McKenzie E, Adair C, Smith H, Addington JM. Evaluating Early Psychosis Treatment Services with Performance Measures. International Congress of Schizophrenia Research, Colorado Springs, CO, March 28 – April 1 2007.
134. **Patten SB.** Fibromyalgia: Psychiatric Perspective. First Italian Congress of Federdolore. Cascina Terme (Pisa), June 16-18, 2006.
135. Addington DE, Adair C, Addington J, **Patten SB**, Smith H, McKenzie E. Evaluating Early Psychosis Treatment Services with Performance Measures. International Early Psychosis Association. Birmingham, UK, October 4-6, 2006.
136. Metz LM, Lavorato D, Wall W, Harris C, **Patten SB**, MS Treatment Outcomes Group. Patient Reported Side Effects to MS Disease Modifying Therapy Over Five Years. Annual Meeting of the Canadian Congress of Neurological Sciences, Montreal, Quebec, June 13-17, 2006.
137. Metz MM, O’Ferrall EK, Wall W, Lavorato D, Harris C, **Patten SB**, Treatment Outcomes Group. Adherence to MS Disease Modifying Therapy: Why are Injections Missed? Annual Meeting of the Canadian Congress of Neurological Sciences, Montreal, Quebec, June 13-17, 2006.
138. Chuang HT, **Patten SB.** Lifestyle Issues in Mental Health: Social Support, Diet, Fitness, and Recreation. 2006 APA Annual Meeting, Toronto, Canada. May 20 – 25, 2006.
139. Wall W, Lavorato D, Harris C, **Patten SB**, Metz LM, MS Treatment Outcomes Group. The Persistence of Side Effects to MS Disease Modifying Therapy Over Five Years. Consortium of Multiple Sclerosis Centers 2006 Annual Meeting, Scottsdale, Arizona, May 31 – June 3, 2006.
140. Lavorato D, Wall W, Harris C, O’Ferrall E, **Patten SB**, Metz L, Treatment Outcome Group. How Often Do MS Patients Miss Injections of MS Disease Modifying Therapy? Consortium of Multiple Sclerosis Centers 2006 Annual Meeting, Scottsdale, Arizona, May 31 – June 3, 2006.
141. Gilmour H and **Patten SB.** Depression and Work Impairment. Canadian Public Health Association 97th Annual Conference. Vancouver, BC, Canada. May 28-31, 2006.
142. **Patten SB.** Depiction of Confounding by Duration in a Discrete Event Simulation Model. Canadian Association for Population Therapeutics/Canadian Therapeutics Congress. Toronto, Canada. May 10-13, 2006.
143. **Patten SB.** Visual Animation of Epidemiological Dynamics. Alberta Psychiatric Association Annual Meeting. Banff. March 24-26, 2006.
144. Addington DE, Adair C, Addington J, **Patten SB**, Smith H, McKenzie E. Application of Essential Performance Measures For Early Psychosis Treatment. APA Annual Meeting. Toronto,

Canada. May 20-25, 2006.

145. O’Ferrall E, Wall W, Lavarato D, **Patten SB**, Harris CJ. How often do MS Patients Miss Injections of MS Disease Modifying Therapy? Canadian Congress of Neurological Sciences, Montreal, QC, June 13-17, 2006.
146. Metz LM, Lavarato D, Wall W, Harris CJ, **Patten SB**. The Persistence of Side Effects to MS Disease Modifying Therapy Over Five Years. Canadian Congress of Neurological Sciences, Montreal, QC, June 13-17, 2006.
147. Addington D, Adair C, Addington J, **Patten S**, Smith H, McKenzie E. Performance Measures for Early Psychosis Treatment Services. Alberta Mental Health Board Mental Health Research Showcase. Banff, Alberta. November 28th to 30th, 2005.
148. Bulloch A, **Patten S**, Adair C. Forgetting: Role in Non-Compliance with Antidepressant Medication. Alberta Mental Health Board Mental Health Research Showcase. Banff, Alberta. November 28th to 30th, 2005.
149. **Patten SB**. Duration of Major Depressive Episodes. Alberta Mental Health Board Mental Health Research Showcase. Banff, Alberta. November 28th to 30th, 2005.
150. **Patten SB**. Pharmacoepidemiology of Antidepressant Use in Alberta. 55th Annual Canadian Psychiatric Association Annual Conference (Symposium Presentation). Vancouver, BC. November 3-6, 2005
151. O’Ferrall EK, Metz LM, Lavarato D, **Patten SB**. Discontinuation of Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis is Related To Disability Worsening and Low Baseline Health-Related Quality of Life: A Five Year Population-Based Study. 21st Congress of the European Committee/10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. Thessaloniki, Greece. September 28 – October 1, 2005.
152. Zabad RK, Duquette SB, **Patten SB**, Wall W, Roger E, Lavarato D, Metz LM. The Impact of Multiple Sclerosis on Pregnancy Termination. 21st Congress of the European Committee/10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. Thessaloniki, Greece. September 28 – October 1, 2005.
153. Lee R, **Patten SB**. Estimating the Dynamics of Major Depression Using Markov Modeling. 27th Annual Meeting of the Society for Medical Decision Making. San Francisco, CA, October 21-24, 2005.
154. Supina AL, Johnson JA, Maxwell CM, **Patten SB**, Williams JVA. The usefulness of the EQ-5D in differentiating among persons with and without major depressive episode & anxiety. 22nd Annual Plenary Meeting of the EuroQoL Group, Oslo, Norway. Sept. 8-10, 2005.
155. Wang J, Keown LA, **Patten SB**, Williams JVA, Currie SR, Beck CA, Maxwell CJ, El-Guebaly NA. Ways dealing with daily stress: the differences between healthy people and individuals with mental or physical illnesses. Global Perspectives on Chronic Disease Management: The Calgary Conference 2005. Calgary, Alberta. September 26-29.

156. Supina AL, Johnson J, Maxwell CJ, **Patten SB**, Williams J. The Usefulness of the EQ-5D in Differentiating Among Persons with Major Depressive Episode and Anxiety (Poster). ISPOR 10th Annual International Meeting. MAY 15 - 18th. WASHINGTON DC, USA
157. Zabad R, Metz LM, **Patten SB**. Suicide in multiple sclerosis patients exposed to disease modifying therapy (Poster). 40th annual scientific meeting of the Canadian Congress of Neurological Sciences (CCNS), Ottawa, Ontario, June 14-18, 2005.
158. Addington D, Addington J, **Patten SB**. Effectiveness of an early psychosis treatment service. American Psychiatric Association Annual Meeting. Atlanta, Georgia, May 21-26, 2005.
159. Gabriel A, **Patten S**, Fahim G. Efficacy of topiramate in the treatment of refractory bipolar I and II disorder. World Psychiatric Association International Congress. Treatments in Psychiatry: an update. November 10-13, 2004. Florence, Italy.
160. Ahluwalia PS, Wall WL, Roger E, Stoian CA, Duquette P, Hanley DA, **Patten SB**, and Metz LM. Using a Research Database to Screen for Undiagnosed Osteoporosis. (Poster) Presented at the 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers, Toronto, June 2004.
161. Zabad RK, **Patten SB**, Metz LM. The Frequency of Depression in Primary Progressive Multiple Sclerosis. (Poster) Presented at the European Charcot Foundation Symposium "Cognitive decline in MS", Taormina, Italy, November, 2004.
162. Wang J, **Patten SB**, Williams JVA, Currie SR, Beck CA, Maxwell CJ, El-Guebaly N. Help-seeking in individuals with mood disorders: preliminary findings from the CCHS 1.2. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium. Montreal, October 14, 2004.
163. **Patten SB**, Wang J, Williams JVA, Currie SR, Beck CA, El-Guebaly N. Basic descriptive epidemiology of major depression in the CCHS 1.2. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium. Montreal, October 14, 2004.
164. Currie SR, **Patten SB**, Williams JVA, Wang J, Maxwell CJ, Beck CA, El-Guebaly N. Comorbidity of major depression with substance use disorders. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium. Montreal, October 14, 2004.
165. Beck CA⁹¹, Williams JVA, Currie SR, Wang J, Maxwell CJ, El-Guebaly N, **Patten SB**. Antidepressant utilization in Canada. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium. Montreal, October 14, 2004.
166. McKenzie E, Addington J, **Patten S**, Smith H, Adair C & Addington D. Selection of Performance Measures for Testing in Early Psychosis Programs. IEPA, 4th International Congress on Early Psychosis: Translating the Evidence. September 28 to October 1, 2004, Vancouver, British Columbia.
167. McKenzie E, Addington J, **Patten S**, Smith H, Adair C & Addington D. Identification of performance measures for application in early psychosis programs. IEPA, 4th International Congress on Early Psychosis: Translating the Evidence. September 28 to October 1, 2004. Vancouver, British Columbia.

⁹¹ MSc student under my supervision at the time this research was conducted.

168. Kassam A⁹² and **Patten SB**. Co-morbid major depression and fibromyalgia in Canada: A population-based study on functional impairment & disability. Regional Data Centre Conference, University of Calgary. Sept 20-21, 2004.
169. Beck CA⁹³ and **Patten SB**. The relationship between major depression and thyroid disease: Does treatment of thyroid disease make a difference? Regional Data Centre Conference, University of Calgary. Sept 20-21, 2004.
170. **Patten S**. A descriptive Markov Model for major depression in the general population. Regional Data Centre Conference, University of Calgary. Sept 20-21, 2004.
171. Beck CA⁹⁴, **Patten SB**. The effect of thyroid medication on the relationship between thyroid disease and depression. International Federation of Psychiatric Epidemiology, 10th International Congress. Bristol. September 10-13, 2004.
172. **Patten SB**, Adair CE, Kassam A, Beck CA, Barbui C. Telephone surveys for pharmacoepidemiological surveillance in a Canadian province. International Federation of Psychiatric Epidemiology, 10th International Congress. Bristol. September 10-13, 2004.
173. Beck CA⁹⁵, **Patten SB**, Williams JVA, Metz L. Major depression in individuals with heart disease, stroke, diabetes, or hypertension: a population-based study. Theory, Evidence and Psychiatric Epidemiology. World Psychiatric Association, Section of Epidemiology and Public Health Meeting. Paris, July 9 – 11, 2003.
174. Crockford D, **Patten S**, el-Guebaly N. A pilot, open-label trial of gabapentin for smoking cessation: interim analysis (Poster). American Academy of Addiction Psychiatry, 14th Annual Meeting, New Orleans, Louisiana, USA, December 04-07, 2003.
175. **Patten SB**, Lee RC. Epidemiological theory, decision theory and mental health services research. Theory, Evidence and Psychiatric Epidemiology. World Psychiatric Association, Section of Epidemiology and Public Health Meeting. Paris, July 9 – 11, 2003.
176. **Patten SB**, Arboleda-Florez J. Epidemic theory and group violence. Theory, Evidence and Psychiatric Epidemiology. World Psychiatric Association, Section of Epidemiology and Public Health Meeting. Paris, July 9 – 11, 2003.
177. Metz LM, Yong VW, Yeung M, Patry DG, Bell RB, Zhang Y, **Patten SB**, Duquette P, Wallace C, Sevick R, Antel J, Bar-Or A, Mitchell RB. Open-label Trial of Minocycline in Active Relapsing-remitting Multiple Sclerosis. American Academy of Neurology 55th Annual Meeting. Honolulu, Hawaii. March 29 to April 5, 2003.
178. Zabad RK, **Patten SB**, Metz LM. The Frequency of Depression in Primary Progressive Multiple Sclerosis. American Academy of Neurology 55th Annual Meeting. Honolulu, Hawaii. March 29 to April 5, 2003

⁹² MSc student under my supervision at the time this research was conducted.

⁹³ MSc student under my supervision at the time this research was conducted.

⁹⁴ MSc student under my supervision at the time this research was conducted.

⁹⁵ MSc student under my supervision at the time this research was conducted.

179. Wall WL, Stoian CA, Roger E, Swinton D, **Patten SB**, Duquette P, Metz LM. The Perfect Database: The Journey from Dream to Reality. Consortium of Multiple Sclerosis Centers, San Diego, California from May 28 to June 1, 2003.
180. Beck CA⁹⁶, **Patten SB**. Trends in Antidepressant Use & Mental Health Consultation for Major Depression in Canada. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium. Banff, October 31, 2002.
181. Kassam A⁹⁷, Beck CA, Williams JVA, **Patten SB**. Trends in Antidepressant Use & Mental Health Consultation for Major Depression in Canada. Canadian Academy of Psychiatric Epidemiology Annual Scientific Symposium. Banff, October 31, 2002.
182. **Patten SB**. Using the High and Lows: Application of Data From the NPHS Survey to Examine Changes in Rates of Depression in Canada. Canadian Psychiatric Association Annual Meeting. Banff, October 31 - November 4, 2002.
183. Gabriel A, **Patten SB**. Changes in plasma cholesterol in depressed patients: does treatment make a difference? Canadian Psychiatric Association Annual Meeting. Banff, October 31 - November 4, 2002.
184. Gabriel A, **Patten SB**. Changes in plasma cholesterol in bipolar patients: does treatment make a difference? Canadian Psychiatric Association Annual Meeting. Banff, October 31 - November 4, 2002.
185. **Patten S**. Randomized Controlled Trial of a Preventive Intervention for Depressive Symptoms. Mental Health Problems in Primary Care: From Research to Practice. 9th International Congress of the International Federation of Psychiatric Epidemiology. Edmonton, May 12-15, 2002.
186. **Patten S**. Simulating the Epidemiological Dynamics of Mood Disorders in Community Populations. Mental Health Problems in Primary Care: From Research to Practice. 9th International Congress of the International Federation of Psychiatric Epidemiology. Edmonton, May 12-15, 2002.
187. **Patten S**. Trends in Antidepressant Use in Canada. Mental Health Problems in Primary Care: From Research to Practice. 9th International Congress of the International Federation of Psychiatric Epidemiology. Edmonton, May 12-15, 2002.
188. Beck C⁹⁸, **Patten SB**. A Descriptive Analysis of the WHO Mental Health 2000 Distress Scale in the Canadian Population Using Data from the 1996-97 National Population Health Survey. Canadian Academy of Psychiatric Epidemiology. Montréal, November 19, 2001.
189. **Patten SB**. Progress Against Major Depression in Canada? Canadian Academy of Psychiatric Epidemiology. Montréal, November 19, 2001.
190. Addington DE, Addington J, **Patten S**. Reliability of relapse as an outcome measure for evaluating the effectiveness of an early psychosis program. Canadian Psychiatric Association Annual Meeting. Montréal, November 15-18, 2001.

⁹⁶ MSc student under my supervision at the time this research was conducted.

⁹⁷ MSc student under my supervision at the time this research was conducted.

⁹⁸ MSc student under my supervision at the time this research was conducted.

191. Addington DE, Addington J, **Patten S**, Remington G, Moamai J, Labelle A. Sertraline for depression in remitted schizophrenia. International Conference on Schizophrenia Research. Whistler, BC. April 28 - May 2, 2001
192. **Patten SB**, Metz LM. Interferon -1a (Rebif) does not increase depressive symptoms or risk of depression in multiple sclerosis: evidence from a randomized controlled trial. American Neurological Association Annual Meeting: Neurology Outcomes Symposium. October 15-18, 2000. Boston, Massachusetts.
193. Addington D, Addington J, Beauclair L, Labelle A, Moamai J, **Patten S**, Remington G. A double-blind, placebo-controlled comparison of sertraline for major depression in patients with remitted schizophrenia. Canadian Psychiatric Association Annual Meeting. October 4-6, 2000. Victoria, British Columbia
194. **Patten S**, Metz L, Reimer M. Major depression in multiple sclerosis (Poster). Canadian Psychiatric Association Annual Meeting. October 4-6, 2000. Victoria, British Columbia.
195. **Patten SB**. Epidemiological relationships between medication exposure and major depressive episodes: an argument for randomization. Canadian Academy of Psychiatric Epidemiologists Annual Meeting. October 3, 2000. Victoria, British Columbia.
196. Oster A, **Patten SB**, Bernbaum S. Determinants of violent incidents among psychiatric emergency patients. Conference on Risk Assessment and Risk Management. Implications for the Prevention of Violence. November 17-19, 1999.
197. **Patten SB**. Determinants of Delirium in Psychiatric Inpatients: A Pharmacoepidemiological Study. The XV International Scientific Meeting of the International Epidemiological Association, August 31- September 4, 1999, Florence, Italy.
198. **Patten SB**. Chronic medical conditions and major depression in the general population (Poster). American Psychiatric Association Annual Meeting, May 30 - June 4, 1998, Toronto, Ontario.
199. Singh N, **Patten SB**, Bell R. Psychiatric presentation of acute disseminated encephalitis. World Psychiatric Association Regional Meeting, January 4-8, 1998, Jaipur, India.
200. **Patten SB**, Williams JVA, Haynes L, McCrudden J, Arboleda-Florez J. The incidence of delirium in psychiatric inpatients. Canadian Psychiatric Association Annual Meeting. September 16-19, 1997, Calgary, Alberta.
201. Addington D, Addington J, **Patten SB**. Two Year Course of Depression in Schizophrenia. Canadian Psychiatric Association Annual Meeting. September 16 - 19, 1997, Calgary, Alberta.
202. Beck CA, Simpson JSA, **Patten S**. A Study of Psychiatric Morbidity and Social Support in Women with Breast Cancer (Poster). Canadian Psychiatric Association Annual Meeting. October 1 - 4, 1996, Quebec City, Quebec.
203. **Patten SB**, Williams JVA, Love EJ. Preliminary Evidence of an Association Between ACE Inhibitors and Depressive Disorders (Poster). X World Congress of Psychiatry, August 22-28, 1996, Madrid, Spain.

204. **Patten SB**, Williams JVA, Love EJ. Depressive Symptom Attributable to Medication Exposures in Medical Inpatients. X World Congress of Psychiatry, August 22-28, 1996, Madrid, Spain.
205. **Patten SB**. Selection Bias in Institutional Case-control Studies in Forensic Psychiatry. World Psychiatric Association Annual Meeting, August 22-28, 1996, Madrid, Spain.
206. **Patten SB**, Williams JVA. A data collection instrument for studies of drug-induced depression. Canadian Pharmacoepidemiology Forum, April 29-30, 1996, Saskatoon, Saskatchewan.
207. **Patten SB**, Williams JVA, Love EJ. A Possible Association Between ACE-inhibitors and Depressive Disorders (Poster). Canadian Pharmacoepidemiology Forum, April 29-30, 1996, Saskatoon, Saskatchewan.
208. **Patten SB**, Williams JVA, Love EJ. Population Attributable Risk for Drug-induced Depressive Symptoms in Medical Inpatients. Canadian Pharmacoepidemiology Forum, April 29-30, 1996, Saskatoon, Saskatchewan.
- 209.
210. Addington D, Addington J, **Patten S**. Depression in First Episode Schizophrenia. First International Conference on Early Psychosis, June 1996, Melbourne, Australia.
211. Addington D, Addington J, **Patten S**. Course, Correlates and Predictors of Depression in Schizophrenia. Canadian Psychiatric Association Annual Meeting. Victoria, September 21-22, 1995.
212. **Patten SB**: An Instrument to Diagnose Organic Depression in Epidemiological Research. Canadian Academy of Psychiatric Epidemiologists, Annual Scientific Symposium, September 19, Victoria, 1995.
213. **Patten SB**, Russell ML, Fick GH: Misclassification Bias in Psychiatric Epidemiology. Canadian Academy of Psychiatric Epidemiology, Annual Scientific Symposium, Ottawa, 1994.
214. **Patten SB**, Russell ML: A Mathematical Model Relating Misclassification Bias to Statistical Power in Alternative Pharmacoepidemiological Design Strategies. Canadian Pharmacoepidemiology Forum, Toronto 1994.
215. **Patten SB**, Fick G, Love EJ: The Comparative Efficacy of "New" Versus Established Antidepressants. Canadian Psychiatric Association Annual Meeting, Winnipeg, Manitoba, 1993.
216. **Patten SB**, Love EJ: Drugs and Depression. A Prospective Cohort Study of Hospitalized Patients. Canadian Pharmacoepidemiology Forum, Toronto, 1993.
217. **Patten SB**, Love EJ: An Epidemiological Perspective on the Passive Reports of Neuropsychiatric Adverse Drug Reactions to Health and Welfare Canada's Adverse Drug Reaction Program, 1965 to present. Canadian Pharmacoepidemiology Forum, Toronto, 1993.
218. **Patten SB**, Love EJ: Neuropsychiatric Adverse Drug Reactions: Passive Reports to Health and Welfare Canada's Adverse Drug Reaction Program, 1965-1992. Human Rights, Mental Health and Therapy in a Radically Changing World. Banff, 1993.

219. **Patten SB:** Early Parental Loss as a Risk Factor for Depression. Canadian Psychiatric Association Annual Meeting. Toronto, 1990.
220. Lamarre CJ, **Patten SB:** A Clinical Evaluation of the Neuro-Behavioral Cognitive Status Examination. (Poster) Canadian Psychiatric Association Annual Meeting. Toronto, 1990.
221. **Patten SB.** Early Parental Loss and Depression (Poster - New Research). American Psychiatric Association Annual Meeting, New York, 1990.
222. **Patten SB:** Alpha-2-Agonists and Depression. Canadian College of Neuro-Psychopharmacology Annual Meeting. Banff, 1990.
223. **Patten SB:** Early Parental Loss as a Risk Factor for Depression. Alberta Psychiatric Association Meeting. Banff, 1990.
224. **Patten SB,** Lamarre CJ: The Dexamethasone Suppression Test: Estimation of Predictive Value with Bayes' Theorem. (Poster) American Psychiatric Association Meeting, 1989.
225. **Patten SB:** Non-Psychiatric Therapeutic Medications in the Etiology of Organic Depression. Alberta Psychiatric Association Meeting, 1989.
226. Lamarre CJ, **Patten SB:** A Clinical Evaluation of the Modified Mini-Mental State Examination. Canadian Psychiatric Association Meeting 1988.
227. **Patten SB,** Lamarre CJ: The Face-Hand Test, a Useful Addition to the Psychiatric Physical Examination. Canadian Psychiatric Association Meeting 1988.
228. **Patten SB,** Lamarre CJ: The Face-Hand Test in General Psychiatry. Alberta Psychiatric Association Meeting, 1988.